INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6501, 0, 'Estrone sulfate', 'Liver Neoplasms', 'The use of oral contraceptives is contraindicated in patients with liver tumors.  An increased risk of benign hepatic adenomas and hepatocellular carcinomas has been associated with long-term, oral estrogen- progestin contraceptive use of at least 4 years and 8 years, respectively.  Although these tumors are rare and have not been reported with other types of estrogen or progestogen therapies, any preparation containing estrogens and/or progestogens should probably be avoided in patients with existing tumors of the liver.  Hepatic hemangiomas and nodular hyperplasia of the liver have been reported with isolated estrogen therapy.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6502, 0, 'Estrone sulfate', 'Angioedema', 'The use of exogenous estrogens may induce or exacerbate symptoms of angioedema, particularly in women with hereditary angioedema.  Close monitoring is recommended when prescribing these agents to patients predisposed to angioedema.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6503, 0, 'Estrone sulfate', 'Gallbladder Diseases', 'A two- to four-fold increase in risk of gallbladder disease has been noted in women receiving postmenopausal estrogen therapy.  The risk for gallbladder disease may be less for premenopausal women using oral contraceptives containing low-dose estrogens and/or progestins.  Therapy with estrogens should be administered cautiously in patients with preexisting gallbladder disease.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6504, 0, 'Estrone sulfate', 'Hypercalcemia', 'Estrogens influence the metabolism of calcium and phosphorus.  Intestinal absorption and retention of calcium are increased, which may occasionally result in hypercalcemia.  Therapy with estrogens should be administered cautiously in patients with preexisting hypercalcemia, renal dysfunction, or metabolic bone diseases that are associated with hypercalcemia.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6505, 0, 'Estrone sulfate', 'Hyperlipidemias', 'Although estrogens have generally favorable effects on plasma lipids, including increases in HDL and decreases in total cholesterol and LDL, they have also been associated with significant elevations in triglyceride levels, particularly when high dosages are used.  Severe hyperlipidemia is known to sometimes cause pancreatitis.  Patients with preexisting hyperlipidemia may require closer monitoring during estrogen therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6506, 0, 'Estrone sulfate', 'Liver Diseases', 'Estrogens are primarily metabolized by the liver.  Patients with impaired hepatic function may be at increased risk for adverse effects associated with estrogen administration due to decreased drug clearance.  Therapy with estrogens should be administered cautiously in patients with liver disease.  In addition, clinicians should be aware that estrogen therapy may affect liver function tests.  Increased sulfobromophthalein retention has been reported with the use of estrogen-containing oral contraceptives and may be expected with larger doses of estrogens.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6507, 0, 'Estrone sulfate', 'Melanosis', 'The use of exogenous estrogens may occasionally cause chloasma, especially in women with a history of chloasma gravidarum.  Women with a tendency to chloasma should avoid exposure to the sun or ultraviolet radiation while taking combination oral contraceptives.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6508, 0, 'Estrone sulfate', 'Depressive Disorder', 'The use of oral contraceptives has been associated with an increased incidence of depression.  It is uncertain whether this effect is related to the estrogenic or the progestogenic component of the contraceptive, although excess progesterone activity is associated with depression.  Patients with a history of depression receiving estrogen and/or progestogen therapy should be followed closely.  The manufacturer of medroxyprogesterone recommends monitoring patients who have a history of depression and to not re- administer medroxyprogesterone if depression recurs.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6509, 0, 'Estrone sulfate', 'Water-Electrolyte Imbalance', 'Estrogens and progestogens may cause fluid retention, particularly when given in high dosages or for prolonged periods.  Therapy with these agents should be administered cautiously in patients who have preexisting problems with excess fluid.  In addition, patients with conditions that may be adversely affected by fluid accumulation, such as asthma, epilepsy, migraine, and cardiovascular or renal dysfunction, should be observed for exacerbation of their condition during estrogen and/or progestogen therapy.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6510, 0, 'Estrone sulfate', 'Glucose Intolerance', 'Impaired glucose tolerance has been observed in some patients administered oral contraceptives and appears to be related primarily to the estrogen dose.  However, progestogens can increase insulin secretion and produce insulin resistance to varying degrees, depending on the agent.  Patients with diabetes mellitus should be monitored more closely during therapy with estrogens and/or progestogens, and adjustments made accordingly in their antidiabetic regimen.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6511, 0, 'Estrone sulfate', 'Eye Diseases', 'Estrogens and progestogens may cause retinal thrombosis.  Oral contraceptives should be discontinued if there is unexplained partial or complete loss of vision; onset of proptosis or diplopia; papilledema; or retinal vascular lesions.  Therapy with these agents should be administered cautiously in patients who have preexisting ocular problems and appropriate diagnostic and therapeutic measures should be instituted.  Contact lens wearers who develop visual changes or changes in lens tolerance should be assessed by an ophthalmologist.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6512, 0, 'Estrone sulfate', 'Thyroid Diseases', 'When administering estrogen and/or progestogen therapy in patients with thyroid disorders, clinicians should be aware that these hormones may affect thyroid function tests.  Changes have mostly been reported with the use of combination oral contraceptives.  Specifically, thyroid-binding globulin (TBG) may be increased, resulting in elevated circulating total thyroid hormone, as measured by PBI (protein-bound iodine), T4 by column or radioimmunoassay, or T3 by radioimmunoassay.  Free T3 resin uptake may be decreased.  On the contrary, a decrease in TBG and, consequently, thyroxine concentration, has been reported by the manufacturers of the progestin-only (norethindrone) oral contraceptives.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6513, 0, 'Eszopiclone', 'Depressive Disorder', 'A variety of abnormal thinking and behavior changes have been reported to occur in association with the use of most anxiolytics, sedatives and hypnotics.  Some of these changes include decreased inhibition, aggressiveness, agitation, and hallucinations.  These drugs can cause or exacerbate mental depression and cause suicidal behavior and ideation.  Therapy with these drugs should be administered cautiously in patients with a history of depression or other psychiatric disorders.  Patients should be monitored for any changes in mood or behavior.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6514, 0, 'Eszopiclone', 'Glaucoma', 'Some hypnotic drugs can have an anticholinergic effect and should be used with caution in patients with glaucoma, and trouble urinating due to retention or enlarged prostate.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6515, 0, 'Eszopiclone', 'Liver Diseases', 'In general, anxiolytics, sedatives and hypnotics are extensively metabolized by the liver.  Their plasma clearance may be decreased and their half-life prolonged in patients with impaired hepatic function.  Therapy with these drugs should be administered cautiously in patients with liver disease (some are not recommended in severe liver impairment), and the dosage should be adjusted accordingly.  Laboratory testing is recommended prior and during treatment.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6516, 0, 'Etacrynic acid', 'Anuria', 'The use of loop diuretics is contraindicated in patients with anuria.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6517, 0, 'Etacrynic acid', 'Fibrosis', 'Loop diuretic therapy should be initiated in the hospital under strict observation in patients with liver cirrhosis and ascites.  Sudden alteration of fluid and electrolyte balance may precipitate hepatic encephalopathy and coma in such patients, who are also at increased risk for the development of hypokalemia.  Supplemental potassium and/or concomitant use of an aldosterone antagonist or potassium-sparing agent may help prevent hypokalemia and metabolic alkalosis.  Loop diuretics should be withheld in patients with hepatic coma until the condition improves.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6518, 0, 'Etacrynic acid', 'Water-Electrolyte Imbalance', 'The use of loop diuretics, particularly at high dosages or during chronic therapy, is commonly associated with loss of electrolytes, including potassium, sodium, chloride, magnesium, and calcium.  Potassium and magnesium depletion may lead to cardiac arrhythmias and cardiac arrest.  Other electrolyte-related complications include metabolic alkalosis and hyponatremia, which are rarely life-threatening.  Excessive diuresis, as indicated by rapid weight loss, may induce dehydration and hypovolemia, which can result in acute hypotension, orthostasis, circulatory collapse, vascular thrombosis and embolism, and abrupt reduction in glomerular filtration and renal blood flow.  Severe dehydration is most likely to occur in the elderly and patients under prolonged sodium restriction.  Therapy with loop diuretics should be administered cautiously in patients with or predisposed to fluid and electrolyte depletion, including patients with primary or secondary aldosteronism (may have low potassium levels); those with severe or prolonged diarrhea or vomiting; and those with poor nutritional status.  Fluid and electrolyte abnormalities should be corrected before initiating therapy, and blood pressure as well as serum electrolyte concentrations monitored periodically and maintained at normal ranges during therapy.  Patients should be advised to immediately report signs and symptoms of fluid or electrolyte imbalance, including dry mouth, thirst, weakness, lethargy, drowsiness, restlessness, muscle pains or cramps, muscular fatigue, hypotension, oliguria, tachycardia, arrhythmia, or gastrointestinal disturbances such as nausea and vomiting.  Digitalized patients and patients with a history of ventricular arrhythmias should be monitored carefully, since the development of hypokalemia may be particularly dangerous in these patients.  The risk of hypokalemia may be minimized by slow diuresis, a lower diuretic dosage, potassium supplementation, or combined use with a potassium-sparing diuretic.  Similarly, to prevent excessive dehydration and hyponatremia, sodium intake should be liberalized if clinically feasible.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6519, 0, 'Etacrynic acid', 'Ototoxicity', 'Tinnitus and hearing loss, both reversible and permanent, have been reported with the use of loop diuretics.  Ototoxic effects have generally been associated with rapid intravenous or intramuscular injection, severe renal impairment, unusually high dosages (i.e. several times the usual recommended dosages), and/or concomitant use of other ototoxic agents.  Therapy with loop diuretics should be administered cautiously in patients with preexisting vestibular and/or auditory impairment, since it may delay the recognition or confound the diagnosis of a drug-induced ototoxic effect.  High-dose parenteral therapy should be administered as controlled infusion.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6520, 0, 'Etacrynic acid', 'Kidney Diseases', 'Impaired effectiveness and possible delayed excretion of loop diuretics may occur in patients with severe renal dysfunction.  These individuals may require high dosages that are associated with an increased risk of electrolyte abnormalities (hyponatremia, hypochloremic alkalosis, hypokalemia, hypomagnesemia, hypocalcemia) and ototoxicity (tinnitus, hearing loss).  Therapy with loop diuretics should be administered cautiously in patients with significantly impaired renal function.  Prolongation of the dosing intervals may be appropriate to prevent drug accumulation.  The patient should be monitored closely for the signs and symptoms of fluid or electrolyte imbalance, including dry mouth, thirst, weakness, lethargy, drowsiness, restlessness, muscle pains or cramps, muscular fatigue, hypotension, oliguria, tachycardia, arrhythmia, or gastrointestinal disturbances such as nausea and vomiting.  Excessive diuresis should be avoided as it may induce dehydration and hypovolemia, which can result in an abrupt reduction in glomerular filtration and renal blood flow.  If increasing azotemia and oliguria occur during treatment of severe progressive renal disease, or if renal function becomes progressively worse as indicated by rising BUN or serum creatinine levels, an interruption or discontinuation of therapy should be considered.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6521, 0, 'Etacrynic acid', 'Diabetes Mellitus', 'Loop diuretics may cause hyperglycemia, glycosuria, and alterations in glucose tolerance tests.  Rarely, precipitation of diabetes mellitus has been reported.  Therapy with loop diuretics should be administered cautiously in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia.  Patients with diabetes mellitus should be monitored more closely during therapy, and their antidiabetic regimen adjusted accordingly.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6522, 0, 'Etacrynic acid', 'Hyperuricemia', 'Loop diuretics may decrease the rate of uric acid excretion.  Hyperuricemia can occur but is usually asymptomatic and rarely leads to clinical gout except in patients with a history of gout or chronic renal failure.  Therapy with loop diuretics should be administered cautiously in such patients.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6523, 0, 'Ethionamide', 'Liver Diseases', 'The use of ethionamide is contraindicated in patients with severe liver damage.  Like many other antituberculous agents, ethionamide is hepatotoxic.  Transient elevations in bilirubin and serum SGOT (AST) and SGPT (ALT) have been reported in 5% of the patients treated with ethionamide.  Hepatitis, with or without jaundice, has also been observed, particularly in patients with diabetes mellitus.  Therapy with ethionamide should be administered cautiously in patients with liver disease, a history of alcoholism, or diabetes.  Liver function tests should be measured at baseline and monthly during therapy, and ethionamide withdrawn at the first signs or symptoms suggestive of liver damage.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6524, 0, 'Ethionamide', 'Peripheral Nervous System Diseases', 'Peripheral neuropathy has been associated with the use of ethionamide, but much less frequently than with isoniazid, a structurally related agent.  Therapy with ethionamide should be administered cautiously in patients with preexisting peripheral neuropathy or risk factors for developing the condition, such as malnutrition, diabetes, and alcoholism.  Pyridoxine (vitamin B6) at a dosage of 25 to 50 mg/day has been recommended to prevent or attenuate isoniazid-related peripheral neuropathy and may be considered for patients receiving ethionamide.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6525, 0, 'Ethionamide', 'Diabetes Mellitus', 'The use of ethionamide has occasionally been associated with poor diabetic control.  Patients with diabetes mellitus should be monitored more closely during therapy with ethionamide, and their antidiabetic regimen adjusted accordingly.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6526, 0, 'Ethchlorvynol', 'Alcoholic Intoxication', 'Anxiolytic, sedative, and hypnotic agents should generally not be given to patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of these agents may be additive with those of alcohol.  Severe respiratory depression and death may occur.  Therapy with such agents should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6527, 0, 'Ethchlorvynol', 'Depressive Disorder', 'A variety of abnormal thinking and behavior changes have been reported to occur in association with the use of most anxiolytics, sedatives and hypnotics.  Some of these changes include decreased inhibition, aggressiveness, agitation, and hallucinations.  These drugs can cause or exacerbate mental depression and cause suicidal behavior and ideation.  Therapy with these drugs should be administered cautiously in patients with a history of depression or other psychiatric disorders.  Patients should be monitored for any changes in mood or behavior.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6528, 0, 'Ethchlorvynol', 'Substance-Related Disorders', 'Anxiolytic, sedative, and hypnotic agents have the potential to cause dependence and abuse.  Tolerance as well as physical and psychological dependence can develop, particularly after prolonged use of excessive dosages, and abrupt cessation and/or a reduction in dosage may precipitate withdrawal symptoms.  In patients who have developed tolerance, overdosage can still produce respiratory depression and death.  Therapy with anxiolytic, sedative, and hypnotic agents should be administered cautiously and for as brief a period as possible.  Addiction-prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance or medical supervision when treated with these agents.  In addition, it may be prudent to refrain from dispensing large quantities of medication to such patients.  After prolonged use or if dependency is suspected, withdrawal of medication should be undertaken gradually using a dosage-tapering schedule.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6529, 0, 'Ethchlorvynol', 'Porphyrias', 'The use of ethchlorvynol is contraindicated in patients with a history of porphyria.  Ethchlorvynol has been reported to precipitate acute attacks of porphyria in susceptible patients.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6530, 0, 'Ethchlorvynol', 'Liver Diseases', 'Ethchlorvynol is thought to be metabolized by the liver and subsequently excreted in the urine, primarily as metabolites.  Patients with renal and/or liver disease may be at greater risk for adverse effects from ethchlorvynol, including central nervous system and respiratory depression, due to decreased drug clearance.  Therapy with ethchlorvynol should be administered cautiously in patients with impaired renal and/or hepatic function.  In one study, patients with renal impairment experienced excessive drowsiness following repeated dosing of the drug, presumably due to its accumulation in the plasma.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6531, 0, 'Ethchlorvynol', 'Glaucoma', 'Some hypnotic drugs can have an anticholinergic effect and should be used with caution in patients with glaucoma, and trouble urinating due to retention or enlarged prostate.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6532, 0, 'Ethchlorvynol', 'Respiratory Insufficiency', 'Oral anxiolytic, sedative, and hypnotic agents may cause respiratory depression and apnea when given in high dosages or following acute overdose.  However, some patients may be susceptible at commonly used dosages, including the elderly, debilitated or severely ill patients, those receiving other CNS depressants, and those with limited ventilatory reserve, chronic pulmonary insufficiency or other respiratory disorders.  Therapy with anxiolytic, sedative, and hypnotic agents should be administered cautiously in these patients.  Appropriate monitoring and individualization of dosage are recommended.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6533, 0, 'Ethosuximide', 'Hematologic Diseases', 'Hematologic toxicities, some with fatal outcome, have been associated with the use of succinimide anticonvulsants.  Leukopenia, agranulocytosis, aplastic anemia, thrombocytopenia, pancytopenia, and eosinophilia have been reported.  Therapy with succinimide anticonvulsants should be administered cautiously in patients with preexisting blood dyscrasias and/or bone marrow suppression.  Complete blood counts, including platelets, should be performed prior to initiating therapy and periodically during therapy.  Marked depression of blood counts may be indication for withdrawal of succinimide therapy.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6534, 0, 'Ethosuximide', 'Liver Diseases', 'Succinimide anticonvulsants have produced morphological and functional changes in the liver of animals.  In humans, abnormalities in liver and renal function studies have been reported.  Therapy with succinimide anticonvulsants should be administered with extreme caution in patients with known hepatic or renal diseases.  Periodic urinalysis and liver function tests are recommended for all patients treated with these drugs.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6535, 0, 'Ethosuximide', 'Lupus Erythematosus, Systemic', 'Cases of systemic lupus erythematosus (SLE) have been reported in association with the use of succinimide anticonvulsants, primarily ethosuximide.  Some of the patients recovered promptly following discontinuation of the drug, while others continued to have active disease long after.  Therapy with succinimide anticonvulsants should be administered cautiously in patients with a history of SLE.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6536, 0, 'Ethosuximide', 'Depressive Disorder', 'Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication.  Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo.  AEDs should be administered cautiously in patients with depression or other psychiatric disorders.  The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.  Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior.  If patients have symptoms of suicidal ideation or behavior, a dosage reduction or treatment discontinuation should be considered.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6537, 0, 'Ethosuximide', 'Diseases requiring dialysis', 'Ethosuximide has been shown to be removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6538, 0, 'Abemaciclib', 'Liver Diseases', 'The dosing frequency of abemaciclib should be reduced to once daily when it is administered to patients with severe hepatic impairment (Child-Pugh C).  No dosage adjustments are necessary for patients with mild or moderate hepatic impairment (Child-Pugh A or B).  Hepatotoxicity has been reported with the use of abemaciclib.  It is recommended to monitor liver function tests prior to the start of therapy, every 2 weeks for the first 2 months, monthly for the next 2 months, and as clinically indicated.  Dose interruption, dose reduction, dose discontinuation, or delay in starting treatment cycles is recommended for patients who develop persistent or recurrent Grade 2, or Grade 3 or 4, hepatic transaminase elevation.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6539, 0, 'Abemaciclib', 'Diarrhea', 'Diarrhea, sometimes associated with dehydration and infection, has occurred in patients receiving abemaciclib.  Diarrhea incidence was greatest during the first month of abemaciclib dosing.  Care should be exercised when treating patients with symptoms of diarrhea.  Treatment discontinuation may be required for Grade 3 or 4 diarrhea, or diarrhea that requires hospitalization.  Resume treatment at the next lower dose once toxicity resolves to <= Grade 1 diarrhea.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6540, 0, 'Abemaciclib', 'Lung Diseases, Interstitial', 'Patients treated with abemaciclib have reported severe, life-threatening, or fatal interstitial lung disease (ILD) and/or pneumonitis.  It is recommended to monitor patients for pulmonary symptoms indicative of ILD/pneumonitis such as, hypoxia, cough, dyspnea, or interstitial infiltrates on radiologic exams.  Dose interruption or dose reduction is recommended for patients who develop persistent or recurrent Grade 2 ILD/pneumonitis.  Permanently discontinue therapy in all patients with Grade 3 or 4 ILD or pneumonitis.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6541, 0, 'Abemaciclib', 'Neutropenia', 'Neutropenia, including febrile neutropenia has occurred in patients receiving abemaciclib.  Care should be exercised when prescribing this agent to patients with preexisting neutropenia.  It is recommended to monitor complete blood counts prior to the start of therapy, every 2 weeks for the first 2 months, monthly for the next 2 months, and as clinically indicated.  Dose interruption, dose reduction, or delay in starting treatment cycles is recommended for patients who develop Grade 3 or 4 neutropenia.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6542, 0, 'Abemaciclib', 'Venous Thromboembolism', 'Venous thromboembolic events have been reported with the use of abemaciclib.  Care should be exercised when using this agent in patients with risk factors or history of venous thromboembolic events.  It is recommended to monitor patients for signs and symptoms of venous thrombosis and pulmonary embolism and treat as medically appropriate.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6543, 0, 'Abemaciclib', 'Lung Diseases', 'The use of certain multikinase inhibitors has been associated with pulmonary toxicity.  Serious cases of interstitial lung disease (ILD), including fatal cases and interstitial pneumonitis or pulmonary fibrosis have been reported.  Caution is recommended when using these agents in patients with a history of interstitial pneumonitis or pulmonary fibrosis or those patients presenting with acute onset of new or progressive unexplained pulmonary symptoms such as dyspnea, cough, and fever pending diagnostic evaluation.  If ILD is confirmed, permanently discontinue these agents and institute appropriate measures.  Immediately withhold treatment in patients diagnosed with ILD/pneumonitis and permanently discontinue therapy if no other potential causes of ILD/pneumonitis have been identified.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6544, 0, 'Etravirine', 'Liver Diseases', 'Etravirine is primarily metabolized by the liver.  No dose adjustment of etravirine is required in patients with mild (Child-Pugh Class A) or moderate (Child-Pugh Class B) hepatic impairment.  Caution is recommended when using this agent in patients with severe hepatic impairment (Child-Pugh Class C) as the pharmacokinetics of etravirine have not been evaluated in these patients.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6545, 0, 'Etelcalcetide', 'Arrhythmias, Cardiac', 'The use of etelcalcetide lowers serum calcium and can lead to hypocalcemia, sometimes severe.  A decrease in serum calcium can cause paresthesias, myalgias, muscle spasms, seizures, QT interval prolongation, and ventricular arrhythmia.  Patients with congenital long QT syndrome, history of QT interval prolongation, family history of long QT syndrome or sudden cardiac death, and other conditions that predispose to QT interval prolongation and ventricular arrhythmia may be at increased risk for QT interval prolongation and ventricular arrhythmias if they develop hypocalcemia.  Closely monitor corrected serum calcium and QT interval in patients at risk receiving etelcalcetide.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6546, 0, 'Etelcalcetide', 'Peptic Ulcer Hemorrhage', 'The use of etelcalcetide may increase the risk of upper gastrointestinal (GI) bleeding.  Patients with risks factors for upper GI bleeding (such as known gastritis, esophagitis, ulcers, or severe vomiting) may be at increased risk for GI bleeding while receiving etelcalcetide treatment.  It is recommended to monitor patients for worsening of GI adverse reactions such as nausea and vomiting and for signs and symptoms of GI bleeding and ulcerations during therapy with etelcalcetide.  Promptly evaluate and treat any suspected GI bleeding according to medical guidelines.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6547, 0, 'Etelcalcetide', 'Heart Failure', 'The use of etelcalcetide may cause hypotension, congestive heart failure, and decreased myocardial performance and worsening heart failure.  Reductions in corrected serum calcium may be associated with congestive heart failure.  Close monitoring is recommended for worsening signs and symptoms of heart failure.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6548, 0, 'Etelcalcetide', 'Seizures', 'The use of etelcalcetide may cause seizures due to significant reductions in corrected serum calcium.  Patients with a history of seizure disorder may be at increased risk for seizures if they develop hypocalcemia due to etelcalcetide therapy.  It is recommended to measure corrected serum calcium prior to and within 1 week after initiation or dose adjustment and every 4 weeks during treatment.  Do not initiate in patients if the corrected serum calcium is less than the lower limit of normal.  Close monitor corrected serum calcium in patients with seizure disorders receiving etelcalcetide.  Dose reduction or discontinuation of therapy may be necessary if corrected serum calcium falls below the lower limit of normal or symptoms of hypocalcemia develop.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6549, 0, 'Etidronic acid', 'Osteomalacia', 'The use of etidronate (for the treatment of Paget''s disease or the treatment/prevention of heterotopic ossification) is contraindicated in patients with clinically overt osteomalacia.  Etidronate can inhibit bone mineralization, which has resulted in osteomalacia and bone fractures in some patients.  Accumulation of unmineralized osteoid is usually noticeable during prolonged, continuous use of high dosages (10 to 20 mg/kg/day) but may occur at lower dosages when use exceeds 6 months.  The newer bisphosphonates (e.g., alendronate, pamidronate, risedronate, and tiludronate) do not cause mineralization defects and may be more appropriate for patients with osteomalacia, although clinical data may be lacking for the treatment of some conditions for which etidronate is used.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6550, 0, 'Etidronic acid', 'Gastrointestinal Diseases', 'Etidronate administered orally may cause local irritation of the upper gastrointestinal mucosa.  Its use is contraindicated in patients with esophageal abnormalities that delay esophageal emptying such as achalasia or strictures.  Etidronate should be used with caution in patients with active upper gastrointestinal problems, such as Barrett''s esophagus, dysphagia, gastritis, duodenitis, ulcers, etc, as cases of erosions, bleeding and perforation have been reported.  Patients should be instructed to discontinue treatment immediately and seek medical attention if they develop dysphagia, retrosternal pain, or new or worsening heartburn.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6551, 0, 'Etidronic acid', 'Kidney Diseases', 'Etidronate is eliminated intact by the kidney.  There is no experience to specifically make recommendations in patients with impaired renal function.  Etidronate dosage should be reduced when reductions in glomerular filtration rates are present.  Patients with renal impairment should be closely monitored.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6552, 0, 'Etodolac', 'Asthma', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) are contraindicated in patients with history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs; severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients.  A subpopulation of patients with asthma may have aspirin-sensitive asthma which may include chronic rhinosinusitis complicated by nasal polyps, severe potentially fatal bronchospasm, and/or intolerance to aspirin and other NSAIDs.  Since cross-reactivity between aspirin and other NSAIDs has been reported in such aspirin-sensitive patients, therapy with any NSAID should be avoided in patients with this form of aspirin sensitivity.  NSAIDs should be used with caution in patients with preexisting asthma (without known aspirin sensitivity), and these patients should be monitored for changes in the signs and symptoms of asthma.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6553, 0, 'Etodolac', 'Water-Electrolyte Imbalance', 'Fluid retention and edema have been reported in association with the use of nonsteroidal anti-inflammatory drugs (NSAIDs).  Therapy with NSAIDs should be administered cautiously in patients with preexisting fluid retention, hypertension, or a history of heart failure.  Blood pressure and cardiovascular status should be monitored closely during the initiation of NSAID treatment and throughout the course of therapy.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6554, 0, 'Etodolac', 'Peptic Ulcer', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) can cause serious gastrointestinal (GI) adverse events including inflammation, bleeding, ulceration, and perforation of the esophagus, stomach, small intestine, or large intestine, which can be fatal.  These serious adverse events can develop at any time, with or without warning symptoms.  Only 1 in 5 patients who develop a serious upper GI side effect on NSAIDs is symptomatic.  NSAIDs should be used with caution in patients with history of peptic ulcer disease and/or GI bleeding, as these patients had a greater than 10-fold increased risk for developing a GI bleed compared to patients without these risk factors.  Caution is also advised if NSAIDs are prescribed to patients with other factors that increase risk of GI bleeding, such as:  prolonged NSAID therapy; concomitant use of oral corticosteroids, antiplatelet agents (e.g., aspirin), anticoagulants, selective serotonin reuptake inhibitors; alcohol use; smoking; history of gastrointestinal surgery or anastomosis, older age; poor general health status; and advanced liver disease and/or coagulopathy.  Particular vigilance is necessary when treating elderly or debilitated patients since most postmarketing reports of fatal GI events occurred in these patients.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6555, 0, 'Etodolac', 'Exanthema', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) can cause serious skin adverse reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis, and exfoliative dermatitis), which can be fatal.  These serious events may occur without warning.  Patients should be advised to discontinue the NSAID and seek medical attention promptly at the first sign of skin rash or any other sign of hypersensitivity.  NSAIDs are contraindicated in patients with previous serious skin reactions to these drugs.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6556, 0, 'Etodolac', 'Kidney Diseases', 'Long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs) has resulted in renal papillary necrosis and other renal injury.  Renal toxicity has been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion:  in such patients, NSAIDs may cause a dose-dependent reduction in prostaglandin synthesis and, secondarily, in renal blood flow, which may precipitate overt renal decompensation.  Patients at greatest risk for this reaction include the elderly, those with impaired renal function, dehydration, hypovolemia, heart failure, or liver dysfunction, and those taking diuretics, angiotensin-converting enzyme inhibitors, or angiotensin receptor blockers; discontinuation of NSAID therapy will usually lead to recovery to the pretreatment state.  No information is available regarding use NSAIDs in patients with advanced renal disease; the renal effects of NSAIDs may hasten the progression of renal dysfunction in patients with preexisting renal disease.  Volume status should be corrected in dehydrated or hypovolemic patients prior to initiating treatment.  Renal function should be monitored during therapy in patients with renal or liver dysfunction, heart failure, dehydration, or hypovolemia.  NSAIDs should be avoided in patients with advanced renal disease unless the benefits are expected to outweigh the risk of worsening renal function; if an NSAID is used in such patients, they should be monitored for signs of worsening renal function.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6557, 0, 'Etodolac', 'Thrombosis', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal.  This risk may occur early in treatment and may increase with duration of use.  Clinical trials of several cyclooxygenase-2 (COX-2) selective and nonselective NSAIDs of up to 3 years duration have supported this increased risk.  It is unclear from available data if the risk for cardiovascular thrombotic events is similar for all NSAIDs.  Therapy with NSAIDs should be administered cautiously in patients with a history of cardiovascular or cerebrovascular disease.  Patients should be treated with the lowest effective dosage for the shortest duration necessary.  Appropriate antiplatelet therapy should be administered to patients requiring cardioprotection; however, there is no consistent evidence that concurrent use of aspirin mitigates the increased risk of serious cardiovascular thrombotic events associated with NSAID use, while the risk of serious gastrointestinal events is increased.  Physicians and patients should remain alert for the development of adverse cardiovascular events throughout the entire duration of therapy, even without prior cardiovascular symptoms.  Patients should be advised to promptly seek medical attention if they experience symptoms of cardiovascular thrombotic events (including chest pain, shortness of breath, weakness, or slurring of speech).NSAIDs are contraindicated in the setting of coronary artery bypass graft (CABG) surgery.  Two large clinical trials of a COX-2 selective NSAID for the treatment of pain in the first 10 to 14 days following CABG surgery found an increased incidence of myocardial infarction and stroke.The use of NSAIDs should be avoided in patients with a recent myocardial infarction unless the benefits are expected to outweigh the risk of recurrent cardiovascular thrombotic events.  If an NSAID is used in patients with a recent myocardial infarction, they should be monitored for signs of cardiac ischemia.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6558, 0, 'Etodolac', 'Anemia', 'Anemia has been reported in patients treated with nonsteroidal anti-inflammatory drugs (NSAIDs).  This may be due to fluid retention, occult/gross blood loss, or an incompletely described effect on erythropoiesis.  Hemoglobin or hematocrit should be monitored in patients with any signs/symptoms of anemia or blood loss, especially during long-term therapy.  NSAIDs may increase risk of bleeding events; comorbid conditions (e.g., coagulation disorders; concomitant use of warfarin/other anticoagulants, antiplatelet agents, serotonin/serotonin norepinephrine reuptake inhibitors) may increase this risk, and patients with these conditions should be monitored for signs of bleeding.  Therapy with NSAIDs should be administered cautiously in patients with or predisposed to anemia.  Clinical monitoring of hematopoietic function may be appropriate, particularly during chronic therapy.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6559, 0, 'Etodolac', 'Heart Failure', 'Fluid retention and edema have been observed in patients treated with nonsteroidal anti-inflammatory drugs (NSAIDs), including some topical formulations.  These drugs should be avoided in patients with severe heart failure unless the benefits are expected to outweigh the risk of worsening heart failure.  If an NSAID is used in patients with severe heart failure, they should be monitored for signs of worsening heart failure.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6560, 0, 'Etodolac', 'Liver Diseases', 'Borderline elevations of 1 or more liver tests may occur in up to 15% of patients treated with nonsteroidal anti-inflammatory drugs (NSAIDs).  These laboratory abnormalities may progress, remain unchanged, or regress with continuing therapy.  Elevations of ALT or AST (at least 3 times the upper limit of normal) have been reported in about 1% of patients in clinical trials.  In addition, rare (sometimes fatal) cases of severe hepatotoxicity, including liver necrosis, hepatic failure, jaundice, and fulminant hepatitis have been reported.  Therapy with NSAIDs should be administered cautiously in patients with preexisting liver disease.  Periodic monitoring of liver function is recommended during prolonged therapy.  NSAIDs are also highly protein-bound and some are extensively metabolized by the liver.  Metabolic activity and/or plasma protein binding may be altered in patients with hepatic impairment.  A dosage reduction may be required in some cases.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6561, 0, 'Etodolac', 'Hyperkalemia', 'Increases in serum potassium concentration (including hyperkalemia) have been reported with use of nonsteroidal anti-inflammatory drugs (NSAIDs), even in some patients without renal impairment.  In patients with normal renal function, these effects have been attributed to a hyporeninemic-hypoaldosteronism state.  Caution is advised in patients with hyperkalemia.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6562, 0, 'Etodolac', 'Hypertension', 'Nonsteroidal anti-inflammatory drugs (NSAIDs), including topicals, can lead to new onset of hypertension or worsening of preexisting hypertension, either of which can contribute to the increased incidence of cardiovascular events.  NSAIDs should be used with caution in patients with hypertension.  Blood pressure should be monitored closely during the initiation of NSAID therapy and throughout the course of therapy.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6563, 0, 'Etodolac', 'Blood Platelet Disorders', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) reversibly inhibit platelet adhesion and aggregation and may prolong bleeding time in some patients.  With the exception of aspirin, the platelet effects seen with most NSAIDs at usual recommended dosages are generally slight and of relatively short duration but may be more pronounced in patients with underlying hemostatic abnormalities.  Thrombocytopenia has also been reported rarely during NSAID use.  Therapy with NSAIDs should be administered cautiously in patients with significant active bleeding or a hemorrhagic diathesis, including hemostatic and/or coagulation defects associated with hemophilia, vitamin K deficiency, hypoprothrombinemia, thrombocytopenia, thrombocytopathy, or severe hepatic impairment.  NSAIDs that selectively inhibit cyclooxygenase-2 (i.e., COX-2 inhibitors) do not appear to affect platelet function or bleeding time at indicated dosages and may be preferable if risk of bleeding is a concern.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6564, 0, 'Aminocaproic acid', 'Muscular Diseases', 'Skeletal muscle toxicity ranging from mild myalgia to rhabdomyolysis has been reported rarely during prolonged administration of aminocaproic acid.  Therapy with aminocaproic acid should be administered cautiously in patients with or predisposed to myopathy.  Clinical monitoring of muscle enzymes (particularly CPK) are recommended.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6565, 0, 'Aminocaproic acid', 'Kidney Diseases', 'Aminocaproic acid is primarily eliminated by the kidney.  Approximately 65% of aminocaproic acid is excreted unchanged in the urine.  Serum concentrations of aminocaproic acid can be increased in patients with renal impairment.  Therapy with aminocaproic acid should be administered with extreme caution in patients with upper urinary tract bleeding.  Glomerular capillary thrombosis or clots in the renal pelvis and ureters have occurred in patients with upper urinary tract bleeding during aminocaproic acid therapy.  Clinical monitoring of renal function, clot lysis activity and fibrinolytic determinants (profibrinolysin, fibrinolysin and anti-fibrinolysin) is recommended.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6566, 0, 'Aminocaproic acid', 'Disseminated Intravascular Coagulation', 'The use of aminocaproic acid is contraindicated in patients with active intravascular clotting.  Aminocaproic acid should not be used in the presence of disseminated intravascular coagulation (DIC) without concomitant administration of heparin.  Aminocaproic acid inhibits plasminogen activators and, to a lesser extent, plasmin activity, resulting in decreased fibrinolysis.  Clinical monitoring of clot lysis activity and fibrinolytic determinants (profibrinolysin, fibrinolysin and anti-fibrinolysin) is recommended.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6567, 0, 'Ethambutol', 'Optic Neuritis', 'Ethambutol is contraindicated in patients with known optic neuritis unless clinical judgement determines that it may be used.  Ethambutol can produce decreases in visual acuity which appear to be due to optic neuritis.  This may be related to dose and duration of treatment, and is generally reversible when administration of the drug is discontinued promptly.  However, irreversible blindness has been reported.  Ethambutol should not be used in patients who are unable to identify and report visual side effects or changes in vision such as young children or unconscious patients.  It should be administered cautiously and only after careful consideration of risks and benefits in patients with preexisting visual defects such as cataracts, diabetic retinopathy, or recurrent inflammatory conditions of the eye.  Ophthalmologic testing of visual acuity, visual field, and color discrimination is required before and during treatment.  However, visual changes may be difficult to evaluate in some cases, since they may be related to the underlying disease rather than the drug.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6568, 0, 'Ethambutol', 'Hepatic Insufficiency', 'Liver toxicities including fatalities have been reported when using ethambutol.  Caution is advised, especially if using in patients with hepatic impairment.  Baseline and periodic assessment of hepatic function should be performed.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6569, 0, 'Ethambutol', 'Hyperuricemia', 'Ethambutol may commonly cause hyperuricemia, which has been reported in up to two-thirds of treated patients.  Occasionally, it has led to joint arthralgias and gouty arthritis after 1 to 2 months of therapy.  Serum uric acid levels should be monitored in patients with preexisting hyperuricemia or gout during ethambutol therapy, and appropriate measures (e.g., administration of uricosuric agents) taken to prevent the development or exacerbation of gout.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6570, 0, 'Ethambutol', 'Kidney Diseases', 'Ethambutol is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from ethambutol, including optic neuritis, due to decreased drug clearance.  Therapy with ethambutol should be administered cautiously in patients with renal impairment.  Dosage adjustments are recommended in moderate renal impairment but should be based on serum levels of ethambutol.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6571, 0, 'Everolimus', 'Liver Diseases', 'Everolimus exposure was increased in patients with mild (Child-Pugh class A), moderate (Child-Pugh class B), and severe (Child-Pugh class C) hepatic impairment.  In patients with mild or moderate hepatic impairment, a dose reduction is recommended.  Patients with severe hepatic impairment, everolimus may be used at a reduced dose if the desired benefit outweighs the risk.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6572, 0, 'Everolimus', 'Kidney Diseases', 'Cases of renal failure, including acute renal failure and elevations of serum creatinine and proteinuria, some with a fatal outcome, have been observed in patients treated with inhibitors of mTOR (mammalian target of rapamycin).  Therapy with these agents should be administered cautiously in patients with renal dysfunction, in particularly where patients have additional risk factors that may further impair renal function.  Renal impairment is not expected to influence drug exposure, and no dosage adjustment is recommended in patients with renal impairment.  Monitoring of renal function, including measurement of blood urea nitrogen (BUN), urinary protein, or serum creatinine, is recommended prior to the start of therapy and periodically thereafter.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6573, 0, 'Everolimus', 'Hematologic Diseases', 'Hematologic abnormalities, including decreased levels of hemoglobin, lymphocytes, platelets, and white blood cell have been observed in patients taking everolimus.  Caution is recommended when treating patients predisposed to hematologic changes.  Periodic monitoring of complete blood count is recommended before starting therapy and periodically thereafter.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6574, 0, 'Everolimus', 'Hyperglycemia', 'Elevations in serum blood glucose levels have been reported in patients taking inhibitors of mTOR (mammalian target of rapamycin).  Monitoring of fasting serum glucose levels is recommended prior to the start of therapy and periodically thereafter.  Clinicians should achieve control of glucose levels before initiating therapy with these agents.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6575, 0, 'Everolimus', 'Hypercholesterolemia', 'Elevations in cholesterol and triglyceride levels have been reported in patients taking inhibitors of mTOR (mammalian target of rapamycin).  Monitoring of fasting lipid profile is recommended prior to the start of therapy and periodically thereafter.  Clinicians should achieve control of lipid levels before initiating therapy with these agents.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6576, 0, 'Everolimus', 'Infections', 'The immunosuppressant effect of inhibitors of mTOR (mammalian target of rapamycin) may decrease host resistance to infectious agents and may predispose patients to bacterial, fungal, viral, or protozoal infections, infections with opportunistic pathogens, and reactivation of viral infections.  Therapy with these agents should be administered with caution in patients with an infection, particularly active infections or any untreated systemic fungal, bacterial, parasitic, or viral infection.  It is recommended to complete the treatment of preexisting invasive fungal infections prior to starting treatment and if a diagnosis of invasive systemic fungal infection is made during treatment, discontinue and treat with appropriate antifungal therapy.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6577, 0, 'Everolimus', 'Wounds and Injuries', 'Inhibition of mTOR activity results in delays of wound healing and increases the occurrence of wound-related complications, which might require surgical intervention.  Patients with central nervous system tumors (primary CNS tumor or metastases) and/or receiving anticoagulation therapy may be at an increased risk of developing intracerebral bleeding (including fatal outcomes).  Caution is recommended when using these agents, particularly in the perioperative period.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6578, 0, 'Exemestane', 'Osteoporosis', 'Reductions in bone mineral density (BMD) over time are seen with the use of exemestane.  Women with osteoporosis or at risk of osteoporosis should have their BMD formally assessed by densitometry at treatment initiation.  Monitoring for BMD loss is recommended, and treatment for it should be started as appropriate.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6579, 0, 'Exemestane', 'Vitamin D Deficiency', 'Routine assessment of vitamin D levels prior to the start of aromatase inhibitor treatment should be performed, due to the high prevalence of vitamin D deficiency in women with early breast cancer.  Women with vitamin D deficiency should receive supplementation.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6580, 0, 'Exenatide', 'Kidney Failure, Chronic', 'Exenatide should not be used in patients with severe renal impairment (CrCl <30 mL/min) or end-stage renal disease, and should be used with caution in patients with moderate renal impairment and renal transplantation.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6581, 0, 'Exenatide', 'Pancreatitis', 'The use of GLP-1 receptor agonists has been associated with rare reports of acute pancreatitis.  Other antidiabetic therapies should be considered in patients with a previous history of pancreatitis, although it is not known if they are at increased risk.  Patients receiving treatment with GLP-1 receptor agonists should be observed carefully for signs and symptoms of pancreatitis.  If this diagnosis is suspected, the treatment should be discontinued immediately and appropriate management should be initiated.  Treatment with GLP-1 receptor agonists should be permanently discontinued if pancreatitis is confirmed.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6582, 0, 'Exenatide', 'Thyroid Neoplasms', 'GLP-1 receptor agonist antidiabetic drugs are contraindicated in patients with a personal or family history of medullary thyroid carcinoma and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN2).  Carcinogenicity studies in rodents and limited postmarketing data suggest that GLP-1 inhibitors may cause a dose-related and treatment duration-related increase in risk of thyroid C-cell tumors, although a causal relationship has not been established.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6583, 0, 'Exenatide', 'Kidney Diseases', 'There have been reports of acute renal failure and worsening of chronic renal failure sometimes requiring hemodialysis in patients treated with GLP-1 receptor inhibitors.  Some of these events occurred in patients without known underlying renal disease.  These drugs should be used with caution in patients with renal impairment, especially during treatment initiation or dose escalation.  Patients should be monitored, especially if they report severe gastrointestinal reactions such as nausea, vomiting, diarrhea, or dehydration.  The frequency of gastrointestinal events is increased as renal function declines.  There is limited clinical experience with most of these drugs in patients with severe renal impairment.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6584, 0, 'Ethotoin', 'Hematologic Diseases', 'Hematologic toxicities have been associated with the use of hydantoin anticonvulsants, particularly mephenytoin.  Thrombocytopenia, leukopenia, neutropenia, agranulocytosis, pancytopenia and, rarely, hemolytic anemia, aplastic anemia and pure red cell aplasia have been reported.  Therapy with hydantoin anticonvulsants should be administered cautiously in patients with preexisting blood dyscrasias and/or bone marrow depression.  Complete blood counts, including platelets, should be performed prior to initiating therapy and regularly for several months thereafter.  For mephenytoin, the manufacturer recommends performing counts after 2 weeks on a low dosage, after another 2 weeks when full dosage is reached, then monthly for a year, and every 3 months thereafter.  Marked depression of blood counts may be indication for withdrawal of hydantoin therapy.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6585, 0, 'Ethotoin', 'Liver Diseases', 'Hydantoin anticonvulsants are primarily metabolized by the liver.  Both metabolic activity and plasma protein binding may be significantly altered in patients with liver disease, resulting in elevated drug levels (total and unbound fraction) and increased risk of toxicity.  Therapy with hydantoin anticonvulsants should be administered cautiously in patients with impaired hepatic function.  Reduced dosages and slower titration may be necessary.  In addition, periodic monitoring of liver function is recommended, since the use of anticonvulsants, including hydantoins, has been associated with hepatotoxicity related to drug hypersensitivity.  Hepatic failure and death have occurred.  Hydantoin therapy should be discontinued and not readministered if evidence of liver damage is observed and felt to be drug-related.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6586, 0, 'Ethotoin', 'Porphyrias', 'The use of phenytoin has rarely been associated with exacerbation of porphyria.  Therapy with phenytoin should be administered cautiously in patients with porphyria.  The same precaution should also be observed with other hydantoin anticonvulsants (i.e. ethotoin and mephenytoin) because of their structural and pharmacological similarities to phenytoin.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6587, 0, 'Ethotoin', 'Depressive Disorder', 'Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication.  Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo.  AEDs should be administered cautiously in patients with depression or other psychiatric disorders.  The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.  Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior.  If patients have symptoms of suicidal ideation or behavior, a dosage reduction or treatment discontinuation should be considered.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6588, 0, 'Ethotoin', 'Hyperglycemia', 'Phenytoin, particularly in high dosages, may cause hyperglycemia by inhibiting insulin release.  The drug may also raise serum glucose levels in diabetic patients.  Therapy with phenytoin should be administered cautiously in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia.  Patients with diabetes mellitus should be monitored more closely during phenytoin therapy, and their antidiabetic regimen adjusted accordingly.  The same precautions should also be observed with other hydantoin anticonvulsants (i.e. ethotoin and mephenytoin) because of their structural and pharmacological similarities to phenytoin.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6589, 0, 'Ethotoin', 'Anemia, Megaloblastic', 'Hydantoin anticonvulsants may interfere with folate metabolism and precipitate macrocytosis and megaloblastic anemia, which usually respond to folic acid therapy.  These reactions have been fairly uncommon but may be of concern in patients with megaloblastic anemia or folate deficiency receiving hydantoin therapy.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6590, 0, 'Ethotoin', 'Osteomalacia', 'Phenytoin may interfere with vitamin D metabolism.  Hypocalcemia and osteomalacia have been reported.  Therapy with phenytoin should be administered cautiously in patients with preexisting vitamin D deficiency.  The same precaution should also be observed with other hydantoin anticonvulsants (i.e. ethotoin and mephenytoin) because of their structural and pharmacological similarities to phenytoin.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6591, 0, 'Etonogestrel', 'Abnormal Genital Bleeding', 'The use of contraceptives is contraindicated when there is an undiagnosed abnormal genital bleeding.  Adequate diagnostic measures should be undertaken to rule out the presence of any malignancy.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6592, 0, 'Etonogestrel', 'Liver Neoplasms', 'The use of oral contraceptives is contraindicated in patients with liver tumors.  An increased risk of benign hepatic adenomas and hepatocellular carcinomas has been associated with long-term, oral estrogen- progestin contraceptive use of at least 4 years and 8 years, respectively.  Although these tumors are rare and have not been reported with other types of estrogen or progestogen therapies, any preparation containing estrogens and/or progestogens should probably be avoided in patients with existing tumors of the liver.  Hepatic hemangiomas and nodular hyperplasia of the liver have been reported with isolated estrogen therapy.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6593, 0, 'Etonogestrel', 'Breast Neoplasms', 'The use of progestogens is considered by manufacturers to be contraindicated in patients with existing or suspected malignancy of the breast.  Some supportive data are available for medroxyprogesterone.  Specifically, medroxyprogesterone treatment may be associated with breast cancer, primarily when the drug is administered intramuscularly.  A pooled analysis of two case-control studies, one from the World Health Organization and the other from New Zealand, revealed a small overall relative risk of breast cancer in women who have ever used intramuscular medroxyprogesterone acetate.  The relative risk was higher in the subgroup of women who had initiated therapy within the previous 5 years.  Thus, an increased risk (approximately 2-fold) is associated with intramuscular medroxyprogesterone use in the first 5 years.  A more recent U.S. study also found a statistically significant increase in breast cancer risk among recent users (defined as last use within the past five years) who used depo-medroxyprogesterone acetate for 12 months or longer.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6594, 0, 'Etonogestrel', 'Liver Diseases', 'The use of progestogens, in general, is contraindicated in patients with impaired hepatic function or liver disease.  There are little or no data concerning the pharmacokinetic disposition of the different progestogens in patients with hepatic disease.  However, most hormones, including progestational hormones, are known to be extensively metabolized by the liver.  Medroxyprogesterone should not be used by women with significant liver disease and should be discontinued if jaundice or disturbances of liver function occur.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6595, 0, 'Etonogestrel', 'Thromboembolism', 'The use of progestogens, in general, is considered by manufacturers to be contraindicated in patients with active thrombophlebitis, cerebrovascular disease, or a current or past history of thromboembolic disorders.  While the role of progestogens in the development of thromboembolic events associated with hormonal therapy is often unclear and thought to be secondary to that of estrogens, it may not be insignificant.  Medroxyprogesterone, a common progestational agent, has been shown to produce a hypercoagulable state in high dosages.  Whether or not this effect contributes to the development of thrombotic events is unknown.  However, thrombophlebitis and pulmonary embolism have been reported with megestrol, an antineoplastic and progestational agent.  In addition, an increased risk of nonfatal venous thrombosis has been associated with oral contraceptive combinations containing desogestrel or gestodene relative to those that contain other progestins (e.g., levonorgestrel, norethindrone), suggesting some degree of hemostatic effect by progestogens.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6596, 0, 'Etonogestrel', 'Depressive Disorder', 'The use of oral contraceptives has been associated with an increased incidence of depression.  It is uncertain whether this effect is related to the estrogenic or the progestogenic component of the contraceptive, although excess progesterone activity is associated with depression.  Patients with a history of depression receiving estrogen and/or progestogen therapy should be followed closely.  The manufacturer of medroxyprogesterone recommends monitoring patients who have a history of depression and to not re- administer medroxyprogesterone if depression recurs.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6597, 0, 'Etonogestrel', 'Water-Electrolyte Imbalance', 'Estrogens and progestogens may cause fluid retention, particularly when given in high dosages or for prolonged periods.  Therapy with these agents should be administered cautiously in patients who have preexisting problems with excess fluid.  In addition, patients with conditions that may be adversely affected by fluid accumulation, such as asthma, epilepsy, migraine, and cardiovascular or renal dysfunction, should be observed for exacerbation of their condition during estrogen and/or progestogen therapy.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6598, 0, 'Etonogestrel', 'Eye Diseases', 'Estrogens and progestogens may cause retinal thrombosis.  Oral contraceptives should be discontinued if there is unexplained partial or complete loss of vision; onset of proptosis or diplopia; papilledema; or retinal vascular lesions.  Therapy with these agents should be administered cautiously in patients who have preexisting ocular problems and appropriate diagnostic and therapeutic measures should be instituted.  Contact lens wearers who develop visual changes or changes in lens tolerance should be assessed by an ophthalmologist.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6599, 0, 'Etonogestrel', 'Gallbladder Diseases', 'Etonogestrel might increase the risk of gallbladder disease.  Caution and monitoring of symptoms is suggested in patients with history or active gallbladder disease.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6600, 0, 'Ezogabine', 'Depressive Disorder', 'Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication.  Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo.  AEDs should be administered cautiously in patients with depression or other psychiatric disorders.  The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.  Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior.  If patients have symptoms of suicidal ideation or behavior, a dosage reduction or treatment discontinuation should be considered.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6601, 0, 'Ezogabine', 'Alcoholism', 'The use ezogabine with alcohol increases the systemic exposure to ezogabine.  Patients should be advised of possible worsening of dose-related adverse reactions if they take ezogabine with alcohol.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6602, 0, 'Ezogabine', 'Hepatic Insufficiency', 'No dosage adjustment is recommended in patients with mild hepatic impairment.  Dosage adjustment is recommended in patients with moderate or severe hepatic impairment.  Close monitoring is recommended.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6603, 0, 'Ezogabine', 'Hyperbilirubinemia', 'Ezogabine has been shown to interfere with clinical laboratory assays of both serum and urine bilirubin, which can result in falsely elevated readings.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6604, 0, 'Ezogabine', 'Long QT Syndrome', 'QT prolongation was observed in patients treated with ezogabine.  It is recommended to monitor the QT interval when ezogabine is used with medicines known to increase QT interval and in patients with known prolonged QT interval, congestive heart failure, ventricular hypertrophy, hypokalemia, or hypomagnesemia.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6605, 0, 'Ezogabine', 'Kidney Diseases', 'Dosage adjustment is recommended in patients with creatinine clearance <50 mL/min or patients with end-stage renal disease receiving hemodialysis.  A supplemental dose is recommended immediately following hemodialysis.  Close monitoring is recommended.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6606, 0, 'Ezogabine', 'Retinal Diseases', 'The use of ezogabine can cause abnormalities of the retina.  Patients should have baseline ophthalmologic testing by an ophthalmic professional and follow-up testing as clinically indicated.  Patients who cannot be monitored should not be treated with ezogabine.  The ophthalmologic monitoring program should include visual acuity testing, dilated fundus photography, and optical coherence tomography.  Additional testing may include fluorescein angiograms, perimetry, and electroretinograms.  If retinal pigmentary abnormalities or vision changes are detected, ezogabine should be discontinued unless no other suitable treatment options are available and the benefits of treatment outweigh the potential risk of vision loss.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6607, 0, 'Ezogabine', 'Urinary Retention', 'The use of ezogabine may cause urinary retention.  A comprehensive evaluation of urologic symptoms should be conducted prior to and during treatment with ezogabine as clinically indicated.  It is recommended to monitor closely for urologic symptoms in patients at risk.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6608, 0, 'Etoposide', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6609, 0, 'Etoposide', 'Bone Marrow Failure Disorders', 'Etoposide induces dose-related myelosuppression.  Leukopenia, thrombocytopenia, and anemia have been reported during etoposide therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Therapy should be administered cautiously in patients whose bone marrow reserve may be severely depressed and should be withheld if an absolute neutrophil counts fall below 500/mm3 and/or platelet counts fall below 50,000/mm3.  Clinical monitoring of hematopoetic function is recommended.  Periodic complete blood counts should be done during the course of etoposide treatment and it should be performed prior to each cycle of therapy and at appropriate intervals during and after therapy.  At least one determination should be done prior to each dose.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6610, 0, 'Etoposide', 'Kidney Diseases', 'Etoposide is primarily eliminated by the kidney.  Less than 50% is eliminated as unchanged drug in the urine.  Reduced clearance, increased AUC, and decreased volume of distribution have been noted in patients with impaired renal function.  Therapy should be administered cautiously and dosages reduced in patients with compromised renal function.  Patients with a creatinine clearance between 15 to 50 mL/min should receive 75% of the recommended dosage of etoposide.  Data are not available in patients with creatinine clearances <15 mL/min and further dosage reductions are recommended.  Clinical monitoring of renal function is recommended.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6611, 0, 'Ezetimibe', 'Liver Diseases', 'Ezetimibe is partially metabolized in the liver.  After a single 10 mg dose, the mean area under the plasma concentration-time curve (AUC) for total ezetimibe was increased approximately 1.7-fold, 3- to 4-fold, and 5- to 6-fold, in patients with mild (Child-Pugh score 5 to 6), moderate (Child-Pugh score 7 to 9), and severe hepatic impairment (Child-Pugh score 10 to 15), respectively, compared to healthy subjects.  Due to the unknown effects of increased exposure to ezetimibe in patients with moderate or severe hepatic impairment, therapy with ezetimibe is not recommended in these patients.  The combination of ezetimibe with a statin is contraindicated in patients with active liver disease or unexplained persistent elevations in hepatic transaminase levels.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6612, 0, 'Ezetimibe', 'Rhabdomyolysis', 'Myopathy and rhabdomyolysis are known adverse reactions to statins and other lipid-lowering drugs.  In post-marketing experience with ezetimibe, cases of myopathy and rhabdomyolysis have been reported.  Most patients who developed rhabdomyolysis were taking a statin prior to initiating ezetimibe.  However, rhabdomyolysis has been reported with ezetimibe monotherapy and with the addition of ezetimibe to agents known to be associated with increased risk of rhabdomyolysis, such as fibrates.  In the presence of muscle symptoms and a CPK level >10  the ULN indicative of myopathy, ezetimibe and any statin or fibrate that the patient is taking concomitantly should be immediately discontinued if myopathy is diagnosed or suspected.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6613, 0, 'Ezetimibe', 'Kidney Diseases', 'No dosage adjustment of ezetimibe is necessary in patients with renal impairment.  However, when ezetimibe therapy is given in combination with simvastatin in patients with moderate to severe renal impairment (estimated glomerular filtration rate <60 mL/min/1.73 m2), doses of simvastatin exceeding 20 mg should be used with caution and close monitoring is recommended.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6614, 0, 'Factor XIII (human)', 'Thromboembolism', 'Thromboembolic complications have been reported after therapy with factor XIII, particularly in patients with risk factors for thrombosis.  Monitor for early signs and symptoms of thrombosis such as pain, swelling, discoloration, dyspnea, cough, hemoptysis, and syncope and have prophylaxis measures against thromboembolism instituted according to current recommendations.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6615, 0, 'Factor IX Complex (Human)', 'Thromboembolism', 'The use of factor IX complex concentrates has been associated with the development of thromboembolic complications.  Patients at increased risk for thrombosis include those undergoing surgery, post surgery, with known liver disease, and with signs of fibrinolysis, thrombosis, or disseminated intravascular coagulation.  When administering factor IX complex to these high-risk patients, monitor for early signs of consumptive coagulopathy with appropriate laboratory testing.  Only administer factor IX complex to patients when the benefits outweigh the risks.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6616, 0, 'Aminoglutethimide', 'Adrenal Insufficiency', 'Aminoglutethimide suppresses adrenal function and is indicated for the treatment of selected cases of Cushing''s syndrome.  It generally should not be used in patients with adrenocortical insufficiency.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6617, 0, 'Fenfluramine', 'Heart Diseases', 'Serotonergic drugs with 5-HT2B receptor agonist activity, including fenfluramine have been associated with valvular heart disease.  Exercise care when using this agent in patients with cardiac disease.  Cardiac monitoring is required prior to starting, during, and after treatment.  If valvular heart disease is observed on an echocardiogram, the prescriber must consider the benefits versus the risks of initiating or continuing treatment.  Echocardiograms should be repeated every six months, and once 3-6 months posttreatment.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6618, 0, 'Fenfluramine', 'Lung Diseases', 'Serotonergic drugs with 5-HT2B receptor agonist activity, including fenfluramine, have been associated with pulmonary arterial hypertension.  Exercise care when using this agent in patients with pulmonary disease.  Cardiac monitoring is required before starting, during, and after treatment.  Cardiac monitoring via echocardiogram can identify evidence of pulmonary arterial hypertension.  If pulmonary arterial hypertension is observed on an echocardiogram, the prescriber must consider the benefits versus the risks of initiating or continuing treatment.  Echocardiograms should be repeated every six months, and once 3-6 months posttreatment.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6619, 0, 'Fenfluramine', 'Depressive Disorder', 'Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication.  Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo.  AEDs should be administered cautiously in patients with depression or other psychiatric disorders.  The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.  Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior.  If patients have symptoms of suicidal ideation or behavior, a dosage reduction or treatment discontinuation should be considered.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6620, 0, 'Fenfluramine', 'Bipolar Disorder', 'Central nervous system (CNS) stimulants may induce a mixed/manic episode in patients with bipolar disorder.  Prior to initiating treatment, screen patients for risk factors for developing a manic episode (e.g., comorbid or history of depressive symptoms or a family history of suicide, bipolar disorder, and depression).  Close monitoring is recommended when using these agents in patients with bipolar disorders.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6621, 0, 'Fenfluramine', 'Psychotic Disorders', 'Central nervous system (CNS) stimulants may exacerbate symptoms of behavior disturbance and thought disorder in patients with a preexisting psychotic disorder.  Close monitoring is recommended when using these agents in patients with psychotic disorders.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6622, 0, 'Fenfluramine', 'Alcoholism', 'Fenfluramine can cause somnolence, sedation, and lethargy.  Central nervous system depressants, including alcohol, could potentiate these effects.  Exercise caution when using this agent in alcoholic patients or those at risk of sedation.  Close monitoring is advised.  Advise patients not to drive or operate machinery until they know how this drug will affect them.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6623, 0, 'Fenfluramine', 'Anorexia', 'Fenfluramine can cause decreases in appetite and weight.  Exercise care when using this agent in patients at risk of decreased appetite or weight.  It is recommended to monitor the growth of pediatric patients carefully.  Weight should be monitored regularly during treatment, and dose modifications should be considered if a decrease in weight is observed.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6624, 0, 'Fenfluramine', 'Hypertension', 'Fenfluramine can cause an increase in blood pressure.  Exercise care when using this agent in hypertensive patients.  It is recommended to monitor blood pressure in patients treated with fenfluramine.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6625, 0, 'Fenfluramine', 'Liver Failure', 'Fenfluramine is primarily metabolized to norfenfluramine by CYP450 1A2, CYP450 2B6, and CYP450 2D6.  The use of fenfluramine in patients with hepatic impairment is not recommended.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6626, 0, 'Fenfluramine', 'Kidney Diseases', 'Most of an orally administered dose of fenfluramine (greater than 90%) is excreted in the urine as fenfluramine, norfenfluramine, or other metabolites.  The use of fenfluramine in patients with moderate or severe renal impairment is not recommended.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6627, 0, 'Fenfluramine', 'Vision Disorders', 'Fenfluramine can cause mydriasis and can precipitate angle-closure glaucoma.  Exercise care when using this agent in patients with visual disturbances.  Consider discontinuing treatment in patients with acute decrease in visual acuity or ocular pain.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6628, 0, 'Febuxostat', 'Hyperuricemia', 'No studies with febuxostat or lesinurad have been conducted in patients with secondary hyperuricemia (including organ transplant recipients).  The use of these drugs is contraindicated in patients where the uric acid formation is greatly increased, such as patients with malignant disease, tumor lysis syndrome or Lesch-Nyhan syndrome.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6629, 0, 'Febuxostat', 'Cardiovascular Diseases', 'Major adverse cardiovascular events (cardiovascular deaths, non- fatal myocardial infarctions and non- fatal strokes), were reported during clinical trials with some antihyperuricemic agents, such as febuxostat and lesinurad.  Although a causal relationship has not been established, caution is advised when used in patients with cardiovascular disease.  Monitoring for signs or symptoms of myocardial infarction or stroke is recommended.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6630, 0, 'Febuxostat', 'Kidney Diseases', 'There are insufficient data on the use of febuxostat in patients with severe renal impairment (ClCr less than 30 mL/min), therefore caution should be exercised on these patients.  No dose adjustment is needed in patients with mild or moderate renal impairment.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6631, 0, 'Febuxostat', 'Hepatic Insufficiency', 'No studies have been conducted in patients with severe hepatic impairment (Child-Pugh Class C), therefore caution should be exercised if using febuxostat or lesinurad on these patients.  No dose adjustment is necessary in patients with mild or moderate hepatic impairment.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6632, 0, 'Famotidine', 'Peptic Ulcer Hemorrhage', 'Histamine H2 receptor antagonists should not be used in the presence of vomit with blood, or bloody or black stools.  These might be serious conditions and the diagnosis needs to be ruled out.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6633, 0, 'Famotidine', 'Kidney Diseases', 'Famotidine is partially eliminated by the kidney as unchanged drug, the extent of which is dependent upon the route of administration (25% to 30% oral; 65% to 70% intravenous).  The elimination half-life of famotidine may be prolonged considerably in patients with severe renal impairment (CrCl < 10 mL/min), possibly exceeding 20 hours and approaching approximately 24 hours in anuric patients.  Since central nervous system adverse effects such as grand mal seizures and psychic disturbances have been reported in patients with moderate (CrCl < 50 mL/min) and severe renal impairment, dosage adjustments are recommended for these patients.  Reducing the normally recommended dosage by one-half or prolonging the dosing interval to 36 to 48 hours may be appropriate, depending on the patient''s clinical response.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6634, 0, 'Fedratinib', 'Liver Failure', 'The pharmacokinetics of fedratinib have not been evaluated in patients with severe hepatic impairment (total bilirubin > 3 times ULN and any AST), and its use should be avoided on these patients.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6635, 0, 'Fedratinib', 'Thiamine Deficiency', 'Serious and fatal encephalopathy, including Wernicke''s disease, has occurred in patients treated with fedratinib.  Wernicke''s encephalopathy is a neurologic emergency.  Assess thiamine levels in all patients prior to starting treatment, periodically during treatment, and as clinically indicated.  Do not start fedratinib in patients with thiamine deficiency; replete thiamine prior to treatment initiation.  If encephalopathy is suspected, immediately discontinue fedratinib and initiate parenteral thiamine.  Patients who develop any change in their mental status during treatment, including confusion or memory impairment, should be evaluated for potential encephalopathy (e.g., neurologic examination, thiamine level assessment, imaging).  Monitor until symptoms resolve or improve and thiamine levels normalize.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6636, 0, 'Fedratinib', 'Gastrointestinal Diseases', 'Gastrointestinal (GI) toxicities are the most frequent adverse reactions reported with fedratinib; diarrhea, nausea, and vomiting occurred in more than half of patients.  The median time to onset was 1 day, with 75% of cases occurring within 2 weeks of initiating therapy.  Consuming a high-fat meal with fedratinib may reduce GI adverse events.  Prophylactic antiemetic therapy (e.g., 5-HT3 receptor antagonists) should be considered.  Treat diarrhea with antidiarrheals at the first onset of symptoms.  For Grade 3 or higher nausea, vomiting, or diarrhea not responsive to supportive measures within 48 hours:  Interrupt this drug until resolved to Grade 1 or less or baseline; restart dose at 100 mg/day below the last given dose.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6637, 0, 'Fedratinib', 'Cardiovascular Diseases', 'In a major safety study of a Janus kinase (JAK) inhibitor, tofacitinib, in rheumatoid arthritis patients 50 years and older with at least 1 cardiovascular risk factor, higher rates of all-cause mortality (including sudden cardiovascular death) and major adverse cardiovascular events (MACE) (defined as cardiovascular death, myocardial infarction, and stroke) were observed with the JAK inhibitor when compared with tumor necrosis factor (TNF) blockers; patients who are current or past smokers are at additional increased risk.  Based on a shared mechanism of action, this risk should be considered for other JAK inhibitors, including baricitinib, upadacitinib, ruxolitinib, fedratinib, and pacritinib.  Before starting or continuing therapy, the benefits and risks for the individual patient should be considered, especially in patients with other cardiovascular risk factors and patients who are current or past smokers.  Patients should be informed about the symptoms of serious cardiovascular events and what to do if they occur.  Tofacitinib, baricitinib, and upadacitinib are indicated for patients with inadequate response or intolerance to 1 or more TNF blockers, but should be discontinued in patients who have experienced a myocardial infarction or stroke.  The dosage recommended for tofacitinib should not be exceeded; for the treatment of ulcerative colitis, tofacitinib should be used at the lowest effective dose and for the shortest duration needed to achieve and/or maintain therapeutic response.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6638, 0, 'Fedratinib', 'Neoplasms', 'Malignancies (including lymphomas and solid tumors) have been reported in patients treated with tofacitinib and other Janus kinase (JAK) inhibitors used to treat inflammatory conditions; lymphomas and other malignancies have been seen in patients treated with baricitinib or upadacitinib.  Patients who are current or past smokers are at additional increased risk of malignancies.  Based on a shared mechanism of action, this risk should be considered for other JAK inhibitors, including ruxolitinib, pacritinib, and fedratinib.  Before starting or continuing therapy, the benefits and risks for the individual patient should be considered, especially in patients with a known malignancy (other than successfully treated nonmelanoma skin cancer), patients who develop a malignancy during therapy, and patients who are current or past smokers.  Periodic skin examination is recommended for patients who are at increased risk for skin cancer.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6639, 0, 'Fedratinib', 'Thrombosis', 'Thrombosis (including deep venous thrombosis, pulmonary embolism, and arterial thrombosis) has occurred in patients treated for inflammatory conditions with Janus kinase (JAK) inhibitors, including baricitinib, tofacitinib, and upadacitinib; many of these adverse events were serious and some resulted in death.  Based on a shared mechanism of action, this risk should be considered for other JAK inhibitors, including ruxolitinib, fedratinib, and pacritinib.  Baricitinib, pacritinib, tofacitinib, and upadacitinib should be avoided in patients who may be at increased risk of thrombosis; for the treatment of ulcerative colitis, tofacitinib should be used at the lowest effective dose and for the shortest duration needed to achieve/maintain therapeutic response.  If symptoms of thrombosis occur, baricitinib, pacritinib, tofacitinib, and upadacitinib should be discontinued and patients should be evaluated promptly and treated appropriately.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6640, 0, 'Fedratinib', 'Kidney Diseases', 'Due to potential increase of exposure, patients with preexisting-existing moderate renal impairment require more intensive safety monitoring, and if necessary, dose modifications based on adverse reactions when treated with fedratinib.  Reduce fedratinib dose when administered to patients with severe renal impairment (CrCl 15 mL/min to 29 mL/min by Cockcroft-Gault).  No modification of the starting dose is recommended for patients with mild to moderate renal impairment (CrCl 30 mL/min to 89 mL/min by Cockcroft-Gault).', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6641, 0, 'Fedratinib', 'Cytopenias', 'Adverse hematologic effects including neutropenia, thrombocytopenia, and anemia have been associated with the use of fedratinib.  It is recommended to modify the starting dose in patients with a baseline platelet count (PLT) less than 50 x 10(9)/L.  Therapy should be interrupted until grade 4 thrombocytopenia, grade 3 thrombocytopenia with active bleeding, OR grade 4 neutropenia has normalized to grade 2 or lower (or baseline), then restart treatment at 100 mg/day below the last given dose.  Fedratinib dose reductions should be considered in patients who become dependent on red blood cell transfusions.  CBC counts should be monitored at baseline and every 3 months thereafter; treatment should be modified based on PLT levels and active bleeding.  Caution is recommended in patients who may be at increased risk.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6642, 0, 'Fedratinib', 'Pancreatitis', 'Pancreatitis occurred in patients receiving fedratinib.  It is recommended to monitor lipase and amylase prior to the start of therapy with fedratinib and periodically thereafter as clinically indicated.  Therapy should be interrupted until grade 3 or higher elevations in amylase and/or lipase levels resolve to grade 1 or less (or baseline), then restart treatment at 100 mg/day below the last given dose.  Care is recommended when using this agent in patients at risk.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6643, 0, 'Felodipine', 'Shock, Cardiogenic', 'In general, calcium channel blockers (CCBs) should not be used in patients with hypotension (systolic pressure < 90 mm Hg) or cardiogenic shock.  Due to potential negative inotropic and peripheral vasodilating effects, the use of CCBs may further depress cardiac output and blood pressure, which can be detrimental in these patients.  The use of verapamil and diltiazem is specifically contraindicated under these circumstances.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6644, 0, 'Felodipine', 'Coronary Artery Disease', 'Increased frequency, duration, and/or severity of angina, as well as acute myocardial infarction, have rarely developed during initiation or dosage increase of calcium channel blockers (CCBs), particularly in patients with severe obstructive coronary artery disease and those treated with immediate-release formulations.  The mechanism of this effect is not established.  Therapy with CCBs should be administered cautiously in patients with significant coronary artery disease.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6645, 0, 'Felodipine', 'Liver Diseases', 'Calcium channel blockers (CCBs) are extensively metabolized by the liver.  The half-lives of CCBs may be prolonged substantially in patients with severe hepatic impairment, with the potential for significant drug accumulation.  In addition, the use of some CCBs has been associated with elevations in serum transaminases, both with and without concomitant elevations in alkaline phosphatase and bilirubin.  While these effects may be transient and reversible, some patients have developed cholestasis or hepatocellular injury.  Therapy with CCBs should be administered cautiously and often at reduced dosages in patients with significantly impaired hepatic function.  Periodic monitoring of liver function is advised.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6646, 0, 'Felodipine', 'Heart Failure', 'Calcium channel blockers (CCBs) may have varying degrees of negative inotropic effect.  Congestive heart failure (CHF), worsening of CHF, and pulmonary edema have occurred in some patients treated with a CCB, primarily verapamil.  Some CCBs have also caused mild to moderate peripheral edema due to localized vasodilation of dependent arterioles and small blood vessels, which can be confused with the effects of increasing left ventricular dysfunction.  Although some CCBs have been used in the treatment of CHF, therapy with CCBs should be administered cautiously in patients with severe left ventricular dysfunction (e.g., ejection fraction < 30%) or moderate to severe symptoms of cardiac failure and in patients with any degree of ventricular dysfunction if they are receiving a beta-adrenergic blocker.  Likewise, caution is advised in patients with acute myocardial infarction and pulmonary congestion documented by X-ray on admission, since associated heart failure may be acutely worsened by administration of a CCB.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6647, 0, 'Famciclovir', 'Kidney Diseases', 'Penciclovir, the active antiviral metabolite of famciclovir, is primarily eliminated by the kidney.  Acute renal failure has been reported in patients with underlying renal disease who did not receive an appropriate dosage reduction.  Dosage adjustments are recommended for patients with moderate to severe renal impairment (CrCl < 60 mL/min).', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6648, 0, 'Famciclovir', 'Liver Diseases', 'Famciclovir is converted by the liver to the active antiviral metabolite, penciclovir.  The bioavailability of penciclovir following a dose of famciclovir was not affected in patients with well-compensated chronic liver disease.  However, there are no data on the pharmacokinetic disposition of famciclovir in patients with severe uncompensated liver disease.  Therapy with famciclovir should be administered cautiously in these patients, since the clinical significance of possible famciclovir accumulation is unknown.  Theoretically, famciclovir may also not be effective in these patients.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6649, 0, 'Fenofibrate', 'Liver Cirrhosis, Biliary', 'The use of fibric acid derivatives is contraindicated in patients with primary biliary cirrhosis.  These agents may further raise the already elevated cholesterol in these patients.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6650, 0, 'Fenofibrate', 'Cholelithiasis', 'The use of fibric acid derivatives is contraindicated in patients with gallbladder disease.  A significantly increased incidence of cholelithiasis has been observed in patients treated with the fibric acid derivative, clofibrate, presumably because of increased cholesterol excretion into the bile.  Based on two separate studies (the WHO study and the Coronary Drug Project study), clofibrate use was associated with twice the risk of developing cholelithiasis and cholecystitis requiring surgery.  Due to their structural and pharmacologic similarities, use of other fibric acid derivatives may be expected to carry the same risk.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6651, 0, 'Fenofibrate', 'Hypolipoproteinemias', 'There have been reports of severe decreases in HDL cholesterol (HDL-C) levels (as low as 2 mg/dL) occurring in diabetic and non-diabetic patients initiated on fibric acid derivatives therapy.  The decrease has been reported to occur within 2 weeks to years after initiation of therapy.  It is recommended that HDL-C levels be checked within the first few months after initiation therapy and if a severely depressed HDL-C level is detected, therapy with these agents should be withdrawn.  Monitor HDL-C level until it has returned to baseline, and therapy with these agents should not be re-initiated in these patients.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6652, 0, 'Fenofibrate', 'Liver Diseases', 'The use of fibric acid derivatives is contraindicated in patients with active liver disease or unexplained, persistent elevations of serum transaminases.  Fibric acid derivatives therapy is associated with dose-related hepatotoxicity, including biochemical abnormalities of liver function, hepatitis (hepatocellular, chronic active, as well as cholestatic) and, rarely, cirrhosis.  Postmarketing cases of severe drug-induced liver injury, including liver transplantation and death, have been reported.  Therapy with these agents should be administered cautiously in patients with a history of liver disease and/or heavy alcohol use.  Liver function tests, including serum transaminase levels and total bilirubin, should be performed at baseline and periodically throughout the duration of therapy.  Therapy should be discontinued if signs or symptoms of liver injury develop or if elevated enzyme levels persist (ALT or AST greater than 3 times the upper limit of normal, or if accompanied by elevation of bilirubin).  Do not restart therapy if there is no alternative explanation for the liver injury.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6653, 0, 'Fenofibrate', 'Kidney Diseases', 'The use of fibric acid derivatives is contraindicated in patients with significantly impaired renal function.  The rate of clearance of fenofibric acid has been shown to decrease substantially when CrCl is below 50 mL/min, with drug accumulation during chronic dosing.  Increased adverse effects, including rhabdomyolysis (with or without secondary renal failure) and severe hyperkalemia, have been associated with the use of fibric acid derivatives in patients with renal insufficiency.  Therapy with these agents should be administered cautiously in patients with mild or moderate renal impairment.  Close clinical monitoring is recommended during therapy.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6654, 0, 'Fenofibrate', 'Rhabdomyolysis', 'Severe myopathy, including rhabdomyolysis with acute renal failure secondary to myoglobinuria, has been reported rarely with the use of fibric acid derivatives.  The myopathy may be dose-related and is characterized by muscle aches and/or weakness in conjunction with increases in creatine phosphokinase (CPK) values exceeding 10 times the upper limit of normal.  Therapy with fibric acid derivatives should be administered cautiously in patients with preexisting myopathy or a myoneural disorder, since it may delay the recognition or confound the diagnosis of a drug-induced musculoskeletal effect.  Patients should be advised to report promptly any unusual muscle pain, tenderness or weakness, particularly if accompanied by malaise or fever.  Periodic CPK determinations may be considered in some patients, although the value of such monitoring is uncertain.  Therapy should be withdrawn if markedly elevated CPK levels occur or if drug-related myopathy is diagnosed or suspected.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6655, 0, 'Fenofibrate', 'Hematologic Diseases', 'Mild to moderate hemoglobin, hematocrit and white blood cell decreases have been observed in patients following initiation of fibric acid derivatives therapy.  However, these levels stabilize during long-term administration.  Thrombocytopenia and agranulocytosis have been reported in individuals treated with these agents.  Caution is recommended when treating patients predisposed to hematologic changes.  Periodic monitoring of red and white blood cell counts is recommended during the first 12 months of therapy.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6656, 0, 'Felbamate', 'Anemia, Aplastic', 'The use of felbamate is contraindicated in patients with bone marrow suppression or a current or prior history of blood dyscrasias.  A marked increase in the incidence of aplastic anemia has been associated with the use of felbamate, reportedly exceeding 100 times the incidence observed in the general population (2 to 5 per million persons per year).  In the few cases that have been reported in felbamate patients, the onset of clinical manifestations of aplastic anemia ranged from 5 to 30 weeks.  However, the injury to bone marrow stem cells that is believed to be ultimately responsible for the anemia may occur much earlier.  Currently, it is not known whether the risk is related to dose, duration of exposure, and/or concomitant use of other antiepileptic or myelotoxic drugs.  Expert hematologic consultation should be available for all patients treated with felbamate.  Since aplastic anemia typically develops without premonitory clinical or laboratory signs, it should be borne in mind that routine blood testing may not be reliably used to prevent development of the syndrome.  However, in some cases, it may allow the detection of hematologic changes before the condition is full-blown.  Felbamate therapy should be withdrawn if evidence of bone marrow depression is observed.  Patients who are discontinued from the drug may remain at risk for developing anemia for a variable and unknown period afterwards and should be monitored accordingly.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6657, 0, 'Felbamate', 'Liver Diseases', 'The use of felbamate is contraindicated in patients with a history of hepatic impairment.  A marked increase in the incidence of hepatic failure, some resulting in fatality, has been associated with the use of felbamate relative to that expected in the general population (approximately 2000 cases per year).  Currently, it is not known whether the risk is related to dose, duration of exposure, and/or concomitant use of other antiepileptic or hepatotoxic drugs.  All patients treated with felbamate should have serum transaminase and bilirubin levels checked prior to initiating therapy and at 1- to 2-week intervals while treatment continues.  Felbamate therapy should be withdrawn if abnormal liver function tests occur.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6658, 0, 'Felbamate', 'Kidney Diseases', 'Felbamate is partially eliminated by the kidney as unchanged drug (approximately 40% to 50% of absorbed dose).  The plasma clearance of felbamate may be decreased and the half-life prolonged in patients with impaired renal function.  Therapy with felbamate should be administered cautiously in patients with renal impairment.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6659, 0, 'Felbamate', 'Depressive Disorder', 'Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication.  Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo.  AEDs should be administered cautiously in patients with depression or other psychiatric disorders.  The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.  Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior.  If patients have symptoms of suicidal ideation or behavior, a dosage reduction or treatment discontinuation should be considered.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6660, 0, 'Fenofibric acid', 'Liver Cirrhosis, Biliary', 'The use of fibric acid derivatives is contraindicated in patients with primary biliary cirrhosis.  These agents may further raise the already elevated cholesterol in these patients.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6661, 0, 'Fenofibric acid', 'Cholelithiasis', 'The use of fibric acid derivatives is contraindicated in patients with gallbladder disease.  A significantly increased incidence of cholelithiasis has been observed in patients treated with the fibric acid derivative, clofibrate, presumably because of increased cholesterol excretion into the bile.  Based on two separate studies (the WHO study and the Coronary Drug Project study), clofibrate use was associated with twice the risk of developing cholelithiasis and cholecystitis requiring surgery.  Due to their structural and pharmacologic similarities, use of other fibric acid derivatives may be expected to carry the same risk.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6662, 0, 'Fenofibric acid', 'Hypolipoproteinemias', 'There have been reports of severe decreases in HDL cholesterol (HDL-C) levels (as low as 2 mg/dL) occurring in diabetic and non-diabetic patients initiated on fibric acid derivatives therapy.  The decrease has been reported to occur within 2 weeks to years after initiation of therapy.  It is recommended that HDL-C levels be checked within the first few months after initiation therapy and if a severely depressed HDL-C level is detected, therapy with these agents should be withdrawn.  Monitor HDL-C level until it has returned to baseline, and therapy with these agents should not be re-initiated in these patients.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6663, 0, 'Fenofibric acid', 'Liver Diseases', 'The use of fibric acid derivatives is contraindicated in patients with active liver disease or unexplained, persistent elevations of serum transaminases.  Fibric acid derivatives therapy is associated with dose-related hepatotoxicity, including biochemical abnormalities of liver function, hepatitis (hepatocellular, chronic active, as well as cholestatic) and, rarely, cirrhosis.  Postmarketing cases of severe drug-induced liver injury, including liver transplantation and death, have been reported.  Therapy with these agents should be administered cautiously in patients with a history of liver disease and/or heavy alcohol use.  Liver function tests, including serum transaminase levels and total bilirubin, should be performed at baseline and periodically throughout the duration of therapy.  Therapy should be discontinued if signs or symptoms of liver injury develop or if elevated enzyme levels persist (ALT or AST greater than 3 times the upper limit of normal, or if accompanied by elevation of bilirubin).  Do not restart therapy if there is no alternative explanation for the liver injury.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6664, 0, 'Fenofibric acid', 'Kidney Diseases', 'The use of fibric acid derivatives is contraindicated in patients with significantly impaired renal function.  The rate of clearance of fenofibric acid has been shown to decrease substantially when CrCl is below 50 mL/min, with drug accumulation during chronic dosing.  Increased adverse effects, including rhabdomyolysis (with or without secondary renal failure) and severe hyperkalemia, have been associated with the use of fibric acid derivatives in patients with renal insufficiency.  Therapy with these agents should be administered cautiously in patients with mild or moderate renal impairment.  Close clinical monitoring is recommended during therapy.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6665, 0, 'Fenofibric acid', 'Rhabdomyolysis', 'Severe myopathy, including rhabdomyolysis with acute renal failure secondary to myoglobinuria, has been reported rarely with the use of fibric acid derivatives.  The myopathy may be dose-related and is characterized by muscle aches and/or weakness in conjunction with increases in creatine phosphokinase (CPK) values exceeding 10 times the upper limit of normal.  Therapy with fibric acid derivatives should be administered cautiously in patients with preexisting myopathy or a myoneural disorder, since it may delay the recognition or confound the diagnosis of a drug-induced musculoskeletal effect.  Patients should be advised to report promptly any unusual muscle pain, tenderness or weakness, particularly if accompanied by malaise or fever.  Periodic CPK determinations may be considered in some patients, although the value of such monitoring is uncertain.  Therapy should be withdrawn if markedly elevated CPK levels occur or if drug-related myopathy is diagnosed or suspected.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6666, 0, 'Fenofibric acid', 'Hematologic Diseases', 'Mild to moderate hemoglobin, hematocrit and white blood cell decreases have been observed in patients following initiation of fibric acid derivatives therapy.  However, these levels stabilize during long-term administration.  Thrombocytopenia and agranulocytosis have been reported in individuals treated with these agents.  Caution is recommended when treating patients predisposed to hematologic changes.  Periodic monitoring of red and white blood cell counts is recommended during the first 12 months of therapy.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6667, 0, 'Fenoldopam', 'Heart Failure', 'Fenoldopam causes a dose-related fall in blood pressure that may worsen congestive heart failure.  Therapy with fenoldopam should be administered cautiously in patients with heart failure.  Monitoring blood pressure at regular intervals is recommended.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6668, 0, 'Fenoldopam', 'Glaucoma', 'Fenoldopam causes a dose-dependent increase in intraocular pressure.  Therapy with fenoldopam should be administered cautiously in patients with glaucoma or intraocular hypertension.  Intraocular pressure may return to baseline in 2 hours following discontinuation of fenoldopam.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6669, 0, 'Fenoldopam', 'Hypokalemia', 'The use of fenoldopam is associated with hypokalemia (less than 3 mEq/L after 6 hours of infusion).  Therapy with fenoldopam should be administered cautiously in patients with preexisting hypokalemia.  Monitoring serum electrolytes and potassium replacement as required is recommended.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6670, 0, 'Fenoldopam', 'Hypotension', 'Fenoldopam may cause symptomatic hypotension that may exacerbate cerebral infarction or hemorrhage.  Monitoring blood pressure closely during administration is recommended.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6671, 0, 'Fenoldopam', 'Tachycardia', 'The use of fenoldopam is associated with producing dose-related compensatory tachycardia, particularly with infusion rates greater than 0.1 mcg/kg/min in adults and >0.8 mcg/kg/min in pediatric patients.  Tachycardia may diminish over time, but remains substantial at higher doses.  Care should be exercised when using this agent in patients at risk.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6672, 0, 'Fenoprofen', 'Asthma', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) are contraindicated in patients with history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs; severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients.  A subpopulation of patients with asthma may have aspirin-sensitive asthma which may include chronic rhinosinusitis complicated by nasal polyps, severe potentially fatal bronchospasm, and/or intolerance to aspirin and other NSAIDs.  Since cross-reactivity between aspirin and other NSAIDs has been reported in such aspirin-sensitive patients, therapy with any NSAID should be avoided in patients with this form of aspirin sensitivity.  NSAIDs should be used with caution in patients with preexisting asthma (without known aspirin sensitivity), and these patients should be monitored for changes in the signs and symptoms of asthma.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6673, 0, 'Fenoprofen', 'Water-Electrolyte Imbalance', 'Fluid retention and edema have been reported in association with the use of nonsteroidal anti-inflammatory drugs (NSAIDs).  Therapy with NSAIDs should be administered cautiously in patients with preexisting fluid retention, hypertension, or a history of heart failure.  Blood pressure and cardiovascular status should be monitored closely during the initiation of NSAID treatment and throughout the course of therapy.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6674, 0, 'Fenoprofen', 'Peptic Ulcer', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) can cause serious gastrointestinal (GI) adverse events including inflammation, bleeding, ulceration, and perforation of the esophagus, stomach, small intestine, or large intestine, which can be fatal.  These serious adverse events can develop at any time, with or without warning symptoms.  Only 1 in 5 patients who develop a serious upper GI side effect on NSAIDs is symptomatic.  NSAIDs should be used with caution in patients with history of peptic ulcer disease and/or GI bleeding, as these patients had a greater than 10-fold increased risk for developing a GI bleed compared to patients without these risk factors.  Caution is also advised if NSAIDs are prescribed to patients with other factors that increase risk of GI bleeding, such as:  prolonged NSAID therapy; concomitant use of oral corticosteroids, antiplatelet agents (e.g., aspirin), anticoagulants, selective serotonin reuptake inhibitors; alcohol use; smoking; history of gastrointestinal surgery or anastomosis, older age; poor general health status; and advanced liver disease and/or coagulopathy.  Particular vigilance is necessary when treating elderly or debilitated patients since most postmarketing reports of fatal GI events occurred in these patients.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6675, 0, 'Fenoprofen', 'Exanthema', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) can cause serious skin adverse reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis, and exfoliative dermatitis), which can be fatal.  These serious events may occur without warning.  Patients should be advised to discontinue the NSAID and seek medical attention promptly at the first sign of skin rash or any other sign of hypersensitivity.  NSAIDs are contraindicated in patients with previous serious skin reactions to these drugs.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6676, 0, 'Fenoprofen', 'Kidney Diseases', 'Long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs) has resulted in renal papillary necrosis and other renal injury.  Renal toxicity has been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion:  in such patients, NSAIDs may cause a dose-dependent reduction in prostaglandin synthesis and, secondarily, in renal blood flow, which may precipitate overt renal decompensation.  Patients at greatest risk for this reaction include the elderly, those with impaired renal function, dehydration, hypovolemia, heart failure, or liver dysfunction, and those taking diuretics, angiotensin-converting enzyme inhibitors, or angiotensin receptor blockers; discontinuation of NSAID therapy will usually lead to recovery to the pretreatment state.  No information is available regarding use NSAIDs in patients with advanced renal disease; the renal effects of NSAIDs may hasten the progression of renal dysfunction in patients with preexisting renal disease.  Volume status should be corrected in dehydrated or hypovolemic patients prior to initiating treatment.  Renal function should be monitored during therapy in patients with renal or liver dysfunction, heart failure, dehydration, or hypovolemia.  NSAIDs should be avoided in patients with advanced renal disease unless the benefits are expected to outweigh the risk of worsening renal function; if an NSAID is used in such patients, they should be monitored for signs of worsening renal function.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6677, 0, 'Fenoprofen', 'Thrombosis', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal.  This risk may occur early in treatment and may increase with duration of use.  Clinical trials of several cyclooxygenase-2 (COX-2) selective and nonselective NSAIDs of up to 3 years duration have supported this increased risk.  It is unclear from available data if the risk for cardiovascular thrombotic events is similar for all NSAIDs.  Therapy with NSAIDs should be administered cautiously in patients with a history of cardiovascular or cerebrovascular disease.  Patients should be treated with the lowest effective dosage for the shortest duration necessary.  Appropriate antiplatelet therapy should be administered to patients requiring cardioprotection; however, there is no consistent evidence that concurrent use of aspirin mitigates the increased risk of serious cardiovascular thrombotic events associated with NSAID use, while the risk of serious gastrointestinal events is increased.  Physicians and patients should remain alert for the development of adverse cardiovascular events throughout the entire duration of therapy, even without prior cardiovascular symptoms.  Patients should be advised to promptly seek medical attention if they experience symptoms of cardiovascular thrombotic events (including chest pain, shortness of breath, weakness, or slurring of speech).NSAIDs are contraindicated in the setting of coronary artery bypass graft (CABG) surgery.  Two large clinical trials of a COX-2 selective NSAID for the treatment of pain in the first 10 to 14 days following CABG surgery found an increased incidence of myocardial infarction and stroke.The use of NSAIDs should be avoided in patients with a recent myocardial infarction unless the benefits are expected to outweigh the risk of recurrent cardiovascular thrombotic events.  If an NSAID is used in patients with a recent myocardial infarction, they should be monitored for signs of cardiac ischemia.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6678, 0, 'Fenoprofen', 'Anemia', 'Anemia has been reported in patients treated with nonsteroidal anti-inflammatory drugs (NSAIDs).  This may be due to fluid retention, occult/gross blood loss, or an incompletely described effect on erythropoiesis.  Hemoglobin or hematocrit should be monitored in patients with any signs/symptoms of anemia or blood loss, especially during long-term therapy.  NSAIDs may increase risk of bleeding events; comorbid conditions (e.g., coagulation disorders; concomitant use of warfarin/other anticoagulants, antiplatelet agents, serotonin/serotonin norepinephrine reuptake inhibitors) may increase this risk, and patients with these conditions should be monitored for signs of bleeding.  Therapy with NSAIDs should be administered cautiously in patients with or predisposed to anemia.  Clinical monitoring of hematopoietic function may be appropriate, particularly during chronic therapy.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6679, 0, 'Fenoprofen', 'Heart Failure', 'Fluid retention and edema have been observed in patients treated with nonsteroidal anti-inflammatory drugs (NSAIDs), including some topical formulations.  These drugs should be avoided in patients with severe heart failure unless the benefits are expected to outweigh the risk of worsening heart failure.  If an NSAID is used in patients with severe heart failure, they should be monitored for signs of worsening heart failure.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6680, 0, 'Fenoprofen', 'Liver Diseases', 'Borderline elevations of 1 or more liver tests may occur in up to 15% of patients treated with nonsteroidal anti-inflammatory drugs (NSAIDs).  These laboratory abnormalities may progress, remain unchanged, or regress with continuing therapy.  Elevations of ALT or AST (at least 3 times the upper limit of normal) have been reported in about 1% of patients in clinical trials.  In addition, rare (sometimes fatal) cases of severe hepatotoxicity, including liver necrosis, hepatic failure, jaundice, and fulminant hepatitis have been reported.  Therapy with NSAIDs should be administered cautiously in patients with preexisting liver disease.  Periodic monitoring of liver function is recommended during prolonged therapy.  NSAIDs are also highly protein-bound and some are extensively metabolized by the liver.  Metabolic activity and/or plasma protein binding may be altered in patients with hepatic impairment.  A dosage reduction may be required in some cases.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6681, 0, 'Fenoprofen', 'Hyperkalemia', 'Increases in serum potassium concentration (including hyperkalemia) have been reported with use of nonsteroidal anti-inflammatory drugs (NSAIDs), even in some patients without renal impairment.  In patients with normal renal function, these effects have been attributed to a hyporeninemic-hypoaldosteronism state.  Caution is advised in patients with hyperkalemia.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6682, 0, 'Fenoprofen', 'Hypertension', 'Nonsteroidal anti-inflammatory drugs (NSAIDs), including topicals, can lead to new onset of hypertension or worsening of preexisting hypertension, either of which can contribute to the increased incidence of cardiovascular events.  NSAIDs should be used with caution in patients with hypertension.  Blood pressure should be monitored closely during the initiation of NSAID therapy and throughout the course of therapy.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6683, 0, 'Fenoprofen', 'Blood Platelet Disorders', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) reversibly inhibit platelet adhesion and aggregation and may prolong bleeding time in some patients.  With the exception of aspirin, the platelet effects seen with most NSAIDs at usual recommended dosages are generally slight and of relatively short duration but may be more pronounced in patients with underlying hemostatic abnormalities.  Thrombocytopenia has also been reported rarely during NSAID use.  Therapy with NSAIDs should be administered cautiously in patients with significant active bleeding or a hemorrhagic diathesis, including hemostatic and/or coagulation defects associated with hemophilia, vitamin K deficiency, hypoprothrombinemia, thrombocytopenia, thrombocytopathy, or severe hepatic impairment.  NSAIDs that selectively inhibit cyclooxygenase-2 (i.e., COX-2 inhibitors) do not appear to affect platelet function or bleeding time at indicated dosages and may be preferable if risk of bleeding is a concern.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6684, 0, 'Fentanyl', 'Gastrointestinal Diseases', 'Narcotic (opioid) analgesic agents increase smooth muscle tone in the gastrointestinal tract and decrease peristalsis, which can lead to elevated intraluminal pressure, spasm, and constipation following prolonged use.  In patients with severe or acute inflammatory bowel disease, the decrease in colonic motility may induce toxic megacolon.  Therapy with opioids should be administered cautiously in patients with gastrointestinal obstruction, constipation, inflammatory bowel disease, or recent gastrointestinal tract surgery.  Gastrointestinal effects appear to be the most pronounced with morphine.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6685, 0, 'Fentanyl', 'Dysentery', 'Narcotic (opioid) analgesic agents may prolong and/or worsen diarrhea associated with organisms that invade the intestinal mucosa, such as toxigenic E. coli, Salmonella, Shigella, and pseudomembranous colitis due to broad-spectrum antibiotics.  These agents decrease gastrointestinal motility, which may delay the excretion of infective gastroenteric organisms and/or their toxins.  Other symptoms and complications such as fever, shedding of organisms and extraintestinal illness may also be increased or prolonged.  Therapy with opioids should be avoided or administered cautiously in patients with infectious diarrhea, particularly that due to pseudomembranous enterocolitis or enterotoxin-producing bacteria or if accompanied by high fever, pus, or blood in the stool.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6686, 0, 'Fentanyl', 'Liver Diseases', 'Narcotic (opioid) analgesic agents are extensively metabolized by the liver, and several of them (e.g., codeine, hydrocodone, meperidine, methadone, morphine, propoxyphene) have active metabolites that are further converted to inactive substances.  The serum concentrations of these agents and their metabolites may be increased and the half-lives prolonged in patients with impaired hepatic function.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with liver disease.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6687, 0, 'Fentanyl', 'Premature Birth', 'The use of narcotic (opioid) analgesic agents is contraindicated in premature infants.  These agents may cross the immature blood-brain barrier to a greater extent than in adults, resulting in disproportionate respiratory depression.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6688, 0, 'Fentanyl', 'Alcoholic Intoxication', 'The use of opiate agonists is contraindicated in patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of opiate agonists may be additive with those of alcohol.  Severe respiratory depression and death may occur.  Therapy with opiate agonists should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6689, 0, 'Fentanyl', 'Substance-Related Disorders', 'Opiate agonists have the potential to cause dependence and abuse.  Tolerance as well as physical and psychological dependence can develop after prolonged use.  Abrupt cessation, reduction in dosage, or administration of an opiate antagonist such as naloxone may precipitate withdrawal symptoms.  In patients who have developed tolerance to an opiate agonist, overdosage can still produce respiratory depression and death, and cross-tolerance usually will occur with other agents in the class.  Addiction-prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance or medical supervision when treated with opiate agonists.  It may be prudent to refrain from dispensing large quantities of medication to these patients.  After prolonged use or if dependency is suspected, withdrawal of opiate therapy should be undertaken gradually using a dosage-tapering schedule.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6690, 0, 'Fentanyl', 'Intestinal Obstruction', 'Opioid agonists are contraindicated in patients with known or suspected gastrointestinal obstruction, including paralytic ileus.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6691, 0, 'Fentanyl', 'Hypotension', 'Opiate agonists can induce vasodilation and significant hypotension, particularly when given in high dosages and/or by rapid intravenous administration.  Opiate analgesics cause vasodilatation that may exacerbate hypotension and hypoperfusion and, therefore, are contraindicated in circulatory shock.  At therapeutic analgesic dosages, ambulatory patients are more likely to experience dizziness and hypotension than patients who are confined to bed.  However, orthostatic hypotension may occur in supine patients upon rising.  Therapy with opiate agonists should be administered cautiously and initiated at reduced dosages in patients with hypovolemia, or a predisposition to hypotension.  When given by intramuscular or subcutaneous administration, clinicians should also be aware that impaired perfusion in these patients may prevent complete absorption of the drug.  With repeated injections, an excessive amount may be absorbed suddenly if normal circulation is reestablished.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6692, 0, 'Fentanyl', 'Intracranial Hypertension', 'The hypoventilation associated with administration of opiate agonists, particularly by the intravenous route, can induce cerebral hypoxia and vasodilatation with resultant increase in intracranial pressure.  Opiate agonists should not be used in patients with suspected or known head injury or increased intracranial pressure.  Also, clinicians treating such patients should be aware that opiate agonists may interfere with the evaluation of CNS function, especially with respect to consciousness levels, respiratory status, and pupillary changes.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6693, 0, 'Fentanyl', 'Respiratory Insufficiency', 'Opiate agonists may produce significant central nervous system and respiratory depression of varying duration, particularly when given in high dosages and/or by rapid intravenous administration.  Apnea may result from decreased respiratory drive as well as increased airway resistance, and rigidity of respiratory muscles may occur during rapid IV administration or when these agents are used in the induction of anesthesia.  At therapeutic analgesic dosages, the respiratory effects are usually not clinically important except in patients with preexisting pulmonary impairment.  Therapy with opiate agonists should be avoided or administered with extreme caution and initiated at reduced dosages in patients with severe CNS depression; sleep apnea; hypoxia, anoxia, or hypercapnia; upper airway obstruction; chronic pulmonary insufficiency; a limited ventilatory reserve; or other respiratory disorders.  In the presence of excessive respiratory secretions, the use of opiate agonists may also be problematic because they decrease ciliary activity and reduce the cough reflex.  Caution is also advised in patients who may be at increased risk for respiratory depression, such as comatose patients or those with head injury, intracranial lesions, or intracranial hypertension.  Clinical monitoring of pulmonary function is recommended, and equipment for resuscitation should be immediately available if parenteral or neuraxial routes are used.  Naloxone may be administered to reverse clinically significant respiratory depression, which may be prolonged depending on the opioid agent, cumulative dose, and route of administration.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6694, 0, 'Fentanyl', 'Fever', 'The release of fentanyl from the transdermal system may be temperature-dependent.  According to the manufacturer, a body temperature of 40 C (102 F) may theoretically increase serum fentanyl concentrations by approximately one-third due to increased drug release and skin permeability.  Therapy with fentanyl transdermal systems should be administered cautiously and possibly at reduced dosages in patients with a high fever.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6695, 0, 'Fentanyl', 'Adrenal Insufficiency', 'Patients with Addison''s disease may have increased risk of respiratory depression and prolonged CNS depression associated with the use of narcotic (opioid) analgesic agents.  Conversely, these agents may cause or potentiate adrenal insufficiency.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with adrenocortical insufficiency.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6696, 0, 'Fentanyl', 'Gallbladder Diseases', 'Narcotic (opioid) analgesic agents increase smooth muscle tone in the biliary tract, which can lead to spasm and elevated biliary tract pressure, especially in the sphincter of Oddi.  Biliary effects appear to be the most pronounced with morphine, although they do not always occur with therapeutic doses.  Therapy with opioids should be administered cautiously in patients with biliary or gallbladder disease.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6697, 0, 'Fentanyl', 'Hypothyroidism', 'Patients with hypothyroidism may have increased risk of respiratory depression and prolonged CNS depression associated with the use of narcotic (opioid) analgesic agents.  These agents may also exacerbate the effects of hypothyroidism such as lethargy, impaired mentation, depression, and constipation.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with uncontrolled hypothyroidism or myxedema.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6698, 0, 'Fentanyl', 'Kidney Diseases', 'Although narcotic (opioid) analgesic agents are generally metabolized by the liver, renal impairment can alter the elimination of these agents and their metabolites (some of which are pharmacologically active), resulting in drug accumulation and increased risk of toxicity.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with significantly impaired renal function.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6699, 0, 'Fentanyl', 'Epilepsy', 'Narcotic (opioid) analgesic agents may exacerbate seizures in patients with seizure disorders and, at higher dosages, have been reported to induce seizures in patients without previous history of seizures.  The proconvulsant activity may be the greatest with meperidine, the active metabolite of which is thought to be responsible.  Therapy with opioids should be administered cautiously in patients with or predisposed to seizures.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6700, 0, 'Fentanyl', 'Urinary Retention', 'Narcotic (opioid) analgesic agents may inhibit the urinary voiding reflex and increase the tone of the vesical sphincter in the bladder.  Acute urinary retention requiring catheterization may occur, particularly in patients with prostatic hypertrophy or urethral stricture and in elderly patients.  These agents may also decrease urine production via direct effects on the kidney and central stimulation of the release of vasopressin.  Therapy with opioids should be administered cautiously in patients with or predisposed to urinary retention and/or oliguria.  The effects on smooth muscle tone appear to be the most pronounced with morphine.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6701, 0, 'Fentanyl', 'Arrhythmias, Cardiac', 'Opiate agonists have cholinergic activity.  Large doses and/or rapid intravenous administration may produce bradycardia and arrhythmia via stimulation of medullary vagal nuclei.  Unlike other agents in the class, meperidine also has anticholinergic activity and may cause either bradycardia or tachycardia.  Therapy with opiate agonists should be administered cautiously in patients with a history of arrhythmias.  Clinical monitoring of cardiovascular status is recommended during therapy.  Bradycardia and other cholinergic effects produced by these agents may be controlled with atropine.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6702, 0, 'Ferrous sulfate anhydrous', 'Hemoglobinopathies', 'There is no excretory mechanism for iron.  Iron will correct only hemoglobin abnormalities due to iron deficiency and should not be used to treat conditions such as thalassemia, hemosiderosis, hemochromatosis, normocytic anemia (unless iron deficiency exists), or in patients receiving blood transfusions.  Clinical monitoring of erythropoietic function and ferritin levels is recommended.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6703, 0, 'Ferrous sulfate anhydrous', 'Achlorhydria', 'Gastric acidity increases iron bioavailability by maintaining the ingested iron in a reduced form as ferrous ions, which are more readily absorbed than ferric ions.  Therefore, when iron therapy is administered orally, higher dosages may be necessary for patients with decreased gastric acid production.  Also, a liquid formulation is recommended in these patients because dissolution of the tablet coating depends on normal gastric acidity.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6704, 0, 'Ferrous sulfate anhydrous', 'Gastrointestinal Diseases', 'Iron can be irritating and damaging to gastrointestinal mucosa.  Iron therapy should be administered cautiously in patients with peptic ulcer disease, enteritis, or ulcerative colitis.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6705, 0, 'Ferric carboxymaltose', 'Hypertension', 'Transient elevation of blood pressure has been reported in clinical trials in patients receiving ferric carboxymaltose.  These elevations generally occurred immediately after dosing and resolved in 30 minutes.  Patients should be monitored for symptoms or signs of hypertension following treatment.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6706, 0, 'Ferric carboxymaltose', 'Hypophosphatemia', 'Patients with malabsorption of fat-soluble vitamins or phosphate, or using medications affection proximal renal tubular function, hyperparathyroidism, vitamin D deficiency, or malnutrition may experience symptomatic hypophosphatemia.  Cases occur mostly after repeat exposure.  Most cases resolved within 3 months.  Monitor serum phosphate in at risk patiens requiring repeat treatment.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6707, 0, 'Ferric carboxymaltose', 'Hypersensitivity, Immediate', 'Serious hypersensitivity reactions, including anaphylaxis- type reactions, some of which have been life-threatening have been reported in patients using some injection iron products.  Patients may present with shock, clinically significant hypotension, loss of consciousness, and/or collapse.  These products should be administered cautiously, especially in patients with a history of significant allergies.  Patients should be monitored during and at least 30 minutes after the administration.  Epinephrine should be immediately available in the event of acute hypersensitivity reactions.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6708, 0, 'Ferrous fumarate', 'Hemoglobinopathies', 'There is no excretory mechanism for iron.  Iron will correct only hemoglobin abnormalities due to iron deficiency and should not be used to treat conditions such as thalassemia, hemosiderosis, hemochromatosis, normocytic anemia (unless iron deficiency exists), or in patients receiving blood transfusions.  Clinical monitoring of erythropoietic function and ferritin levels is recommended.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6709, 0, 'Ferrous fumarate', 'Achlorhydria', 'Gastric acidity increases iron bioavailability by maintaining the ingested iron in a reduced form as ferrous ions, which are more readily absorbed than ferric ions.  Therefore, when iron therapy is administered orally, higher dosages may be necessary for patients with decreased gastric acid production.  Also, a liquid formulation is recommended in these patients because dissolution of the tablet coating depends on normal gastric acidity.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6710, 0, 'Ferrous fumarate', 'Gastrointestinal Diseases', 'Iron can be irritating and damaging to gastrointestinal mucosa.  Iron therapy should be administered cautiously in patients with peptic ulcer disease, enteritis, or ulcerative colitis.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6711, 0, 'Ferric derisomaltose', 'Iron Overload', 'Ferric derisomaltose should not be administered to patients with iron overload.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6712, 0, 'Finasteride', 'Liver Diseases', 'Finasteride and dutasteride are extensively metabolized by the liver.  Therapy with these drugs should be administered cautiously in patients with liver disease as exposure could be higher.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6713, 0, 'Finasteride', 'Urethral Obstruction', 'Patients with large residual urinary volume and/or severely diminished urinary flow should be carefully monitored for obstructive uropathy.  These patients may not be candidates for finasteride therapy.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6714, 0, 'Ferumoxytol', 'Hypersensitivity, Immediate', 'Serious hypersensitivity reactions, including anaphylaxis- type reactions, some of which have been life-threatening have been reported in patients using some injection iron products.  Patients may present with shock, clinically significant hypotension, loss of consciousness, and/or collapse.  These products should be administered cautiously, especially in patients with a history of significant allergies.  Patients should be monitored during and at least 30 minutes after the administration.  Epinephrine should be immediately available in the event of acute hypersensitivity reactions.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6715, 0, 'Ferumoxytol', 'Hypotension', 'Clinically significant hypotension has been reported in clinical trials and postmarketing after the administration of ferumoxytol injection.  Patients should be monitored for signs and symptoms of hypotension after administration.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6716, 0, 'Fibrinogen human', 'Thromboembolism', 'Thrombotic events have been reported in patients receiving human fibrinogen concentrate.  Treatment with human fibrinogen concentrate has been associated with risk of thrombosis at target fibrinogen levels that were less than 150 mg/dL, and the risk may be greater when the target fibrinogen plasma level is 150 mg/dL.  Weigh the benefits of fibrinogen administration versus the risks of thrombosis.  Patients receiving fibrinogen should be monitored for signs and symptoms of thrombosis.  Inform patients that blood clots with or without consequent obstruction of blood flow may occur and that any symptoms of blood clots (unexplained chest and/or leg pain or swelling of the legs or arms, coughing up blood, shortness of breath, increased rate of breathing or unexplained symptoms related to the nervous system such as stroke or weakness) should be reported to their physician immediately.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6717, 0, 'Aminophylline', 'Peptic Ulcer', 'Methylxanthines are known to stimulate peptic acid secretion.  Therapy with products containing methylxanthines should be administered with extreme caution in patients with active peptic ulcer disease.  Some manufacturers consider their use to be contraindicated under such circumstance.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6718, 0, 'Aminophylline', 'Kidney Diseases', 'The metabolites of theophylline, which are generally undetectable in patients with normal renal function, may accumulate in patients with renal impairment and contribute to the toxicity of theophylline.  In addition, the plasma protein binding of theophylline may be significantly decreased in renal impairment, resulting in elevated free drug concentrations and further increasing the risk of toxicity.  Therapy with theophyllines should be administered cautiously in patients with impaired renal function.  Dosage adjustments and more intensive monitoring of serum theophylline concentrations may be required.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6719, 0, 'Aminophylline', 'Epilepsy', 'The use of theophyllines is considered by some manufacturers to be contraindicated in patients with underlying seizure disorders unless they are receiving adequate anticonvulsant therapy.  Theophyllines may cause seizures, which have generally been associated with toxic drug levels but have also been reported at therapeutic concentrations in patients with head trauma or cerebral infarct.  If theophylline therapy is administered in patients with these or other risk factors for seizures, serum drug levels should be monitored closely and maintained in the low therapeutic range.  Intractable seizures and death have been reported during acute theophylline toxicity.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6720, 0, 'Aminophylline', 'Gastroesophageal Reflux', 'Methylxanthines increase gastric acidity and may also relax lower esophageal sphincter, which can lead to gastric reflux into the esophagus.  Therapy with products containing methylxanthines should be administered cautiously in patients with significant gastroesophageal reflux.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6721, 0, 'Aminophylline', 'Diseases requiring hemodialysis', 'Theophylline is removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6722, 0, 'Aminophylline', 'Tachycardia', 'The use of theophyllines is associated with an increase in heart rate which may progress to supraventricular tachycardia or ventricular arrhythmia at high serum drug concentrations.  Appearance of cardiac adverse effects is generally an indication of theophylline toxicity, although patients with a history of tachyarrhythmias may be more susceptible to the chronotropic effect of these drugs.  Therapy with theophyllines should be administered cautiously in such patients.  Caution is also advised in patients with hypertension, hyperthyroidism, angina pectoris, or recent myocardial infarction, since high dosages of the drugs are associated with positive inotropic as well as chronotropic effects.  Clinical monitoring of serum drug concentrations is recommended to prevent toxicity.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6723, 0, 'Ferumoxides', 'Anaphylaxis', 'The possibility of a reaction including serious, life-threatening, fatal, anaphylactoid or cardiovascular reactions should always be considered when using ferumoxides.  Increased risk is associated with a known sensitivity to iron or dextran, history of previous reaction to a radiographic contrast agent, known allergies, other hypersensitivities, and underlying immune disorders, autoimmunity or immunodeficiencies that predispose to specific or non specific mediator release.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6724, 0, 'Ferumoxides', 'Autoimmune Diseases', 'Ferumoxides has not been studied in patients with immune disease, but a high rate of adverse reactions to injectable iron formulations have been reported in the published literature.  Caution is advised.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6725, 0, 'Ferumoxides', 'Iron Overload', 'Ferumoxides which contains iron, should be used with caution in patients with disorders associated with iron over load (e.g., hemosiderosis, chronic hemolytic anemia with frequent blood transfusions).', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6726, 0, 'Ferrous gluconate', 'Hemoglobinopathies', 'There is no excretory mechanism for iron.  Iron will correct only hemoglobin abnormalities due to iron deficiency and should not be used to treat conditions such as thalassemia, hemosiderosis, hemochromatosis, normocytic anemia (unless iron deficiency exists), or in patients receiving blood transfusions.  Clinical monitoring of erythropoietic function and ferritin levels is recommended.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6727, 0, 'Ferrous gluconate', 'Achlorhydria', 'Gastric acidity increases iron bioavailability by maintaining the ingested iron in a reduced form as ferrous ions, which are more readily absorbed than ferric ions.  Therefore, when iron therapy is administered orally, higher dosages may be necessary for patients with decreased gastric acid production.  Also, a liquid formulation is recommended in these patients because dissolution of the tablet coating depends on normal gastric acidity.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6728, 0, 'Ferrous gluconate', 'Gastrointestinal Diseases', 'Iron can be irritating and damaging to gastrointestinal mucosa.  Iron therapy should be administered cautiously in patients with peptic ulcer disease, enteritis, or ulcerative colitis.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6729, 0, 'Fesoterodine', 'Gastroparesis', 'The use of fesoterodine is contraindicated in patients with gastric retention.  Fesoterodine is a competitive muscarinic receptor antagonist and exerts direct antispasmodic effects on smooth muscles.  Caution is advised even when using this agent in patients with decreased gastrointestinal motility.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6730, 0, 'Fesoterodine', 'Glaucoma, Angle-Closure', 'The use of fesoterodine is contraindicated in patients with uncontrolled narrow-angle glaucoma.  Fesoterodine is a competitive muscarinic receptor antagonist.  Its use can result in increased intraocular pressure and loss of accommodation.  Caution is advised even when using this agent in patients being treated for narrow-angle glaucoma.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6731, 0, 'Fesoterodine', 'Urinary Retention', 'The use of fesoterodine is contraindicated in patients with urinary retention.  Fesoterodine is a competitive muscarinic receptor antagonist and exerts direct antispasmodic effects on smooth muscles.  Caution is advised even when using this agent in patients with clinically significant bladder outlet obstruction because of the risk of urinary retention.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6732, 0, 'Fesoterodine', 'Liver Diseases', 'The use of fesoterodine has not been studied in patients with severe hepatic impairment and therefore is not recommended for use in this patient population.  No dose adjustment is recommended in patients with mild or moderate hepatic impairment.  Use caution when using this agent in patients with severe hepatic impairment.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6733, 0, 'Fesoterodine', 'Myasthenia Gravis', 'Fesoterodine is a competitive muscarinic receptor antagonist.  Fesoterodine should be used with caution in patients with myasthenia gravis, a disease characterized by decreased cholinergic activity at the neuromuscular junction.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6734, 0, 'Fesoterodine', 'Kidney Diseases', 'Doses of fesoterodine fumarate greater than 4 mg are not recommended in patients with severe renal impairment.  No dose adjustment is recommended in patients with mild or moderate renal impairment.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6735, 0, 'Flecainide', 'Cardiomyopathies', 'Antiarrhythmic agents can induce severe hypotension (particularly with IV administration) or induce or worsen congestive heart failure (CHF).  Patients with primary cardiomyopathy or inadequately compensated CHF are at increased risk.  Antiarrhythmic agents should be administered cautiously and dosage and/or frequency of administration modified in patients with hypotension or adequately compensated CHF.  Alternative therapy should be considered unless these conditions are secondary to cardiac arrhythmia.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6736, 0, 'Flecainide', 'Arrhythmias, Cardiac', 'Antiarrhythmic agents can induce or worsen ventricular arrhythmias.  Ventricular tachycardia, ventricular fibrillation, and torsades de pointes have occurred in some patients.  Patients with underlying cardiac dysfunction, bradycardia, hypokalemia, hypomagnesemia, or high antiarrhythmic serum concentrations are at increased risk for drug-induced arrhythmias.  Therapy with antiarrhythmics should be used with extreme caution in patients with or predisposed to arrhythmias.  Evidence of improved survival is lacking for use of antiarrhythmic therapy in asymptomatic, non-life-threatening arrhythmias.  Therapy with antiarrhythmic agents should be reserved for patients with life-threatening arrhythmias.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6737, 0, 'Flecainide', 'Sick Sinus Syndrome', 'The use of flecainide is contraindicated in patients with cardiogenic shock, second- or third-degree AV block or right bundle-branch block when associated with a left hemiblock(bifascicular block) in the absence of a functional artificial pacemaker, or congenital QT prolongation.  Therapy with flecainide should be administered with extreme caution in patients with sick sinus syndrome or bradycardia-tachycardia syndrome due to the risk of sinus bradycardia, pause or arrest.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6738, 0, 'Flecainide', 'Water-Electrolyte Imbalance', 'Electrolyte imbalance can alter the therapeutic effectiveness of antiarrhythmic agents.  Hypokalemia and hypomagnesemia can reduce the effectiveness of antiarrhythmic agents.  In some cases, these disorders can exaggerate the degree of QTc prolongation and increase the potential for torsade de pointes.  Hyperkalemia can potentiate the toxic effects of antiarrhythmic agents.  Electrolyte imbalance should be corrected prior to initiating antiarrhythmic therapy.  Clinical monitoring of cardiac function and electrolyte concentrations is recommended.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6739, 0, 'Flecainide', 'Liver Diseases', 'Since flecainide elimination from plasma can be markedly slower in patients with significant hepatic impairment, flecainide should not be used in such patients unless the potential benefits clearly outweigh the risks.  If used, frequent and early plasma level monitoring is required to guide dosage.  Additionally, dosage increases should be made very cautiously when plasma levels have plateaued (after more than four days).', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6740, 0, 'Flecainide', 'Kidney Diseases', 'Flecainide is primarily eliminated by the kidney.  Approximately 30% (10% to 50%) of flecainide is excreted in the urine unchanged.  The serum concentration of flecainide is increased and the half-life prolonged in patients with renal impairment.  Rare conditions such as a strict vegetarian diet or renal tubular acidosis that significantly increase the urinary pH slow the urinary elimination of flecainide.  Adjustment of dosage is necessary and modification should be based on the degree of renal impairment.  Clinical monitoring of cardiac function (ECG) and renal function is recommended.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6741, 0, 'Filgrastim', 'Glomerulonephritis', 'Although it has been reported that renal dysfunction has no effect on the pharmacokinetics of colony stimulating factors (CSF), filgrastim and pegfilgrastim may cause glomerulonephritis.  Symptoms include swelling of the face or ankles, dark colored urine, or blood in the urine, or a decrease in urine production.  Advise patients to report signs or symptoms of glomerulonephritis immediately.  Monitoring of patients with renal dysfunction is recommended.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6742, 0, 'Filgrastim', 'Leukemia, Myeloid', 'Colony stimulating factors primarily stimulates the proliferation of neutrophils but may also, theoretically, enhance tumor growth, particularly in myeloid malignancies.  Therapy with these drugs should be administered cautiously in patients with myeloid tumors.  Additionally, if used for PBPC (peripheral blood progenitor cell) collection in such patients, tumor cells may be released from the marrow and collected in the leukapheresis product.  The effect of reinfusion of tumor cells is uncertain at this time.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6743, 0, 'Filgrastim', 'Leukocytosis', 'Filgrastim and pegfilgrastim are growth factors for neutrophil progenitor cells.  Therefore, these should not be used in patients with leukocytosis.  If excessive white blood cell counts occur during CSF therapy, treatment should be interrupted or the dosage reduced.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6744, 0, 'Filgrastim', 'Sepsis', 'When filgrastim is used in septic patients, clinicians should be alerted to the theoretical possibility of adult respiratory distress syndrome, which may occur as a result of the influx of neutrophils at the site of inflammation.  Monitoring of respiratory status may be appropriate in these patients.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6745, 0, 'Filgrastim', 'Thrombocytopenia', 'Filgrastim may occasionally lower platelet counts.  Thrombocytopenia has been reported, although most often the effects are mild or moderate and not associated with serious hemorrhagic sequelae.  Nevertheless, therapy with filgrastim should be administered cautiously in patients with preexisting thrombocytopenia.  Frequent blood counts are recommended, and the dosage of filgrastim adjusted if necessary.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6746, 0, 'Filgrastim', 'Anemia, Sickle Cell', 'Severe and sometimes fatal sickle cell crises have been reported in sickle cell disease patients receiving filgrastim products.  Consider the potential risks and benefits prior to initiating therapy in these patients.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6747, 0, 'Filgrastim', 'Neoplasms', 'Tbo-filgrastim can act as a growth factor for any tumor type, including myeloid malignancies and myelodysplasia disease, diseases for which its use has not been approved.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6748, 0, 'Aminolevulinic acid (topical)', 'Porphyrias', 'Photoactivation following topical application of aminolevulinic acid topical gel occurs when aminolevulinic acid (prodrug) is metabolized to protoporphyrin IX, a photoactive compound which accumulates in the skin.  Therapy with aminolevulinic acid topical gel increases photosensitivity and it may cause uncontrolled phototoxic effects.  Its use in contraindicated in patients with porphyria or photodermatoses.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6749, 0, 'Aminolevulinic acid (topical)', 'Hemorrhage', 'The use of aminolevulinic acid topical gel increases the risk of bleeding in patients with coagulation disorders.  Care should be exercised during lesion preparation to avoid bleeding.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6750, 0, 'Flavoxate', 'Intestinal Obstruction', 'The use of flavoxate is contraindicated in patients with GI obstruction, ileus, atony, and obstructive uropathy.  Flavoxate exerts direct antispasmodic effects on smooth muscles and possesses weak anticholinergic activity.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6751, 0, 'Flavoxate', 'Glaucoma, Angle-Closure', 'Flavoxate exerts mydriatic activity that can induce increased intraocular pressure and result in angle-closure (narrow angle) glaucoma.  Therapy with flavoxate should be administered cautiously in patients with angle-closure glaucoma.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6752, 0, 'Fexofenadine', 'Kidney Diseases', 'Fexofenadine is primarily eliminated by the kidney, and the risk of toxic reactions may be greater in patients with renal impairment due to decreased drug clearance.  Care should be taken in dose selection and it may be useful to monitor renal function.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6753, 0, 'Flibanserin', 'Alcoholic Intoxication', 'The use of flibanserin is contraindicated along with the ingestion of alcohol, as it increases the risk of hypotension and syncope.  It is important to assess the likelihood of the patient abstaining from alcohol, taking into account the current and past drinking behavior.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6754, 0, 'Flibanserin', 'Hypotension', 'The use of flibanserin can cause hypotension and syncope.  The benefits and risks of therapy should be considered in patients with preexisting conditions that predispose to hypotension.  Flibanserin should be used with caution in these patients.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6755, 0, 'Flibanserin', 'Liver Diseases', 'Flibanserin may accumulate in patients with hepatic impairment.  Therapy with flibanserin is contraindicated in patients with compromised hepatic function.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6756, 0, 'Floxuridine', 'Dihydropyrimidine Dehydrogenase Deficiency', 'An inherited deficiency of dihydropyrimidine can alter the clearance of 5- FU and result in severe toxicity such as stomatitis, diarrhea, neutropenia and neurotoxicity. When administered as a continuous intra-arterial infusion, floxuridine (FUDR) is metabolized to FDUMP.  However, with rapid intra-arterial injection, FUDR is metabolized to 5-FU.  5-FU requires metabolized to an inactive form by dihydropyrimidine dehydrogenase.   FUDR should not be administered by rapid intra-arterial infusion to patients with dihydropyrimidine deficiency.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6757, 0, 'Floxuridine', 'Infections', 'The use of floxuridine (FUDR) is contraindicated in patients with potentially serious infectious diseases.  FUDR can induce myelosuppression.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during therapy with FUDR.  Close clinical monitoring of hematopoietic function is recommended.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6758, 0, 'Floxuridine', 'Malnutrition', 'Floxuridine therapy is contraindicated for patients in a poor nutritional state.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6759, 0, 'Floxuridine', 'Bone Marrow Failure Disorders', 'The use of floxuridine (FUDR) is contraindicated in patients with bone marrow suppression.  FUDR induces myelosuppression at recommended dosages.  Therapy with FUDR should be administered cautiously in patients who have had prior high-dose pelvic irradiation or alkylating agents or who have widespread metastatic tumor involvement of the bone marrow.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Close clinical monitoring of hematopoietic function is recommended and therapy should be withheld if platelet counts falls below 100,000/mm3 and/or white blood cell (WBC) counts falls below 3500/mm3 or a rapid fall in WBC is noted.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6760, 0, 'Floxuridine', 'Stomatitis', 'Floxuridine induces stomatitis within the gastrointestinal tract.  Therapy with floxuridine should be administered with extreme caution in patients with peptic ulcer disease and ulcerative colitis.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6761, 0, 'Floxuridine', 'Hemorrhagic Disorders', 'Floxuridine (FUDR) induces myelosuppression.  Therapy with FUDR should be administered cautiously in patients with bleeding tendencies.  Therapy with FUDR should be promptly discontinued following bleeding from any sight.  Patients should be instructed to immediately report any signs or symptoms suggesting bleeding such as petechiae, purpura, hematuria, or melena.   Close clinical monitoring of hematopoietic function is recommended.  Therapy with FUDR should be withheld if platelet counts falls below 100,000/mm3.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6762, 0, 'Flunisolide', 'Adrenocortical Hyperfunction', 'The use of inhaled and nasal corticosteroids may rarely precipitate or aggravate conditions of hyperadrenocorticism.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.  The development of symptoms such as menstrual irregularities, acneiform lesions, cataracts and cushingoid features during inhaled or nasal corticosteroid therapy may indicate excessive use.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6763, 0, 'Flunisolide', 'Infections', 'The immunosuppressant and anti-inflammatory effects of corticosteroids, particularly in higher dosages, may decrease host resistance to infectious agents, decrease the ability to localize infections, and mask the symptoms of infection.  Secondary infections may be more likely to develop.  Therapy with inhaled and nasal corticosteroids should be administered cautiously in patients with an infection, particularly active or quiescent tuberculosis infection of the respiratory tract or any untreated systemic fungal, bacterial, parasitic, or viral infection.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6764, 0, 'Flunisolide', 'Keratitis, Herpetic', 'Pharmacologic dosages of corticosteroids may increase the risk of corneal perforation in patients with ocular herpes simplex.  Therapy with inhaled and nasal corticosteroids should be administered cautiously in such patients.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6765, 0, 'Flunisolide', 'Toxic Optic Neuropathy', 'Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves.  Therapy with inhaled and nasal corticosteroids has only rarely produced these effects but should be administered cautiously nonetheless in patients with a history of cataracts, glaucoma, or increased intraocular pressure.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6766, 0, 'Flunisolide', 'Osteoporosis', 'Prolonged use of inhaled corticosteroids may be associated with a reduction in bone density.  This effect appears to be dose-related and has been reported primarily with high dosages (>= 800 mcg/day of beclomethasone or equivalent for >= 1 year).  Reduced levels of total body calcium have also been demonstrated in patients receiving lower dosages.  Long-term therapy with inhaled and nasal corticosteroids should be administered cautiously in patients with osteoporosis.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6767, 0, 'Fluconazole', 'Liver Diseases', 'The use of fluconazole has been rarely associated with hepatotoxicity.  Reversible idiosyncratic hepatitis, cholestasis and fatal fulminant hepatic failure have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications.  Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly during prolonged therapy.  Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6768, 0, 'Fluconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6769, 0, 'Fluconazole', 'Diseases requiring hemodialysis', 'Fluconazole is substantially removed by hemodialysis.  Plasma levels of fluconazole has been shown to reduce by 50% following 3 hours of dialysis.  Fluconazole should be administered after hemodialysis.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6770, 0, 'Fluconazole', 'Kidney Diseases', 'Fluconazole is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from fluconazole due to decreased drug clearance.  Dosage adjustments are recommended for patients with moderate to severe renal impairment (CrCl <= 50 mL/min) receiving multiple doses of the drug.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6771, 0, 'Fludeoxyglucose (18F)', 'Diabetes Mellitus', 'The uptake of fludeoxyglucose F18 may be changed by fasting or by blood sugar changes associated with diabetic mellitus.  Blood glucose levels should be stabilized in non-diabetic patients by fasting before 18F-FDG injection.  Diabetic patients may need stabilization of blood glucose on the day preceding, and on the day of the 18F-FDG scan.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6772, 0, 'Flucytosine', 'Bone Marrow Failure Disorders', 'Flucytosine may frequently cause bone marrow toxicity, which can be irreversible and fatal in immunosuppressed patients.  Flucytosine should be used with extreme caution in patients with preexisting bone marrow suppression.  Frequent blood counts are recommended.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6773, 0, 'Flucytosine', 'Kidney Diseases', 'Flucytosine must be given with extreme caution to patients with impaired renal function.  Flucytosine is excreted primarily by the kidneys, and renal impairment may lead to accumulation of the drug.  Serum concentrations of the drug should be monitored to determine the adequacy of renal excretion in such patients.  Dosage adjustments should be made in patients with renal insufficiency to prevent progressive accumulation of active drug.  Close monitoring of renal, hematologic and hepatic function in all patients is recommended.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6774, 0, 'Flucytosine', 'Diseases requiring hemodialysis', 'Flucytosine is substantially removed by hemodialysis and should be administered after dialysis.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6775, 0, 'Flucytosine', 'Hypokalemia', 'Flucytosine may cause hypokalemia.  Patients with preexisting hypokalemia should be monitored closely for worsening electrolyte disturbances during therapy with flucytosine.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6776, 0, 'Aminosalicylic acid', 'Kidney Diseases', 'The use of aminosalicylic acid is contraindicated in patients with severe renal impairment.  Both aminosalicylic acid and its acetyl metabolite are primarily eliminated by the kidney, and the latter tends to accumulate extensively in patients with renal failure.  Some accumulation may also occur in patients with lesser degrees of renal dysfunction.  Caution is advised when aminosalicylic acid is used in these patients.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6777, 0, 'Aminosalicylic acid', 'Liver Diseases', 'Aminosalicylic acid is decarboxylated in stomach acid to an inactive metabolite that is hepatotoxic.  In a retrospective study of nearly 7,500 patients treated with older formulations of the drug, hepatitis developed in 0.5% of them.  Premonitory symptoms (most often rash, followed by fever and, much less frequently, by GI disturbances such as anorexia, diarrhea, or nausea) usually occurred within the first 3 months of therapy and preceded jaundice by a few days to several weeks.  Although the currently marketed granule formulation of aminosalicylic acid contains an acid- resistant coating that protects against degradation in the stomach, the drug should nevertheless be used with caution in patients with liver disease.  These patients should be followed particularly closely for the first three months, and therapy promptly discontinued if liver disease becomes worse or premonitory symptoms appear.  The drug should be administered sprinkled in an acidic food (e.g., apple sauce, yogurt) or suspended in a fruit juice to prevent dissolution of the coating, which occurs under neutral conditions.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6778, 0, 'Flumazenil', 'Seizures', 'Flumazenil has been associated with seizure activity, particularly in patients receiving repeated doses of benzodiazepines for long term sedation, acute overdose involving concurrent cyclic antidepressants, or head injury where it may alter cerebral blood flow in patients receiving benzodiazepines.  Therapy with flumazenil should be administered cautiously in patients with a history of or predisposition to seizures.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6779, 0, 'Flumazenil', 'Alcoholism', 'Flumazenil should be used with caution in patients with alcoholism and other drug dependencies due to the increased frequency of benzodiazepine tolerance and dependence observed in these patient populations.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6780, 0, 'Flumazenil', 'Liver Diseases', 'Flumazenil is a highly extracted drug, dependent on blood flow, and primarily metabolized by the liver.  Hepatic clearance is decreased 40% to 60 % in patients with moderate hepatic dysfunction and 75% in patients with severe hepatic dysfunction.  Care should be exercised as the metabolic and therapeutic activity of flumazenil may be altered in patients with compromised hepatic function or conditions that decrease systemic blood flow.  Following the initial dose, subsequent doses or the frequency of administration should be reduced.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6781, 0, 'Flumazenil', 'Psychotic Disorders', 'Panic attacks have been induced by flumazenil in patients with a history of panic attacks.  Emotional lability, including crying, depersonalization, euphoria, depression, dysphoria and paranoia have also been reported.  Therapy with flumazenil should be administered cautiously in patients with or predisposed to psychosis, particularly panic attacks.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6782, 0, 'Fludrocortisone', 'Infections', 'The immunosuppressant and anti-inflammatory effects of corticosteroids, particularly in higher dosages, may decrease host resistance to infectious agents, decrease the ability to localize infections, and mask the symptoms of infection.  Secondary infections may be more likely to develop.  In general, corticosteroids should not be used in patients with active infections, especially systemic fungal infections, unless they are medically necessary and effective antimicrobial therapy or other appropriate treatment has been instituted.  However, for corticosteroid-dependent patients who develop a severe or life-threatening infection, continuation of corticosteroid therapy with at least physiologic replacement dosages should be considered, since these patients may have secondary adrenocortical insufficiency.  Removal of external steroid during periods of stress may be detrimental to these patients.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6783, 0, 'Fludrocortisone', 'Latent Tuberculosis', 'In patients with latent tuberculosis or tuberculin reactivity, the use of pharmacologic dosages of corticosteroids may cause a reactivation of the disease.  Close monitoring for signs and symptoms of tuberculosis is recommended if corticosteroid therapy is administered to patients with a history of tuberculosis or tuberculin reactivity.  During prolonged corticosteroid therapy, tuberculosis chemoprophylaxis may be considered.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6784, 0, 'Fludrocortisone', 'Fibrosis', 'Corticosteroids may have enhanced effects on patients with cirrhosis due to decreased metabolism of these agents.  Patients with cirrhosis should be monitored more closely for excessive cortisol effects.  Dosage adjustments may be required in these patients.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6785, 0, 'Fludrocortisone', 'Psychotic Disorders', 'Corticosteroids may aggravate the symptoms of psychosis and emotional instability.  Patients with these conditions should be monitored for increased or worsened symptoms during corticosteroid therapy.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6786, 0, 'Fludrocortisone', 'Diabetes Mellitus', 'Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis.  Therapy with corticosteroids should be administered cautiously in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia.  Patients with diabetes mellitus should be monitored more closely during corticosteroid therapy, and their antidiabetic regimen adjusted accordingly.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6787, 0, 'Fludrocortisone', 'Water-Electrolyte Imbalance', 'Corticosteroids can cause hypernatremia, hypokalemia, and fluid retention.  These mineralocorticoid effects are most significant with fludrocortisone, followed by hydrocortisone and cortisone, then by prednisone and prednisolone.  The remaining corticosteroids, betamethasone, dexamethasone, methylprednisolone, and triamcinolone, have little mineralocorticoid activities.  However, large doses of any corticosteroid can demonstrate these effects, particularly if given for longer than brief periods.  All corticosteroids also increase excretion of calcium and can cause hypocalcemia.  Therapy with corticosteroids should be administered cautiously in patients with preexisting electrolyte disturbances.  Caution is also advised when treating patients with seizure disorders, since electrolyte disturbances may trigger seizure activity.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6788, 0, 'Fludrocortisone', 'Peptic Ulcer Perforation', 'Corticosteroids may cause gastrointestinal perforation and hemorrhage, usually when given in high dosages or for prolonged periods.  They may also mask symptoms of complications such as peritonitis or intraabdominal sepsis.  Therapy with corticosteroids should be avoided or administered cautiously in patients with diverticulitis, nonspecific ulcerative colitis (if there is a probability of impending perforation, abscess, or other pyogenic infection), or recent intestinal anastomoses.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6789, 0, 'Fludrocortisone', 'Cushing Syndrome', 'Corticosteroids mimic the effects of endogenous cortisol and aldosterone.  Use of these agents may aggravate conditions of hyperadrenocorticalism in a dose-dependent manner.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6790, 0, 'Fludrocortisone', 'Hyperlipidemias', 'Corticosteroids may elevate serum triglyceride and LDL cholesterol levels if used for longer than brief periods.  Patients with preexisting hyperlipidemia may require closer monitoring during prolonged corticosteroid therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6791, 0, 'Fludrocortisone', 'Hypothyroidism', 'Corticosteroids may have enhanced effects in hypothyroidism due to decreased metabolism of these agents.  Patients with hypothyroidism should be monitored more closely for excessive cortisol effects.  Dosage adjustments may be required secondary to changes in their thyroid condition.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6792, 0, 'Fludrocortisone', 'Liver Diseases', 'Corticosteroids are primarily metabolized by the liver and may have enhanced effects in patients with liver disease.  Dosage adjustments may be necessary in these patients.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6793, 0, 'Fludrocortisone', 'Myocardial Infarction', 'The use of corticosteroids may be associated with left ventricular free-wall rupture in patients who have had a recent myocardial infarction.  Pharmacologic dosages of corticosteroids should be administered with great caution in such patients.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6794, 0, 'Fludrocortisone', 'Myasthenia Gravis', 'Although corticosteroids are commonly used in the treatment of myasthenia gravis to increase muscle strength, these agents should nevertheless be administered with caution in such setting.  Patients should be treated in an intensive care unit and receive respiratory support, since muscle strength may markedly decrease initially, particularly with high dosages.  Preferably, therapy should begin with relatively low dosages (15 to 25 mg/day of prednisone or equivalent) and be increased stepwise as tolerated (approximately 5 mg/day of prednisone or equivalent at 2- to 3-day intervals until marked clinical improvement or a dosage of 50 mg/day is reached).  Improvement may be delayed and gradual.  Thus, it is important not to discontinue therapy prematurely.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6795, 0, 'Fludrocortisone', 'Muscular Diseases', 'Toxic myopathy has been observed with the chronic use or the administration of large doses of corticosteroids, often in patients with disorders of neuromuscular transmission such as myasthenia gravis or in patients receiving neuromuscular blocking agents.  Fluorinated corticosteroids such as betamethasone, dexamethasone, and triamcinolone appear to cause more severe muscle atrophy and weakness than the nonfluorinated agents.  Moreover, multiple-daily doses are more toxic than once-daily or, preferably, alternate-day morning doses.  Steroid myopathy is generalized and sometimes accompanied by respiratory weakness and dyspnea.  In some cases, it has resulted in quadriparesis.  Elevations of creatine kinase (CK) may also occur, albeit infrequently.  After withdrawal of corticosteroid therapy, recovery may be slow and incomplete.  Therapy with corticosteroids should be administered cautiously in patients with preexisting myopathy or myoneural disorders since these conditions may confound the diagnosis of steroid-induced myopathy.  The presence of a normal serum CK level, minimal/no changes of myopathy on electromyography, and type 2 muscle fiber atrophy on biopsy are helpful in suggesting steroid-induced weakness.  If steroid myopathy is suspected, a dosage reduction or discontinuation of the steroid should be considered.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6796, 0, 'Fludrocortisone', 'Keratitis, Herpetic', 'Pharmacologic dosages of corticosteroids should be used cautiously in patients with ocular herpes simplex because of the risk of corneal perforation.  Corticosteroids are not recommended for patients with active ocular herpes simplex.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6797, 0, 'Fludrocortisone', 'Toxic Optic Neuropathy', 'Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves.  Long-term therapy with corticosteroids should be administered cautiously in patients with a history of cataracts, glaucoma, or increased intraocular pressure.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6798, 0, 'Fludrocortisone', 'Osteoporosis', 'Corticosteroids reduce osteoblastic function and inhibit the absorption of intestinal calcium, which can result in bone resorption and bone loss during prolonged therapy.  In addition, bone matrix may be affected by the protein-catabolic effects of corticosteroids, especially when given in high dosages or for prolonged periods, leading to aseptic necrosis and fractures.  Long-term or high-dose corticosteroid therapy should be administered cautiously and only if necessary in patients with or at risk for osteoporosis.  Adverse skeletal effects may be minimized by alternate-day or intermittent administration.  Any patient receiving prolonged therapy with the equivalent of 7.5 mg prednisone/day or more are at risk for glucocorticoid-induced osteoporosis and should be managed according to The American College of Rheumatology (ACR) guidelines.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6799, 0, 'Fludrocortisone', 'Peptic Ulcer', 'Corticosteroids may cause peptic ulcer disease and gastrointestinal (GI) hemorrhage, usually when given in high dosages or for prolonged periods.  However, even conventional dosages may aggravate symptoms in patients with a history of peptic ulcers.  Delayed healing of ulcers has also been reported.  Therapy with corticosteroids should be avoided or administered cautiously in patients with active or latent peptic ulcers or other risk factors for GI bleeding.  Some clinicians recommend the use of prophylactic antacids or H2-antagonists between meals when large doses of corticosteroids are necessary.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6800, 0, 'Fludrocortisone', 'Scleroderma, Localized', 'In patients with scleroderma, corticosteroids may precipitate renal crisis with malignant hypertension, possibly via steroid-induced increases in renin substrate and angiotensin II levels and decreases in vasodilator prostaglandin production.  Renal failure may ensue.  Therapy with corticosteroids should be administered cautiously in patients with scleroderma.  In addition, they should be limited to short-term use.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6801, 0, 'Fludrocortisone', 'Strongyloidiasis', 'Unlike most helminths, Strongyloides stercoralis has the ability to replicate in the human host.  In patients with strongyloidiasis, the use of pharmacologic or immunosuppressive dosages of corticosteroids may result in Strongyloides hyperinfection and dissemination with widespread larval migration, often accompanied by severe enterocolitis and potentially fatal gram-negative septicemia.  Therapy with corticosteroids should be administered with extreme caution, if at all, in these patients.  For patients on corticosteroids who develop known or suspected Strongyloides infestation, withdrawal of corticosteroids or reduction of the dose of corticosteroids is recommended.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6802, 0, 'Fludrocortisone', 'Thromboembolism', 'Corticosteroids may increase blood coagulability and have rarely been associated with the development of intravascular thrombosis, thromboembolism, and thrombophlebitis.  Therapy with corticosteroids should be administered cautiously in patients who have or may be predisposed to thrombotic or thromboembolic disorders.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6803, 0, 'Flunisolide (nasal)', 'Adrenocortical Hyperfunction', 'The use of inhaled and nasal corticosteroids may rarely precipitate or aggravate conditions of hyperadrenocorticism.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.  The development of symptoms such as menstrual irregularities, acneiform lesions, cataracts and cushingoid features during inhaled or nasal corticosteroid therapy may indicate excessive use.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6804, 0, 'Flunisolide (nasal)', 'Infections', 'The immunosuppressant and anti-inflammatory effects of corticosteroids, particularly in higher dosages, may decrease host resistance to infectious agents, decrease the ability to localize infections, and mask the symptoms of infection.  Secondary infections may be more likely to develop.  Therapy with inhaled and nasal corticosteroids should be administered cautiously in patients with an infection, particularly active or quiescent tuberculosis infection of the respiratory tract or any untreated systemic fungal, bacterial, parasitic, or viral infection.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6805, 0, 'Flunisolide (nasal)', 'Keratitis, Herpetic', 'Pharmacologic dosages of corticosteroids may increase the risk of corneal perforation in patients with ocular herpes simplex.  Therapy with inhaled and nasal corticosteroids should be administered cautiously in such patients.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6806, 0, 'Flunisolide (nasal)', 'Toxic Optic Neuropathy', 'Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves.  Therapy with inhaled and nasal corticosteroids has only rarely produced these effects but should be administered cautiously nonetheless in patients with a history of cataracts, glaucoma, or increased intraocular pressure.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6807, 0, 'Flunisolide (nasal)', 'Osteoporosis', 'Prolonged use of inhaled corticosteroids may be associated with a reduction in bone density.  This effect appears to be dose-related and has been reported primarily with high dosages (>= 800 mcg/day of beclomethasone or equivalent for >= 1 year).  Reduced levels of total body calcium have also been demonstrated in patients receiving lower dosages.  Long-term therapy with inhaled and nasal corticosteroids should be administered cautiously in patients with osteoporosis.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6808, 0, 'Fluocinonide (topical)', 'Diabetes Mellitus', 'Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis.  Therapy with topical corticosteroids rarely produces these effects but should be administered cautiously nonetheless in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia.  Systemic absorption of topical corticosteroids may occur depending on the vehicle and concentration of the preparation, the size of the application area, the integrity of the skin, and the duration of administration.  Use of occlusive dressings over the applied areas may also increase percutaneous absorption.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.  If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6809, 0, 'Fluocinonide (topical)', 'Diaper Rash', 'Topical corticosteroids, especially the potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol), are generally not recommended for use in the treatment of diaper rash.  Topical corticosteroids may be systemically absorbed, depending on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Given equivalent doses, small children are usually at the greatest risk for systemic toxicity such as adrenal suppression, Cushing''s syndrome and intracranial hypertension because of their larger skin surface to body mass ratios.  If topical corticosteroids are necessary to treat diaper rash, medium- to low-potency agents should preferably be used, and parents should be advised not to put tight-fitting diapers or plastic pants over the rash, since occlusion of treated area may increase percutaneous drug absorption.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6810, 0, 'Fluocinonide (topical)', 'Adrenocortical Hyperfunction', 'The use of topical corticosteroids may precipitate or aggravate conditions of hyperadrenocorticism.  Systemic absorption of these agents can produce reversible hypothalamic-pituitary-adrenal axis suppression.  Systemic absorption, depends on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.  Patients with an altered skin barrier or liver failure are also at increased risk.  If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults.  The development of symptoms such as menstrual irregularities, acneiform lesions, cataracts and cushingoid features during topical corticosteroid therapy may indicate excessive use.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6811, 0, 'Fluocinonide (topical)', 'Infections', 'Topical corticosteroids may be systemically absorbed, depending on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Clinically significant local as well as systemic immunosuppressant and anti-inflammatory effects may occur, which can cause or exacerbate an infection.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.  Therapy with topical corticosteroids should be administered cautiously in patients with latent or active infections, particularly if a potent agent is used on a large area for prolonged periods or if occlusive dressings are used.  Effective antimicrobial therapy or other appropriate treatment should be instituted to treat the infection.  If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults.  Occlusive dressings should not be used in patients with skin infection.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6812, 0, 'Fluocinonide (topical)', 'Toxic Optic Neuropathy', 'Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves.  Therapy with topical corticosteroids rarely produces these effects but should be administered cautiously nonetheless in patients with a history of cataracts, glaucoma, or increased intraocular pressure, especially when potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) are used in the periorbital area.  Topical corticosteroids may be systemically absorbed, depending on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6813, 0, 'Fluoxymesterone', 'Prostatic Neoplasms', 'The use of androgenic anabolic steroids is contraindicated for male patients with carcinoma of the breast or prostate.  Circulating androgens can be converted in peripheral tissues to estrogens and dihydrotestosterone, which may act as promoters of tumor growth in the breast and prostate, respectively.  Likewise, androgenic agents may cause enlargement of the prostate and should be used cautiously in patients with or predisposed to prostatic hypertrophy.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6814, 0, 'Fluoxymesterone', 'Water-Electrolyte Imbalance', 'Androgenic anabolic steroids may cause sodium and water retention, particularly when given in high dosages or for prolonged periods.  Therapy with these agents should be administered cautiously in patients who have preexisting problems with fluid overload or are at risk for developing edema.  The manufacturers consider the use of androgenic agents to be contraindicated in patients with severe cardiac, renal and/or hepatic dysfunction.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6815, 0, 'Fluoxymesterone', 'Breast Neoplasms', 'When treated with androgenic anabolic steroids, patients with metastatic breast cancer may develop hypercalcemia due to osteolysis.  Frequent determination of urine and serum calcium levels is recommended during therapy with androgenic agents.  If hypercalcemia occurs, therapy should be stopped.  The development of hypercalcemia may indicate progression of metastases to the bone.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6816, 0, 'Fluoxymesterone', 'Hyperlipoproteinemias', 'Androgenic anabolic steroids may adversely affect serum lipids, including lowering HDL and elevating LDL levels.  These changes can be marked, particularly with the 17-alpha-alkyl derivatives (i.e., fluoxymesterone, methyltestosterone, oxandrolone, oxymetholone, and stanozolol), and may significantly impact the risk of atherosclerosis and coronary artery disease.  Patients with preexisting hyperlipoproteinemia may require closer monitoring during therapy with androgenic agents, and adjustments made accordingly in their lipid-lowering regimen.  Androgen therapy should be administered cautiously in patients with coronary artery disease or a history of ischemic heart disease.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6817, 0, 'Fluoxymesterone', 'Liver Diseases', 'The use of androgenic anabolic steroids may be associated with development of cholestatic hepatitis and jaundice.  Other, more serious hepatotoxicities such as peliosis hepatis and hepatocellular neoplasms are rare but may occur with prolonged use or high dosages.  These latter toxicities may be fatal and often not recognized until they become life-threatening.  Patients with preexisting liver diseases should be monitored more closely during therapy with anabolic steroids if they are used.  If liver function declines or toxicity occurs, therapy should be withdrawn and the cause investigated.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6818, 0, 'Fluoxymesterone', 'Polycythemia', 'Androgenic anabolic steroids may cause polycythemia when given in high dosages or for prolonged periods.  Patients with preexisting polycythemia may experience worsening of their condition.  Frequent monitoring of clinical status and hemoglobin and hematocrit levels is recommended if androgen therapy is administered to these patients.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6819, 0, 'Fluoxymesterone', 'Blood Coagulation Disorders', 'Androgenic anabolic steroids may cause suppression of clotting factors II, V, VII, and X, and an increase in prothrombin time.  Androgen therapy should be administered cautiously in patients with bleeding disorders.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6820, 0, 'Fluoxymesterone', 'Diabetes Mellitus', 'The metabolic effects of androgenic anabolic steroids may lower blood glucose.  Decreased glucose tolerance and increased insulin resistance have also been reported.  Patients with diabetes mellitus should be monitored more closely during therapy with androgenic agents, and their antidiabetic regimen adjusted accordingly.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6821, 0, 'Fluoxymesterone', 'Hypercalcemia', 'Androgenic anabolic steroids decrease urinary excretion of calcium, which may result in hypercalcemia.  Therapy with androgenic agents should be administered cautiously in patients with hypercalcemia, disorders of bone metabolism such as hyperparathyroidism, or renal dysfunction.  Some manufacturers consider the use of androgenic anabolic steroids to be contraindicated in patients with hypercalcemia.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6822, 0, 'Fluoxymesterone', 'Asthma', 'The brand name product, Halotestin of fluoxymesterone contain FD&C Yellow No. 5 (tartrazine), which can cause allergic-type reactions (including asthma) in certain susceptible individuals.  Caution is advised when using this product in patients with hypersensitivity to aspirin, serious allergies, and asthma.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6823, 0, 'Fluoxymesterone', 'Thyroid Diseases', 'When androgenic anabolic steroids are used in patients with thyroid disorders, clinicians should be aware that these agents may affect thyroid function tests.  Specifically, thyroid-binding globulin levels may be decreased, resulting in lower total T4 serum levels and increased resin uptake of T3 and T4.  Free thyroid hormone levels remain unchanged, however.', '1', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6824, 0, 'Fluorouracil', 'Bone Marrow Failure Disorders', '5- FU can cause severe and fatal myelosuppression.  Therapy with 5- FU should be administered cautiously in patients who have had prior high-dose pelvic irradiation or alkylating agents or who have widespread metastatic tumor involvement of the bone marrow.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Close clinical monitoring of hematopoietic function is recommended and therapy should be withheld if platelet counts falls below 100,000/mm3 and/or white blood cell (WBC) counts falls below 3500/mm3 or a rapid fall in WBC is noted.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6825, 0, 'Fluorouracil', 'Dihydropyrimidine Dehydrogenase Deficiency', 'Fluorouracil is metabolized to an inactive form by dihydropyrimidine dehydrogenase.  Inherited deficiency of this enzyme results in decreased clearance of 5-FU and severe toxicity such as stomatitis, diarrhea, neutropenia, and neurotoxicity.  Rechallenge with dosage reduction resulted in recurrence and progression of toxicity.  Therapy with fluorouracil should not be administered to patients with dihydropyrimidine deficiency.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6826, 0, 'Fluorouracil', 'Infections', 'Fluorouracil (5-FU) should not be used in patients with potentially serious infectious diseases.  5-FU induces myelosuppression.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during therapy with 5-FU.  Close clinical monitoring of hematopoietic function is recommended.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6827, 0, 'Fluorouracil', 'Stomatitis', 'Fluorouracil (5-FU) induces stomatitis in the gastrointestinal tract.  Therapy with 5-FU should be administered with extreme caution in patients with peptic ulcer disease and ulcerative colitis.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6828, 0, 'Fluorouracil', 'Hemorrhage', 'Fluorouracil (5- FU) induces myelosuppression, including thrombocytopenia.  Therapy with 5- FU should be administered cautiously in patients with bleeding tendencies.  Therapy with 5- FU should be promptly discontinued following bleeding from any sight.  Patients should be instructed to immediately report any signs or symptoms suggesting bleeding such as petechiae, purpura, hematuria, or melena.  Close clinical monitoring of hematopoietic function is recommended.  Therapy with 5- FU should be withheld if platelet counts falls below 100,000/mm3.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6829, 0, 'Fluorouracil', 'Coronary Artery Disease', 'Fluorouracil can cause cardiotoxicity, including angina, myocardial infarction, arrhythmia and heart failure based on post marketing reports.  Reported risk factors for cardiotoxicity include administration by continuous infusion rather than intravenous bolus and presence of coronary artery disease.  Caution and monitoring is advised in patients with coronary artery disease.  Treatment should be discontinued for cardiotoxicity.  The risks of treatment resumption after cardiotoxicity has been resolved have not been established.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6830, 0, 'Fluoxetine', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Families and caregivers should be advised of the need for close observation and communication with the treating physician.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6831, 0, 'Fluoxetine', 'Diabetes Mellitus', 'Fluoxetine may alter blood glucose control in patients with diabetes.  Hypoglycemia may occur during therapy with fluoxetine, and hyperglycemia may occur following discontinuation of the drug.  Dosage adjustments in insulin and/or oral hypoglycemic medications may be necessary in patients with diabetes whenever fluoxetine therapy is initiated or discontinued.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6832, 0, 'Fluoxetine', 'Hyponatremia', 'Treatment with SSRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6833, 0, 'Fluoxetine', 'Glaucoma', 'Some SSRI antidepressants such as fluoxetine, paroxetine and sertraline may have an effect on pupil size causing dilation.  This effect can potentially narrow the eye angle resulting in increased intraocular pressure and angle closure glaucoma, especially in predisposed patients.  These drugs should be used with caution in patients with angle-closure glaucoma or history of glaucoma.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6834, 0, 'Fluoxetine', 'Liver Diseases', 'Selective serotonin reuptake inhibitors (SSRIs) are primarily metabolized by the liver.  The plasma concentrations of SSRIs and their metabolites may be increased and the half-lives prolonged in patients with impaired hepatic function.  Dosage adjustments may be necessary in accordance with the individual product package labeling.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6835, 0, 'Fluoxetine', 'Mania', 'Selective serotonin reuptake inhibitors (SSRIs), like other antidepressants, may occasionally cause or activate mania or hypomania.  The reported incidence ranged from 0.1% to 2% in premarketing testing of several SSRIs.  Patients with bipolar disorder are generally more likely to experience mania from antidepressants.  Therapy with SSRIs should be administered cautiously in patients with a history of mania or bipolar disorder.  Prior to initiating treatment, it is recommended to adequately screen patients for bipolar disorder, including a family history of suicide, bipolar disorder, and depression.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6836, 0, 'Fluoxetine', 'Blood Platelet Disorders', 'The use of selective serotonin reuptake inhibitors (SSRIs) has been associated with altered platelet function.  Petechiae, purpura, ecchymosis, increased bleeding times, epistaxis and gastrointestinal hemorrhage have been reported.  Therapy with SSRIs should be administered cautiously in patients with severe active bleeding or a hemorrhagic diathesis.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6837, 0, 'Fluoxetine', 'Long QT Syndrome', 'Some SSRI antidepressants such as fluoxetine and citalopram have shown to cause QT interval prolongation and ventricular arrhythmias including Torsade de Pointes.  These drugs should be used with caution in patients with congenital QT syndrome, a previous personal or family history of QT prolongation, and ventricular arrhythmia.  Consider periodic EKG assessment on these patients.  Treatment should be discontinued and a cardiac evaluation should be considered if a patient develops signs or symptoms of ventricular arrhythmia.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6838, 0, 'Fluoxetine', 'Epilepsy', 'Selective serotonin reuptake inhibitors (SSRIs) may trigger seizures in approximately 0.2% of patients, and some of them are not recommended in patients with unstable epilepsy.  Therapy with SSRIs should be administered cautiously in patients with seizure disorders.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6839, 0, 'Fluoxetine', 'Inappropriate ADH Syndrome', 'The use of selective serotonin reuptake inhibitors (SSRIs) has rarely been associated with hyponatremia, sometimes secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  These events have generally been reversible following discontinuation of SSRI therapy and/or medical intervention.  SSRI-related hyponatremia may be more common in elderly female patients and those who are volume-depleted or receiving concomitant diuretic therapy.  Caution may be warranted when SSRI therapy is administered in these patients and patients with preexisting hyponatremia or SIADH.  Serum electrolytes, especially sodium as well as BUN and plasma creatinine, should be monitored regularly.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6840, 0, 'Fluoxetine', 'Kidney Diseases', 'Fluoxetine is primarily metabolized by the liver.  All but one metabolites are inactive, and they are excreted by the kidney.  The clearance of norfluoxetine, the active metabolite, is not dependent on renal function.  Dosage adjustments are generally not deemed necessary in patients with impaired renal function, although the clinical significance of possible metabolite accumulation is unknown.  Caution may be warranted when fluoxetine therapy is administered in patients with severe renal dysfunction.', '1', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6841, 0, 'Fluoxetine', 'Weight Loss', 'The use of selective serotonin reuptake inhibitors (SSRIs) may occasionally cause significant weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  Anorexia may occur in approximately 5% to 10% of patients.  Weight change should be monitored during therapy if an SSRI is used in these patients.', '1', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6842, 0, 'Fluorometholone (ophthalmic)', 'Eye Infections', 'The use of ophthalmic corticosteroids is contraindicated in most viral diseases of the cornea and conjunctiva, including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella; fungal diseases of ocular structures; mycobacterial infections, including tuberculosis, of the eye; and any acute, purulent, untreated ocular infections.  Corticosteroids may decrease host resistance to infectious agents, thus prolonging the course and/or exacerbating the severity of the infection while encouraging the development of new or secondary infection.  In addition, administration of ophthalmic corticosteroids in severe ocular disease, especially acute herpes simplex keratitis, may lead to excessive corneal and scleral thinning, increasing the risk for perforation.  In less serious ocular infections, therapy with ophthalmic corticosteroids may be administered but only with caution and accompanied by appropriate antimicrobial agents.  Besides compromising host immune response, corticosteroids may also mask the symptoms of infection, thus hindering the recognition of potential ineffectiveness of the antibiotic therapy.  If infection does not improve or becomes worse during administration of an ophthalmic corticosteroid, the drug should be discontinued and other appropriate therapy initiated.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6843, 0, 'Fluorometholone (ophthalmic)', 'Toxic Optic Neuropathy', 'Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves.  Therapy with ophthalmic corticosteroids should be administered cautiously in patients with a history of cataracts, glaucoma, or increased intraocular pressure.  If these agents are used for more than 10 days, the manufacturers recommend that intraocular pressure be routinely monitored, including in children.  The equatorial and posterior subcapsular portions of the lens should be examined for changes.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6844, 0, 'Amiodarone', 'Diseases requiring dialysis', 'Amiodarone and its active metabolite are not removed by hemodialysis.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6845, 0, 'Amiodarone', 'Respiratory Insufficiency', 'Pulmonary toxicities such as hypersensitivity pneumonitis or interstitial/alveolar pneumonitis are potentially fatal (approximately 10% of the time) and have occurred in as many as 10% to 17% of patients administered daily dosages of approximately 400 mg of amiodarone.  More frequently, asymptomatic abnormal diffusion capacity has been observed.  Patients with preexisting pulmonary dysfunction does not appear to have an increased risk of pulmonary toxicity; however, they have a poorer prognosis if toxicity does develop.  Thus, the risks and benefits of amiodarone therapy should be weighed carefully.  Clinical monitoring of pulmonary function, including chest X-ray (baseline and every 3 to 6 months) and pulmonary function tests (with diffusion capacity), is recommended in all patients receiving amiodarone therapy.  Any new respiratory symptom during treatment should be evaluated promptly and thoroughly, since toxicity is more likely to be reversible if diagnosed and managed early.  Patients who develop hypersensitivity pneumonitis should be withdrawn permanently from amiodarone therapy and treated with steroids.  In the case of interstitial/alveolar pneumonitis, steroid therapy and dosage reduction or discontinuation of amiodarone, if possible, usually result in clinical improvement.  Subsequent rechallenge with amiodarone at reduced dosages does not always lead to return of toxicity and may be considered in some patients.  The use of a lower loading dose and maintenance doses may also decrease the incidence of amiodarone- induced pulmonary toxicity.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6846, 0, 'Amiodarone', 'Sick Sinus Syndrome', 'The use of amiodarone is contraindicated for use in patients with cardiogenic shock, severe sinus node dysfunction causing marked sinus bradycardia, second- or third-degree AV block, or symptomatic bradycardia in the absence of a functioning pacemaker.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6847, 0, 'Amiodarone', 'Vision Disorders', 'Optic neuropathy and/or neuritis has occurred during administration of amiodarone and has resulted in visual impairment such as changes in visual acuity, decrease in peripheral vision, and blindness.  Optic toxicity can occur at any time following initiation of amiodarone.  Therapy with amiodarone should be administered cautiously in patients with visual defects.  Regular ophthalmologic examinations including fundoscopy and slit- lamp examinations are recommended.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6848, 0, 'Amiodarone', 'Cardiomyopathies', 'Antiarrhythmic agents can induce severe hypotension (particularly with IV administration) or induce or worsen congestive heart failure (CHF).  Patients with primary cardiomyopathy or inadequately compensated CHF are at increased risk.  Antiarrhythmic agents should be administered cautiously and dosage and/or frequency of administration modified in patients with hypotension or adequately compensated CHF.  Alternative therapy should be considered unless these conditions are secondary to cardiac arrhythmia.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6849, 0, 'Amiodarone', 'Arrhythmias, Cardiac', 'Antiarrhythmic agents can induce or worsen ventricular arrhythmias.  Ventricular tachycardia, ventricular fibrillation, and torsades de pointes have occurred in some patients.  Patients with underlying cardiac dysfunction, bradycardia, hypokalemia, hypomagnesemia, or high antiarrhythmic serum concentrations are at increased risk for drug-induced arrhythmias.  Therapy with antiarrhythmics should be used with extreme caution in patients with or predisposed to arrhythmias.  Evidence of improved survival is lacking for use of antiarrhythmic therapy in asymptomatic, non-life-threatening arrhythmias.  Therapy with antiarrhythmic agents should be reserved for patients with life-threatening arrhythmias.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6850, 0, 'Amiodarone', 'Hepatic Insufficiency', 'There have been rare reports of fatal hepatocellular necrosis after treatment with amiodarone.  In patients with life-threatening arrhythmias, the potential risk of hepatic injury should be weighed against the potential benefit of amiodarone therapy.  Patients with hepatic impairment should be monitored for evidence of progressive hepatic injury.  Consideration should be given to reducing the rate of administration or withdrawing treatment if needed.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6851, 0, 'Amiodarone', 'Neurologic Manifestations', 'Reversible and dose-related nervous system toxicity such as dizziness, paresthesia, tremor and involuntary movements, lack of coordination, abnormal gait and ataxia is commonly noted in patients receiving amiodarone.  Therapy with amiodarone should be administered cautiously and dosage modifications considered in patients with or predisposed to neurologic dysfunction.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6852, 0, 'Amiodarone', 'Hypothyroidism', 'Amiodarone inhibits peripheral conversion of thyroxine (T4) to triiodothyronine (T3) and also contributes inorganic iodine that can result in altered thyroid function tests, hypothyroidism, or hyperthyroidism.  Therapy with amiodarone should be administered cautiously in patients with thyroid dysfunction.  Clinical monitoring, including baseline and periodic evaluation of thyroid function is recommended.   Modification of thyroid therapy may be necessary.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6853, 0, 'Amiodarone', 'Water-Electrolyte Imbalance', 'Electrolyte imbalance can alter the therapeutic effectiveness of antiarrhythmic agents.  Hypokalemia and hypomagnesemia can reduce the effectiveness of antiarrhythmic agents.  In some cases, these disorders can exaggerate the degree of QTc prolongation and increase the potential for torsade de pointes.  Hyperkalemia can potentiate the toxic effects of antiarrhythmic agents.  Electrolyte imbalance should be corrected prior to initiating antiarrhythmic therapy.  Clinical monitoring of cardiac function and electrolyte concentrations is recommended.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6854, 0, 'Fluticasone (topical)', 'Diabetes Mellitus', 'Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis.  Therapy with topical corticosteroids rarely produces these effects but should be administered cautiously nonetheless in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia.  Systemic absorption of topical corticosteroids may occur depending on the vehicle and concentration of the preparation, the size of the application area, the integrity of the skin, and the duration of administration.  Use of occlusive dressings over the applied areas may also increase percutaneous absorption.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.  If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6855, 0, 'Fluticasone (topical)', 'Diaper Rash', 'Topical corticosteroids, especially the potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol), are generally not recommended for use in the treatment of diaper rash.  Topical corticosteroids may be systemically absorbed, depending on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Given equivalent doses, small children are usually at the greatest risk for systemic toxicity such as adrenal suppression, Cushing''s syndrome and intracranial hypertension because of their larger skin surface to body mass ratios.  If topical corticosteroids are necessary to treat diaper rash, medium- to low-potency agents should preferably be used, and parents should be advised not to put tight-fitting diapers or plastic pants over the rash, since occlusion of treated area may increase percutaneous drug absorption.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6856, 0, 'Fluticasone (topical)', 'Adrenocortical Hyperfunction', 'The use of topical corticosteroids may precipitate or aggravate conditions of hyperadrenocorticism.  Systemic absorption of these agents can produce reversible hypothalamic-pituitary-adrenal axis suppression.  Systemic absorption, depends on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.  Patients with an altered skin barrier or liver failure are also at increased risk.  If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults.  The development of symptoms such as menstrual irregularities, acneiform lesions, cataracts and cushingoid features during topical corticosteroid therapy may indicate excessive use.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6857, 0, 'Fluticasone (topical)', 'Infections', 'Topical corticosteroids may be systemically absorbed, depending on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Clinically significant local as well as systemic immunosuppressant and anti-inflammatory effects may occur, which can cause or exacerbate an infection.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.  Therapy with topical corticosteroids should be administered cautiously in patients with latent or active infections, particularly if a potent agent is used on a large area for prolonged periods or if occlusive dressings are used.  Effective antimicrobial therapy or other appropriate treatment should be instituted to treat the infection.  If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults.  Occlusive dressings should not be used in patients with skin infection.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6858, 0, 'Fluticasone (topical)', 'Toxic Optic Neuropathy', 'Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves.  Therapy with topical corticosteroids rarely produces these effects but should be administered cautiously nonetheless in patients with a history of cataracts, glaucoma, or increased intraocular pressure, especially when potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) are used in the periorbital area.  Topical corticosteroids may be systemically absorbed, depending on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6859, 0, 'Flurazepam', 'Alcoholic Intoxication', 'The use of benzodiazepines with alcohol is not recommended.  Patients with acute alcohol intoxication exhibit depressed vital signs.  The central nervous system depressant effects of benzodiazepines may be additive with those of alcohol, and severe respiratory depression and death may occur.  Therapy with benzodiazepines should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6860, 0, 'Flurazepam', 'Glaucoma, Angle-Closure', 'The manufacturers consider the use of benzodiazepines to be contraindicated in patients with acute angle-closure glaucoma or untreated open-angle glaucoma.  These agents do not possess anticholinergic activity but have very rarely been associated with increased intraocular pressure.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6861, 0, 'Flurazepam', 'Substance-Related Disorders', 'Benzodiazepines have the potential to cause dependence and abuse.  Tolerance as well as physical and psychological dependence can develop, particularly after prolonged use and/or excessive dosages.  However, abrupt cessation following continual use of as few as 6 weeks at therapeutic levels has occasionally precipitated withdrawal symptoms.  Addiction- prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance when treated with benzodiazepines.  It may be prudent to refrain from dispensing large quantities of medication to these patients.  After prolonged use or if dependency is suspected, withdrawal of benzodiazepine therapy should be undertaken gradually using a dosage- tapering schedule.  If withdrawal symptoms occur, temporary reinstitution of benzodiazepines may be necessary.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6862, 0, 'Flurazepam', 'Liver Diseases', 'Benzodiazepines are metabolized by the liver, and the metabolites are excreted in the urine.  Chlordiazepoxide, clorazepate, diazepam, flurazepam and quazepam undergo oxidative N-dealkylation to active metabolites that are substantially longer-acting than the parent compound.  These metabolites then undergo further biotransformation to pharmacologically inactive products before excretion by the kidney.  Therapy with benzodiazepines should be administered cautiously at lower initial dosages in patients with impaired renal and/or hepatic function.  Agents that are converted to weakly active, short-acting, or inactive metabolites may be preferable in hepatic impairment.  Lorazepam, oxazepam and temazepam are conjugated to inactive metabolites, while alprazolam, estazolam and triazolam undergo hydroxylation to weakly active or inactive metabolites.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6863, 0, 'Flurazepam', 'Respiratory Insufficiency', 'Benzodiazepines may cause respiratory depression and apnea, usually when given in high dosages and/or by intravenous administration.  However, some patients may be susceptible at commonly used dosages, including the elderly, debilitated or severely ill patients, those receiving other CNS depressants, and those with limited ventilatory reserve, chronic pulmonary insufficiency or other respiratory disorders.  Therapy with benzodiazepines should be administered cautiously in these patients.  Appropriate monitoring and individualization of dosage are particularly important, and equipment for resuscitation should be immediately available if the parenteral route is used.  Benzodiazepines, especially injectable formulations, should generally be avoided in patients with sleep apnea, severe respiratory insufficiency, or hypoxia.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6864, 0, 'Flurazepam', 'Seizures', 'The use of benzodiazepines in patients with seizure disorders may increase the incidence or precipitate the onset of generalized tonic-clonic seizures (grand mal).  Appropriate anticonvulsant medication might need to be initiated or the dosage increased.  Abrupt cessation of benzodiazepine therapy may precipitate seizures and other withdrawal symptoms, particularly after prolonged use and/or excessive dosages.  Status epilepticus may occur in patients with a history of seizures withdrawn rapidly from benzodiazepine therapy.  Following chronic administration, cessation of benzodiazepine therapy should occur gradually with incrementally reduced dosages.  Patients should be advised not to discontinue medication without first consulting with the physician.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6865, 0, 'Flurazepam', 'Depressive Disorder', 'Benzodiazepines depress the central nervous system and may cause or exacerbate mental depression and cause suicidal behavior and ideation.  Episodes of mania and hypomania have also been reported in depressed patients treated with some of these agents.  Therapy with benzodiazepines should be administered cautiously in patients with a history of depression or other psychiatric disorders.  Patients should be monitored for any changes in mood or behavior.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6866, 0, 'Flurazepam', 'Obesity', 'The plasma half-lives of benzodiazepines may be prolonged in obese patients, presumably due to increased distribution into fat.  Marked increases in distribution (> 100%) have been reported for diazepam and midazolam, and moderate increases (25% to 100%) for alprazolam, lorazepam, and oxazepam.  Therapy with benzodiazepines should be administered cautiously in obese patients, with careful monitoring of CNS status.  Longer dosing intervals may be appropriate.  When dosing by weight, loading doses should be based on actual body weight, while maintenance dose should be based on ideal body weight to avoid toxicity.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6867, 0, 'Flurazepam', 'Psychotic Disorders', 'Paradoxical reactions, including excitability, irritability, aggressive behavior, agitation, nervousness, hostility, anxiety, sleep disturbances, nightmares and vivid dreams, have been reported with the use of benzodiazepines in psychiatric patients and pediatric patients with hyperactive aggressive disorders.  Such patients should be monitored for signs of paradoxical stimulation during therapy with benzodiazepines.  The manufacturers do not recommend the use of benzodiazepines for the treatment of psychosis.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6868, 0, 'Fomepizole', 'Liver Failure', 'The pharmacokinetic disposition of fomepizole has not been determined in patients with hepatic and/or renal impairment.  Fomepizole is extensively metabolized by the liver.  Following multiple dosing, fomepizole induces its own metabolism and the rate of elimination is increased.  About 1% to 3.5% of fomepizole is eliminated unchanged in the urine.  Therapy with fomepizole should be administered cautiously in patients with compromised hepatic and/or renal function.  Fomepizole is dialyzable and the frequency of dosing should be increased to every 4 hours during hemodialysis.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6869, 0, 'Fluphenazine', 'Dementia', 'Older patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death; although the causes were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.  A causal relationship with antipsychotic use has not been established.  In controlled trials in older patients with dementia-related psychosis, patients randomized to risperidone, aripiprazole, and olanzapine had higher incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack), including fatalities, compared to patients treated with placebo.  These agents are not approved for the treatment of patients with dementia-related psychosis.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6870, 0, 'Fluphenazine', 'Alcoholic Intoxication', 'The use of phenothiazines is contraindicated in patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of phenothiazines may be additive with those of alcohol.  Severe respiratory depression and respiratory arrest may occur.  Therapy with phenothiazines should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6871, 0, 'Fluphenazine', 'Cardiovascular Diseases', 'Phenothiazines may cause hypotension (including orthostatic hypotension), reflex tachycardia, increased pulse rate, syncope, and dizziness, particularly after the first parenteral dose but rarely after the first oral dose.  Low-potency agents such as chlorpromazine and thioridazine are more likely to induce these effects, which usually subside within the first couple of hours following administration.  Tolerance to the hypotensive effects often develops after a few doses.  Rarely, fatal cardiac arrest has occurred secondary to severe hypotension.  Other reported adverse cardiovascular effects include edema, thrombosis, and ECG abnormalities such as PR and QT interval prolongation, diffuse T-wave flattening, and ST segment depression.  Therapy with phenothiazines should be avoided or otherwise administered cautiously in patients with severe cardiovascular disease, pheochromocytoma, a predisposition to hypotension, or conditions that could be exacerbated by hypotension such as a history of myocardial infarction, angina, or ischemic stroke.  Close monitoring of cardiovascular status, including ECG changes, is recommended at all dosages.  If parenteral therapy is given, patients should be in a supine position during administration and for at least 30 to 60 minutes afterwards.  Patients who experience orthostatic hypotension should be cautioned not to rise too abruptly.  Occasionally, when severe, hypotension may require treatment with vasoconstrictive agents such as norepinephrine or phenylephrine.  Epinephrine should not be used, however, since phenothiazines can reverse its vasopressor effects and cause a further lowering of blood pressure.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6872, 0, 'Fluphenazine', 'Respiratory Insufficiency', 'The use of phenothiazines is contraindicated in comatose patients and patients with severe central nervous system depression.  Phenothiazines may potentiate the CNS and respiratory depression in these patients.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6873, 0, 'Fluphenazine', 'Craniocerebral Trauma', 'The use of phenothiazines is contraindicated in patients with suspected or established subcortical brain damage, with or without hypothalamic involvement.  Phenothiazines can interfere with thermoregulatory mechanisms, and a hyperthermic reaction with temperatures in excess of 104 F may occur in such patients, sometimes not until 14 to 16 hours after drug administration.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6874, 0, 'Fluphenazine', 'Anticholinergic Syndrome', 'Phenothiazines have anticholinergic activity, to which elderly patients are particularly sensitive.  Low-potency agents such as chlorpromazine and thioridazine tend to exhibit greater anticholinergic effects than other agents in the class.  Therapy with phenothiazines should be administered cautiously in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6875, 0, 'Fluphenazine', 'Breast Neoplasms', 'The chronic use of phenothiazines is associated with persistent elevations in prolactin levels.  Based on in vitro data, approximately one-third of human breast cancers are thought to be prolactin-dependent.  The clinical significance of this observation is unknown.  Chronic administration of neuroleptic drugs has been associated with mammary tumorigenesis in rodent studies but not in human clinical or epidemiologic studies.  Therapy with phenothiazines should be administered cautiously in patients with existing or suspected malignancy of the breast.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6876, 0, 'Fluphenazine', 'Dystonic Disorders', 'Phenothiazines may cause acute, dose-related dystonic reactions secondary to central dopaminergic blockade.  These reactions are characterized by spastic contraction of discrete muscle groups and may include torticollis, opisthotonos, carpopedal spasm, trismus, difficulty swallowing, perioral spasms with protrusion of the tongue, and oculogyric crisis.  Onset is usually within 24 to 96 hours following initiation of therapy or an increase in dosage.  Risk factors include young age, male gender, use of high-potency agents (e.g., fluphenazine, perphenazine, trifluoperazine), high dosages, and IM administration.  Therapy with phenothiazines should be administered cautiously in patients, particularly children, with hypocalcemia or severe dehydration, since these patients may be more susceptible to dystonic reactions.  Most symptoms subside within a few hours and are almost always reversible within 24 to 48 hours following withdrawal of therapy.  However, severe reactions such as laryngospasm may be life-threatening and require appropriate supportive therapy.  Parenteral administration of an anticholinergic antiparkinsonian agent (e.g., benztropine, trihexyphenidyl) or diphenhydramine usually produces a prompt response and may be given orally for short-term maintenance to prevent recurrence of symptoms if phenothiazine therapy must be continued.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6877, 0, 'Fluphenazine', 'Hematologic Diseases', 'Phenothiazines may infrequently cause hematologic toxicity, including agranulocytosis, thrombocytopenia, eosinophilia, aplastic anemia, purpura, granulocytopenia, and hemolytic anemia.  Mild leukopenia may occur frequently with large doses over prolonged periods but is generally reversible despite continued treatment.  Therapy with phenothiazines should be administered cautiously, if at all, in patients with preexisting blood dyscrasias or bone marrow suppression.  Complete blood counts should be obtained regularly, and patients should be instructed to immediately report any signs or symptoms suggestive of blood dyscrasia such as fever, sore throat, local infection, bleeding, pallor, dizziness, or jaundice.  Most cases of agranulocytosis have occurred between the fourth and tenth weeks of therapy.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6878, 0, 'Fluphenazine', 'Liver Diseases', 'Phenothiazines are extensively metabolized by the liver and may accumulate in patients with hepatic impairment.  In addition, the use of some phenothiazines has been associated with adverse hepatic effects including cholestatic jaundice and elevated liver enzymes, generally within the first few months of therapy.  Cholestatic jaundice usually occurs between the second and fourth weeks of therapy in approximately 0.1% to 4% of all patients.  Therapy with phenothiazines should be administered cautiously in patients with preexisting liver disease, liver enzyme abnormalities, or hepatitis.  Liver function and urine bilirubin tests should be performed periodically during prolonged therapy, and patients should be instructed to immediately report any signs or symptoms suggestive of cholestatic jaundice such as upper abdominal pain, nausea, yellow skin, influenza-like symptoms, rash, and fever.  Phenothiazine therapy should be discontinued, preferably permanently, if jaundice occurs and is attributable to the drug.  Clinical recovery is usually observed within a few weeks following withdrawal of therapy, although histopathologic changes may persist for longer periods.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6879, 0, 'Fluphenazine', 'Neuroleptic Malignant Syndrome', 'The central dopaminergic blocking effects of phenothiazines may precipitate or aggravate a potentially fatal symptom complex known as Neuroleptic Malignant Syndrome (NMS).  NMS is observed most frequently when high-potency neuroleptic agents like haloperidol or fluphenazine are administered intramuscularly but may occur with any agent possessing neuroleptic activity given for any length of time.  Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, altered mental status and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac arrhythmias).  Phenothiazine therapy should not be initiated in patients with active NMS and should be immediately discontinued if currently being administered in such patients.  In patients with a history of NMS, introduction or reintroduction of phenothiazines should be carefully considered, since NMS may recur.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6880, 0, 'Fluphenazine', 'Parkinsonian Disorders', 'The use of phenothiazines is associated with pseudo-parkinsonian symptoms such as akinesia, bradykinesia, tremors, pill-rolling motion, cogwheel rigidity, and postural abnormalities including stooped posture and shuffling gait.  The onset is usually 1 to 2 weeks following initiation of therapy or an increase in dosage.  Propylamino derivatives such as chlorpromazine, promazine, and triflupromazine may be more likely to induce these effects.  Therapy with phenothiazines should be administered cautiously in patients with Parkinson''s disease or parkinsonian symptoms.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6881, 0, 'Fluphenazine', 'Kidney Diseases', 'Phenothiazines and their metabolites are excreted by the kidney.  There are very limited data concerning the use of phenothiazines in patients with renal disease.  Therapy with phenothiazines should be administered cautiously in patients with significantly impaired renal function.  The manufacturers recommend periodic renal function tests for all patients during prolonged therapy.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6882, 0, 'Fluphenazine', 'Lung Diseases', 'Phenothiazines may suppress the cough reflex.  Therapy with phenothiazines should be administered cautiously in patients with chronic respiratory disorders, including severe asthma, emphysema, or acute respiratory tract infections.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6883, 0, 'Fluphenazine', 'Epilepsy', 'Phenothiazines can lower the seizure threshold and induce seizures, particularly when dosages are high or increased rapidly and during the initiation of therapy.  Of the phenothiazines used in the treatment of psychosis, chlorpromazine appears to have the greatest epileptogenic potential, while fluphenazine and thioridazine have the least.  Therapy with phenothiazines should be administered cautiously in patients with a history of seizures or other factors predisposing to seizures such as abnormal EEG, preexisting CNS pathology, or head trauma.  Adequate anticonvulsant therapy should be maintained during administration of phenothiazines.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6884, 0, 'Fluphenazine', 'Tardive Dyskinesia', 'Phenothiazines may commonly precipitate symptoms of tardive dyskinesia (TD), a syndrome consisting of rhythmic involuntary movements variously involving the tongue, face, mouth, lips, jaw, and/or trunk and extremities, following chronic use of at least several months but often years.  Elderly patients, particularly women, are most susceptible.  Also, propylpiperazine derivatives like fluphenazine, perphenazine, prochlorperazine, and trifluoperazine may be more likely to induce this syndrome.  Both the risk of developing TD and the likelihood that it will become irreversible increase with the duration and total cumulative dose of phenothiazine therapy administered.  However, patients may infrequently develop symptoms after relatively brief treatment periods at low dosages.  If TD occurs during phenothiazine therapy, prompt withdrawal of the offending agent or at least a lowering of the dosage should be considered.  TD symptoms usually become more severe after drug discontinuation or a dosage reduction, but may gradually improve over months to years.  In patients with preexisting drug-induced TD, initiating or increasing the dosage of phenothiazine therapy may temporarily mask the symptoms of TD but may eventually worsen the condition.  The newer, atypical neuroleptic agents (e.g., risperidone, quetiapine, olanzapine) tend to be associated with a substantially reduced risk of inducing TD and are considered the drugs of choice in patients being treated for psychosis.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6885, 0, 'Flurbiprofen (ophthalmic)', 'Asthma', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) are contraindicated in patients with history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs; severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients.  A subpopulation of patients with asthma may have aspirin-sensitive asthma which may include chronic rhinosinusitis complicated by nasal polyps, severe potentially fatal bronchospasm, and/or intolerance to aspirin and other NSAIDs.  Since cross-reactivity between aspirin and other NSAIDs has been reported in such aspirin-sensitive patients, therapy with any NSAID should be avoided in patients with this form of aspirin sensitivity.  NSAIDs should be used with caution in patients with preexisting asthma (without known aspirin sensitivity), and these patients should be monitored for changes in the signs and symptoms of asthma.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6886, 0, 'Flurbiprofen (ophthalmic)', 'Blood Platelet Disorders', 'Topically applied nonsteroidal anti-inflammatory drugs (NSAIDs) are systemically absorbed, with the potential for producing rare but clinically significant systemic effects.  NSAIDs have been shown to reversibly inhibit platelet adhesion and aggregation and may slightly prolong bleeding time in healthy individuals.  These effects may be more pronounced in patients with underlying hemostatic abnormalities.  Thrombocytopenia has also been reported rarely during NSAID use.  Therapy with ocular NSAIDs should be administered cautiously in patients with significant active bleeding or a hemorrhagic diathesis, including hemostatic and/or coagulation defects associated with hemophilia, vitamin K deficiency, hypoprothrombinemia, thrombocytopenia, thrombocytopathy, or severe hepatic impairment.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6887, 0, 'Fluticasone', 'Hepatic Insufficiency', 'Corticosteroids are predominantly cleared by hepatic metabolism and impairment of the liver function may lead to their accumulation.  Patients with hepatic disease should be closely monitored.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6888, 0, 'Fluticasone', 'Adrenocortical Hyperfunction', 'The use of inhaled and nasal corticosteroids may rarely precipitate or aggravate conditions of hyperadrenocorticism.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.  The development of symptoms such as menstrual irregularities, acneiform lesions, cataracts and cushingoid features during inhaled or nasal corticosteroid therapy may indicate excessive use.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6889, 0, 'Fluticasone', 'Infections', 'The immunosuppressant and anti-inflammatory effects of corticosteroids, particularly in higher dosages, may decrease host resistance to infectious agents, decrease the ability to localize infections, and mask the symptoms of infection.  Secondary infections may be more likely to develop.  Therapy with inhaled and nasal corticosteroids should be administered cautiously in patients with an infection, particularly active or quiescent tuberculosis infection of the respiratory tract or any untreated systemic fungal, bacterial, parasitic, or viral infection.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6890, 0, 'Fluticasone', 'Keratitis, Herpetic', 'Pharmacologic dosages of corticosteroids may increase the risk of corneal perforation in patients with ocular herpes simplex.  Therapy with inhaled and nasal corticosteroids should be administered cautiously in such patients.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6891, 0, 'Fluticasone', 'Toxic Optic Neuropathy', 'Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves.  Therapy with inhaled and nasal corticosteroids has only rarely produced these effects but should be administered cautiously nonetheless in patients with a history of cataracts, glaucoma, or increased intraocular pressure.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6892, 0, 'Fluticasone', 'Osteoporosis', 'Prolonged use of inhaled corticosteroids may be associated with a reduction in bone density.  This effect appears to be dose-related and has been reported primarily with high dosages (>= 800 mcg/day of beclomethasone or equivalent for >= 1 year).  Reduced levels of total body calcium have also been demonstrated in patients receiving lower dosages.  Long-term therapy with inhaled and nasal corticosteroids should be administered cautiously in patients with osteoporosis.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6893, 0, 'Fluvastatin', 'Liver Diseases', 'The use of HMG-CoA reductase inhibitors is contraindicated in patients with active liver disease or unexplained, persistent elevations of serum transaminases.  HMG-CoA reductase inhibitors are extensively metabolized by the liver.  Decreased drug metabolism may lead to accumulation and increased risk of toxicity, including biochemical abnormalities of liver function and, rarely, jaundice, hepatitis, cirrhosis, fatty change in the liver, and fulminant hepatic necrosis.  Therapy with HMG-CoA reductase inhibitors should be administered cautiously in patients with a history of liver disease and/or heavy alcohol use.  A lower initial dosage may be appropriate, and clinical monitoring of liver transaminase levels according to the individual product package labeling is recommended.  Patients who develop elevated  ALT or AST levels during therapy should be monitored until abnormalities resolve.  If an increase above 3 times the upper limit of normal persists, consideration should be given to a reduction in dosage or withdrawal of therapy.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6894, 0, 'Fluvastatin', 'Rhabdomyolysis', 'Severe myopathy, including rhabdomyolysis with acute renal failure secondary to myoglobinuria, has been reported rarely with the use of HMG-CoA reductase inhibitors.  The myopathy may be dose-related and is characterized by muscle aches and/or weakness in conjunction with increases in creatine phosphokinase (CPK) values exceeding 10 times the upper limit of normal.  Therapy with HMG-CoA reductase inhibitors should be administered cautiously in patients with preexisting myopathy, in those with predisposing factors for myopathy or with a history of myoneural disorder, since it may delay the recognition or confound the diagnosis of a drug-induced musculoskeletal effect.  Patients should be advised to report promptly any unusual muscle pain, tenderness or weakness, particularly if accompanied by malaise or fever.  Periodic CPK determinations may be considered in some patients, although the value of such monitoring is uncertain.  HMG-CoA reductase inhibitor therapy should be withdrawn if markedly elevated CPK levels occur or if drug-related myopathy is diagnosed or suspected.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6895, 0, 'Fluvastatin', 'Cognitive Dysfunction', 'Cognitive impairment (e.g., memory loss, forgetfulness, amnesia, memory impairment, confusion) have been observed in patients receiving statins.  The reports are usually not serious, and reversible upon statin discontinuation.  Caution is recommended when using these agents in patients with cognitive impairment.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6896, 0, 'Fluvastatin', 'Diabetes Mellitus', 'Increases in HbA1c and fasting serum glucose levels have been reported with the use of certain HMG-CoA reductase inhibitors.  Caution should be exercised when using these agents in diabetic patients and close monitoring is recommended.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6897, 0, 'Fluvastatin', 'Kidney Diseases', 'Some HMG-CoA reductase inhibitors such as fluvastatin, have not been studied in patients with severe renal impairment or end-stage renal disease.  Some others such as pitavastatin and simvastatin, require a dose reduction when used in this group of patients.  Caution and close monitoring is advised when using these drugs in patients with renal impairment.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6898, 0, 'Fosaprepitant', 'Long QT Syndrome', 'Fosaprepitant, a prodrug of aprepitant, is a weak inhibitor of CYP3A4, and aprepitant is a substrate, inhibitor, and inducer of CYP3A4.  An increased plasma concentration of fosaprepitant could cause QT prolongation.  Caution is advised in patients with long QT, and in patients receiving other drugs that are CYP3A4 substrates as it may result in a risk of higher plasma concentrations and adverse events.  Close monitoring is recommended in these patients.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6899, 0, 'Fosaprepitant', 'Liver Failure', 'There are no clinical or pharmacokinetic data in patients with severe hepatic impairment (Child-Pugh greater than 9), therefore caution and monitoring is recommended when using fosaprepitant in these patients.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6900, 0, 'Fluticasone (nasal)', 'Adrenocortical Hyperfunction', 'The use of inhaled and nasal corticosteroids may rarely precipitate or aggravate conditions of hyperadrenocorticism.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.  The development of symptoms such as menstrual irregularities, acneiform lesions, cataracts and cushingoid features during inhaled or nasal corticosteroid therapy may indicate excessive use.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6901, 0, 'Fluticasone (nasal)', 'Infections', 'The immunosuppressant and anti-inflammatory effects of corticosteroids, particularly in higher dosages, may decrease host resistance to infectious agents, decrease the ability to localize infections, and mask the symptoms of infection.  Secondary infections may be more likely to develop.  Therapy with inhaled and nasal corticosteroids should be administered cautiously in patients with an infection, particularly active or quiescent tuberculosis infection of the respiratory tract or any untreated systemic fungal, bacterial, parasitic, or viral infection.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6902, 0, 'Fluticasone (nasal)', 'Keratitis, Herpetic', 'Pharmacologic dosages of corticosteroids may increase the risk of corneal perforation in patients with ocular herpes simplex.  Therapy with inhaled and nasal corticosteroids should be administered cautiously in such patients.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6903, 0, 'Fluticasone (nasal)', 'Toxic Optic Neuropathy', 'Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves.  Therapy with inhaled and nasal corticosteroids has only rarely produced these effects but should be administered cautiously nonetheless in patients with a history of cataracts, glaucoma, or increased intraocular pressure.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6904, 0, 'Fluticasone (nasal)', 'Osteoporosis', 'Prolonged use of inhaled corticosteroids may be associated with a reduction in bone density.  This effect appears to be dose-related and has been reported primarily with high dosages (>= 800 mcg/day of beclomethasone or equivalent for >= 1 year).  Reduced levels of total body calcium have also been demonstrated in patients receiving lower dosages.  Long-term therapy with inhaled and nasal corticosteroids should be administered cautiously in patients with osteoporosis.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6905, 0, 'Follitropin', 'Adrenal Insufficiency', 'The use of follicle stimulating hormone (FSH) is contraindicated in patients with uncontrolled adrenal dysfunction.  Uncontrolled adrenal dysfunction may involve the pituitary gland and be associated with a tumor or other dysfunction.  Administration of FSH may exacerbate the condition.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6906, 0, 'Follitropin', 'Hypothyroidism', 'The use of follicle stimulating hormone (FSH) is contraindicated in patients with uncontrolled thyroid dysfunction.  FSH is composed of both an alpha and beta subunit.  The amino acid sequence of the alpha subunit of FSH is identical to that of TSH.  Therefore, FSH may have weak TSH receptor- binding and activation.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6907, 0, 'Follitropin', 'Neoplasms', 'The use of follicle stimulating hormone is contraindicated in patients with sex hormone-dependent tumors of the reproductive tract and accessory organs (ovary, breast, uterus) and in patients with pituitary tumors.  FSH is required for normal sex hormone production, which may be detrimental in these patients.  Patients in later reproductive life have a greater predisposition to endometrial carcinoma.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6908, 0, 'Folic acid', 'Anemia', 'The use of folic acid is contraindicated in patients with undiagnosed anemia.  Folic acid in dosages above 1 mg/day can obscure the diagnosis of pernicious anemia by alleviating the hematologic abnormalities while allowing the progression of neurologic complications.  In addition, folic acid alone is improper therapy in the treatment of pernicious anemia and other megaloblastic anemias where vitamin B12 is deficient.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6909, 0, 'Flurbiprofen', 'Asthma', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) are contraindicated in patients with history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs; severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients.  A subpopulation of patients with asthma may have aspirin-sensitive asthma which may include chronic rhinosinusitis complicated by nasal polyps, severe potentially fatal bronchospasm, and/or intolerance to aspirin and other NSAIDs.  Since cross-reactivity between aspirin and other NSAIDs has been reported in such aspirin-sensitive patients, therapy with any NSAID should be avoided in patients with this form of aspirin sensitivity.  NSAIDs should be used with caution in patients with preexisting asthma (without known aspirin sensitivity), and these patients should be monitored for changes in the signs and symptoms of asthma.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6910, 0, 'Flurbiprofen', 'Water-Electrolyte Imbalance', 'Fluid retention and edema have been reported in association with the use of nonsteroidal anti-inflammatory drugs (NSAIDs).  Therapy with NSAIDs should be administered cautiously in patients with preexisting fluid retention, hypertension, or a history of heart failure.  Blood pressure and cardiovascular status should be monitored closely during the initiation of NSAID treatment and throughout the course of therapy.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6911, 0, 'Flurbiprofen', 'Peptic Ulcer', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) can cause serious gastrointestinal (GI) adverse events including inflammation, bleeding, ulceration, and perforation of the esophagus, stomach, small intestine, or large intestine, which can be fatal.  These serious adverse events can develop at any time, with or without warning symptoms.  Only 1 in 5 patients who develop a serious upper GI side effect on NSAIDs is symptomatic.  NSAIDs should be used with caution in patients with history of peptic ulcer disease and/or GI bleeding, as these patients had a greater than 10-fold increased risk for developing a GI bleed compared to patients without these risk factors.  Caution is also advised if NSAIDs are prescribed to patients with other factors that increase risk of GI bleeding, such as:  prolonged NSAID therapy; concomitant use of oral corticosteroids, antiplatelet agents (e.g., aspirin), anticoagulants, selective serotonin reuptake inhibitors; alcohol use; smoking; history of gastrointestinal surgery or anastomosis, older age; poor general health status; and advanced liver disease and/or coagulopathy.  Particular vigilance is necessary when treating elderly or debilitated patients since most postmarketing reports of fatal GI events occurred in these patients.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6912, 0, 'Flurbiprofen', 'Exanthema', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) can cause serious skin adverse reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis, and exfoliative dermatitis), which can be fatal.  These serious events may occur without warning.  Patients should be advised to discontinue the NSAID and seek medical attention promptly at the first sign of skin rash or any other sign of hypersensitivity.  NSAIDs are contraindicated in patients with previous serious skin reactions to these drugs.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6913, 0, 'Flurbiprofen', 'Kidney Diseases', 'Long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs) has resulted in renal papillary necrosis and other renal injury.  Renal toxicity has been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion:  in such patients, NSAIDs may cause a dose-dependent reduction in prostaglandin synthesis and, secondarily, in renal blood flow, which may precipitate overt renal decompensation.  Patients at greatest risk for this reaction include the elderly, those with impaired renal function, dehydration, hypovolemia, heart failure, or liver dysfunction, and those taking diuretics, angiotensin-converting enzyme inhibitors, or angiotensin receptor blockers; discontinuation of NSAID therapy will usually lead to recovery to the pretreatment state.  No information is available regarding use NSAIDs in patients with advanced renal disease; the renal effects of NSAIDs may hasten the progression of renal dysfunction in patients with preexisting renal disease.  Volume status should be corrected in dehydrated or hypovolemic patients prior to initiating treatment.  Renal function should be monitored during therapy in patients with renal or liver dysfunction, heart failure, dehydration, or hypovolemia.  NSAIDs should be avoided in patients with advanced renal disease unless the benefits are expected to outweigh the risk of worsening renal function; if an NSAID is used in such patients, they should be monitored for signs of worsening renal function.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6914, 0, 'Flurbiprofen', 'Thrombosis', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal.  This risk may occur early in treatment and may increase with duration of use.  Clinical trials of several cyclooxygenase-2 (COX-2) selective and nonselective NSAIDs of up to 3 years duration have supported this increased risk.  It is unclear from available data if the risk for cardiovascular thrombotic events is similar for all NSAIDs.  Therapy with NSAIDs should be administered cautiously in patients with a history of cardiovascular or cerebrovascular disease.  Patients should be treated with the lowest effective dosage for the shortest duration necessary.  Appropriate antiplatelet therapy should be administered to patients requiring cardioprotection; however, there is no consistent evidence that concurrent use of aspirin mitigates the increased risk of serious cardiovascular thrombotic events associated with NSAID use, while the risk of serious gastrointestinal events is increased.  Physicians and patients should remain alert for the development of adverse cardiovascular events throughout the entire duration of therapy, even without prior cardiovascular symptoms.  Patients should be advised to promptly seek medical attention if they experience symptoms of cardiovascular thrombotic events (including chest pain, shortness of breath, weakness, or slurring of speech).NSAIDs are contraindicated in the setting of coronary artery bypass graft (CABG) surgery.  Two large clinical trials of a COX-2 selective NSAID for the treatment of pain in the first 10 to 14 days following CABG surgery found an increased incidence of myocardial infarction and stroke.The use of NSAIDs should be avoided in patients with a recent myocardial infarction unless the benefits are expected to outweigh the risk of recurrent cardiovascular thrombotic events.  If an NSAID is used in patients with a recent myocardial infarction, they should be monitored for signs of cardiac ischemia.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6915, 0, 'Flurbiprofen', 'Anemia', 'Anemia has been reported in patients treated with nonsteroidal anti-inflammatory drugs (NSAIDs).  This may be due to fluid retention, occult/gross blood loss, or an incompletely described effect on erythropoiesis.  Hemoglobin or hematocrit should be monitored in patients with any signs/symptoms of anemia or blood loss, especially during long-term therapy.  NSAIDs may increase risk of bleeding events; comorbid conditions (e.g., coagulation disorders; concomitant use of warfarin/other anticoagulants, antiplatelet agents, serotonin/serotonin norepinephrine reuptake inhibitors) may increase this risk, and patients with these conditions should be monitored for signs of bleeding.  Therapy with NSAIDs should be administered cautiously in patients with or predisposed to anemia.  Clinical monitoring of hematopoietic function may be appropriate, particularly during chronic therapy.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6916, 0, 'Flurbiprofen', 'Heart Failure', 'Fluid retention and edema have been observed in patients treated with nonsteroidal anti-inflammatory drugs (NSAIDs), including some topical formulations.  These drugs should be avoided in patients with severe heart failure unless the benefits are expected to outweigh the risk of worsening heart failure.  If an NSAID is used in patients with severe heart failure, they should be monitored for signs of worsening heart failure.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6917, 0, 'Flurbiprofen', 'Liver Diseases', 'Borderline elevations of 1 or more liver tests may occur in up to 15% of patients treated with nonsteroidal anti-inflammatory drugs (NSAIDs).  These laboratory abnormalities may progress, remain unchanged, or regress with continuing therapy.  Elevations of ALT or AST (at least 3 times the upper limit of normal) have been reported in about 1% of patients in clinical trials.  In addition, rare (sometimes fatal) cases of severe hepatotoxicity, including liver necrosis, hepatic failure, jaundice, and fulminant hepatitis have been reported.  Therapy with NSAIDs should be administered cautiously in patients with preexisting liver disease.  Periodic monitoring of liver function is recommended during prolonged therapy.  NSAIDs are also highly protein-bound and some are extensively metabolized by the liver.  Metabolic activity and/or plasma protein binding may be altered in patients with hepatic impairment.  A dosage reduction may be required in some cases.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6918, 0, 'Flurbiprofen', 'Hyperkalemia', 'Increases in serum potassium concentration (including hyperkalemia) have been reported with use of nonsteroidal anti-inflammatory drugs (NSAIDs), even in some patients without renal impairment.  In patients with normal renal function, these effects have been attributed to a hyporeninemic-hypoaldosteronism state.  Caution is advised in patients with hyperkalemia.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6919, 0, 'Flurbiprofen', 'Hypertension', 'Nonsteroidal anti-inflammatory drugs (NSAIDs), including topicals, can lead to new onset of hypertension or worsening of preexisting hypertension, either of which can contribute to the increased incidence of cardiovascular events.  NSAIDs should be used with caution in patients with hypertension.  Blood pressure should be monitored closely during the initiation of NSAID therapy and throughout the course of therapy.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6920, 0, 'Flurbiprofen', 'Blood Platelet Disorders', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) reversibly inhibit platelet adhesion and aggregation and may prolong bleeding time in some patients.  With the exception of aspirin, the platelet effects seen with most NSAIDs at usual recommended dosages are generally slight and of relatively short duration but may be more pronounced in patients with underlying hemostatic abnormalities.  Thrombocytopenia has also been reported rarely during NSAID use.  Therapy with NSAIDs should be administered cautiously in patients with significant active bleeding or a hemorrhagic diathesis, including hemostatic and/or coagulation defects associated with hemophilia, vitamin K deficiency, hypoprothrombinemia, thrombocytopenia, thrombocytopathy, or severe hepatic impairment.  NSAIDs that selectively inhibit cyclooxygenase-2 (i.e., COX-2 inhibitors) do not appear to affect platelet function or bleeding time at indicated dosages and may be preferable if risk of bleeding is a concern.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6921, 0, 'Flutamide', 'Liver Diseases', 'There have been postmarketing reports of hospitalization and rarely death due to liver failure in patients taking flutamide.  Signs of hepatic injury included elevated serum transaminase levels, jaundice, hepatic encephalopathy and death related to acute hepatic failure.  The hepatic injury was reversible after discontinuation of therapy in some patients.  Approximately half of the reported cases occurred within the initial 3 months of treatment.  Serum transaminase levels should be measured prior to starting treatment with flutamide.  Flutamide is not recommended in patients whose ALT values exceed twice the upper limit of normal.  Serum transaminase levels should then be measured monthly for the first 4 months of therapy, and periodically thereafter.  Liver function tests also should be obtained at the first signs and symptoms suggestive of liver dysfunction, e.g., nausea, vomiting, abdominal pain, fatigue, anorexia, "flu-like" symptoms, hyperbilirubinuria, jaundice or right upper quadrant tenderness.  If at any time, a patient has jaundice, or their ALT rises above 2 times the upper limit of normal, flutamide should be immediately discontinued with close follow-up of liver function tests.  Flutamide should be administered with extreme caution in patients with or predisposed to compromised hepatic function, and it is contraindicated in patients with severe hepatic impairment.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6922, 0, 'Flutamide', 'Hemolysis', 'Toxicity consistent with aniline exposure such as methemoglobinemia, hemolytic anemia, and cholestatic jaundice has been reported during flutamide therapy.  Therapy with flutamide should be administered cautiously in patients with glucose-6-phosphate deficiency, hemoglobin M disease, and patients who smoke.  Clinical monitoring of methemoglobin levels in susceptible individuals is recommended,', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6923, 0, 'Fluvoxamine', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Families and caregivers should be advised of the need for close observation and communication with the treating physician.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6924, 0, 'Fluvoxamine', 'Hyponatremia', 'Treatment with SSRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6925, 0, 'Fluvoxamine', 'Liver Diseases', 'Selective serotonin reuptake inhibitors (SSRIs) are primarily metabolized by the liver.  The plasma concentrations of SSRIs and their metabolites may be increased and the half-lives prolonged in patients with impaired hepatic function.  Dosage adjustments may be necessary in accordance with the individual product package labeling.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6926, 0, 'Fluvoxamine', 'Mania', 'Selective serotonin reuptake inhibitors (SSRIs), like other antidepressants, may occasionally cause or activate mania or hypomania.  The reported incidence ranged from 0.1% to 2% in premarketing testing of several SSRIs.  Patients with bipolar disorder are generally more likely to experience mania from antidepressants.  Therapy with SSRIs should be administered cautiously in patients with a history of mania or bipolar disorder.  Prior to initiating treatment, it is recommended to adequately screen patients for bipolar disorder, including a family history of suicide, bipolar disorder, and depression.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6927, 0, 'Fluvoxamine', 'Blood Platelet Disorders', 'The use of selective serotonin reuptake inhibitors (SSRIs) has been associated with altered platelet function.  Petechiae, purpura, ecchymosis, increased bleeding times, epistaxis and gastrointestinal hemorrhage have been reported.  Therapy with SSRIs should be administered cautiously in patients with severe active bleeding or a hemorrhagic diathesis.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6928, 0, 'Fluvoxamine', 'Epilepsy', 'Selective serotonin reuptake inhibitors (SSRIs) may trigger seizures in approximately 0.2% of patients, and some of them are not recommended in patients with unstable epilepsy.  Therapy with SSRIs should be administered cautiously in patients with seizure disorders.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6929, 0, 'Fluvoxamine', 'Inappropriate ADH Syndrome', 'The use of selective serotonin reuptake inhibitors (SSRIs) has rarely been associated with hyponatremia, sometimes secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  These events have generally been reversible following discontinuation of SSRI therapy and/or medical intervention.  SSRI-related hyponatremia may be more common in elderly female patients and those who are volume-depleted or receiving concomitant diuretic therapy.  Caution may be warranted when SSRI therapy is administered in these patients and patients with preexisting hyponatremia or SIADH.  Serum electrolytes, especially sodium as well as BUN and plasma creatinine, should be monitored regularly.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6930, 0, 'Fluvoxamine', 'Weight Loss', 'The use of selective serotonin reuptake inhibitors (SSRIs) may occasionally cause significant weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  Anorexia may occur in approximately 5% to 10% of patients.  Weight change should be monitored during therapy if an SSRI is used in these patients.', '1', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6931, 0, 'Fondaparinux', 'Hemorrhage', 'The use of factor Xa inhibitors is contraindicated in patients with active pathological bleeding as these agents increase the risk of bleeding and can cause serious or fatal hemorrhages.  Caution is recommended when prescribing factor Xa inhibitors to patients at increased risk of bleeding, including patients undergoing procedures where bleeding may cause serious complications.  Such patients include those undergoing spinal/epidural anesthesia or spinal puncture; these patients are at high risk of an epidural or spinal hematoma, which can result in long-term or permanent paralysis.  In general, when using factor Xa inhibitors, the risk of thrombotic events should be weighed against the risk of bleeding.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6932, 0, 'Fondaparinux', 'Endocarditis, Bacterial', 'The manufacturers state that bacterial endocarditis is a contraindication for the use of fondaparinux injection.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6933, 0, 'Fondaparinux', 'Kidney Diseases', 'The use of fondaparinux is contraindicated in patients with severe renal dysfunction (CrCl less than 30 mL/min).  Fondaparinux increases the risk of bleeding in patients with renal dysfunction due to reduced clearance.  This drug may cause prolonged anticoagulation in patients with CrCl 30 to 50 mL/min.  Renal function should be assessed periodically during therapy, and fondaparinux should be discontinued immediately in patients who develop severe renal dysfunction while on treatment.  After discontinuation of fondaparinux, its anticoagulant effects may persist for 2 to 4 days in patients with normal renal function and even longer in patients with renal dysfunction.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6934, 0, 'Fondaparinux', 'Hepatic Insufficiency', 'Patients with liver dysfunction may be vulnerable to bleeding during fondaparinux therapy; these patients should be observed closely for signs/symptoms of bleeding.  No dose adjustment is recommended in patients with mild to moderate liver dysfunction.  No pharmacokinetic data are available for patients with severe liver dysfunction; fondaparinux should be used cautiously in these patients.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6935, 0, 'Fondaparinux', 'Thrombocytopenia', 'Thrombocytopenia can occur with the administration of fondaparinux.  Caution should be used when administered to patients with preexisting thrombocytopenia.  Thrombocytopenia of any degree should be monitored closely and treatment should be discontinued if the platelet count falls below 100,000/mm3.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6936, 0, 'Foscarnet', 'Dehydration', 'Foscarnet is nephrotoxic.  Foscarnet crystals may deposit in renal tubules and capillaries, sometimes causing acute tubular necrosis and renal failure.  Foscarnet may also concentrate in the urine and cause penile or vulvovaginal irritation.  Adequate hydration is crucial to minimize the risk of renal damage and genital ulcerations.  Generally, foscarnet should be administered by an infusion pump over 1 to 2 hours accompanied by hydration.  The manufacturer recommends 750 to 1000 mL of normal saline or 5% dextrose solution prior to the first infusion of foscarnet to establish diuresis, then 500 mL (for 40 to 60 mg/kg dose of foscarnet) or 750 to 1000 mL (for 90 to 120 mg/kg dose of foscarnet) of hydration fluid concurrently with each subsequent foscarnet infusion.  Patients who are dehydrated may be at increased risk for the development of nephrotoxicity and may benefit from additional hydration if tolerated.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6937, 0, 'Foscarnet', 'Water-Electrolyte Imbalance', 'Foscarnet may cause electrolyte disturbances, including hypocalcemia, hypo- or hyperphosphatemia, hypomagnesemia, and hypokalemia.  Ionized serum calcium may also demonstrate a dose-dependent (and possibly rate-dependent) decrease that may not be reflected in total serum calcium.  Patients should be instructed to report symptoms of low ionized calcium such as perioral tingling, numbness in the extremities, and paresthesias.  Other electrolyte-related complications include tetany, seizures, and cardiac disturbances.  Therapy with foscarnet should be administered cautiously in patients with preexisting fluid and electrolyte imbalance and those with underlying cardiac or neurologic abnormalities.  Serum electrolyte levels should be closely monitored and managed in all patients treated with foscarnet.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6938, 0, 'Foscarnet', 'Kidney Diseases', 'Foscarnet is eliminated primarily by the kidney.  Patients with renal impairment may be at greater risk for dose-limiting nephrotoxicity and other adverse effects of foscarnet due to decreased drug clearance.  Renal function should be closely monitored in all patients receiving therapy with foscarnet, and the dosage adjusted based on serum creatinine.  Hydration is recommended to reduce the risk of nephrotoxicity.  The manufacturer recommends 750 to 1000 mL of normal saline or 5% dextrose solution prior to the first infusion of foscarnet to establish diuresis, then 500 mL (for 40 to 60 mg/kg dose of foscarnet) or 750 to 1000 mL (for 90 to 120 mg/kg dose of foscarnet) of hydration fluid concurrently with each subsequent foscarnet infusion.  Foscarnet should be used with caution in patients with abnormal renal function because reduced plasma clearance of foscarnet will result in elevated plasma levels.  Foscarnet dosing must be individualized according to the patient''s renal function status.  The use of foscarnet is not recommended in patients with severe renal impairment indicated by a CrCl < 0.4 mL/min/kg and in those patients undergoing hemodialysis because dosage guidelines have not been established.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6939, 0, 'Foscarnet', 'Neutropenia', 'The use of foscarnet is associated with hematologic toxicities, most commonly anemia and granulocytopenia.  Thrombocytopenia has been reported rarely.  Therapy with foscarnet should be administered cautiously in patients with preexisting blood dyscrasias or bone marrow suppression.  Routine blood counts are recommended.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6940, 0, 'Flurandrenolide (topical)', 'Diabetes Mellitus', 'Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis.  Therapy with topical corticosteroids rarely produces these effects but should be administered cautiously nonetheless in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia.  Systemic absorption of topical corticosteroids may occur depending on the vehicle and concentration of the preparation, the size of the application area, the integrity of the skin, and the duration of administration.  Use of occlusive dressings over the applied areas may also increase percutaneous absorption.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.  If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6941, 0, 'Flurandrenolide (topical)', 'Diaper Rash', 'Topical corticosteroids, especially the potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol), are generally not recommended for use in the treatment of diaper rash.  Topical corticosteroids may be systemically absorbed, depending on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Given equivalent doses, small children are usually at the greatest risk for systemic toxicity such as adrenal suppression, Cushing''s syndrome and intracranial hypertension because of their larger skin surface to body mass ratios.  If topical corticosteroids are necessary to treat diaper rash, medium- to low-potency agents should preferably be used, and parents should be advised not to put tight-fitting diapers or plastic pants over the rash, since occlusion of treated area may increase percutaneous drug absorption.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6942, 0, 'Flurandrenolide (topical)', 'Adrenocortical Hyperfunction', 'The use of topical corticosteroids may precipitate or aggravate conditions of hyperadrenocorticism.  Systemic absorption of these agents can produce reversible hypothalamic-pituitary-adrenal axis suppression.  Systemic absorption, depends on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.  Patients with an altered skin barrier or liver failure are also at increased risk.  If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults.  The development of symptoms such as menstrual irregularities, acneiform lesions, cataracts and cushingoid features during topical corticosteroid therapy may indicate excessive use.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6943, 0, 'Flurandrenolide (topical)', 'Infections', 'Topical corticosteroids may be systemically absorbed, depending on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Clinically significant local as well as systemic immunosuppressant and anti-inflammatory effects may occur, which can cause or exacerbate an infection.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.  Therapy with topical corticosteroids should be administered cautiously in patients with latent or active infections, particularly if a potent agent is used on a large area for prolonged periods or if occlusive dressings are used.  Effective antimicrobial therapy or other appropriate treatment should be instituted to treat the infection.  If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults.  Occlusive dressings should not be used in patients with skin infection.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6944, 0, 'Flurandrenolide (topical)', 'Toxic Optic Neuropathy', 'Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves.  Therapy with topical corticosteroids rarely produces these effects but should be administered cautiously nonetheless in patients with a history of cataracts, glaucoma, or increased intraocular pressure, especially when potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) are used in the periorbital area.  Topical corticosteroids may be systemically absorbed, depending on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6945, 0, 'Formoterol', 'Cardiovascular Diseases', 'Adrenergic bronchodilators can stimulate cardiovascular beta- 1 and beta- 2 receptors, resulting in adverse effects such as tachycardia, palpitation, peripheral vasodilation, blood pressure changes, and ECG changes (e.g., flattening of the T wave; prolongation of the QT interval; ST segment depression).  Direct stimulation of cardiac tissues is mediated by beta- 1 receptors and thus less likely to occur with beta-2-selective agents such as albuterol.  However, beta-2-selectivity is not absolute and can be lost with larger doses.  High dosages of these agents have been associated with precipitation or aggravation of angina, myocardial ischemia, and cardiac arrhythmias.  Therapy with adrenergic bronchodilators should be administered cautiously in patients with sensitivity to sympathomimetic amines, hyperthyroidism, and/or underlying cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, or hypertension.  The recommended dosages should not be exceeded.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6946, 0, 'Formoterol', 'Diabetes Mellitus', 'Adrenergic bronchodilators may cause increases in blood glucose concentrations.  These effects are usually transient and slight, but may be significant with dosages higher than those normally recommended.  Large doses of IV albuterol (not commercially available in the U.S.) and terbutaline sulfate have been reported to cause exacerbation of preexisting diabetes mellitus and ketoacidosis.  Therapy with adrenergic bronchodilators should be administered cautiously in patients with diabetes mellitus.  Closer monitoring of blood glucose concentrations may be appropriate.  Systemic adverse effects are minimized, but not abolished, by administration of these agents via oral inhalation.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6947, 0, 'Formoterol', 'Hypokalemia', 'Adrenergic bronchodilators may cause decreases in serum potassium concentrations, primarily when given by nebulization or intravenous administration.  Although this effect is usually transient and does not require supplementation, clinically significant hypokalemia may occur in some patients, with the potential to induce cardiovascular adverse effects.  The relevance of these observations to oral or oral aerosol/powder for inhalation therapy is unknown.  Therapy with adrenergic bronchodilators should be administered cautiously in patients with or predisposed to hypokalemia.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6948, 0, 'Formoterol', 'Seizures', 'Adrenergic bronchodilators may cause CNS stimulation.  Therapy with adrenergic bronchodilators should be administered cautiously in patients with seizure disorders.  Systemic adverse effects are minimized, but not abolished, by administration of these agents via oral inhalation.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6949, 0, 'Amisulpride', 'Long QT Syndrome', 'Amisulpride causes dose and concentration-dependent prolongation of the QT interval and should be avoided in patients with congenital long QT syndrome and in patients taking some drugs that prolong the QT interval such as droperidol.  ECG monitoring is recommended in patients with pre-existing arrhythmias and cardiac conduction disorders; electrolyte abnormalities (e.g., hypokalemia or hypomagnesemia); congestive heart failure; and in patients taking other medicinal products or with other medical conditions known to prolong the QT interval.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6950, 0, 'Amisulpride', 'Kidney Diseases', 'The pharmacokinetics of amisulpride in patients with severe renal impairment have not been adequately studied, however, the drug is known to be substantially excreted by the kidneys and patients with severe renal impairment may have an increased risk of adverse reactions.  Avoid the use in patients with severe renal impairment (eGFR less than 30 mL/min/1.73 m2).  No dosage adjustment is necessary in patients with mild to moderate renal impairment (eGFR 30 mL/min/1.73 m2 and above).', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6951, 0, 'Fosamprenavir', 'Hemophilia A', 'There have been postmarketing reports of increased bleeding, including spontaneous skin hematomas and hemarthrosis, in types A and B hemophiliac patients treated with protease inhibitors.  However, a causal relationship has not been established.  In some patients, additional Factor VIII was given.  In more than half of the reported cases, protease inhibitor therapy was continued or reintroduced following an interruption.  Hemophiliacs and patients with other coagulation defects should be monitored closely for bleeding during protease inhibitor therapy.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6952, 0, 'Fosamprenavir', 'Nephrolithiasis', 'Cases of nephrolithiasis have been reported during postmarketing surveillance in HIV-infected patients receiving amprenavir or fosamprenavir therapy.  Because these events were reported voluntarily during clinical practice, estimates of frequency cannot be made.  Therapy with amprenavir or fosamprenavir should be administered cautiously in patients with a current or past history of nephrolithiasis.  Adequate hydration is recommended.  Those who are dehydrated may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluids if necessary.  Patients should be instructed to seek medical attention if they experience potential signs and symptoms of urolithiasis such as flank pain, hematuria, dysuria, and urinary urgency.  Temporary interruption or discontinuation of therapy may be required.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6953, 0, 'Fosamprenavir', 'Hyperglycemia', 'New onset diabetes mellitus, exacerbation of preexisting diabetes mellitus, glucose intolerance, hyperglycemia, and some cases of diabetic ketoacidosis have been reported during postmarketing surveillance in HIV-infected patients treated with protease inhibitors (PIs).  In some cases, glucose abnormalities/hyperglycemia persisted despite discontinuation of PI therapy.  Frequently, insulin resistance may accompany fat redistribution and serum lipid elevations in what is collectively termed the HIV-associated lipodystrophy syndrome.  Although a causal relationship has not been established, these metabolic disturbances have most often occurred in HIV-infected patients during treatment with potent antiretroviral regimens containing PIs.  Monitoring patients for hyperglycemia, new onset diabetes mellitus, or exacerbation of diabetes mellitus should be considered during PI therapy.  Dosage adjustments in insulin or oral hypoglycemic medications may be necessary in patients with diabetes.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6954, 0, 'Fosamprenavir', 'Hyperlipidemias', 'Hyperlipidemia has been observed in 10% of patients receiving ritonavir during clinical trials.  Increases of 30% to 40% from baseline have been reported for total cholesterol and 200% to 300% or more for triglycerides.  These effects have also been reported during postmarketing experience with other protease inhibitors (PIs) but may be the most dramatic with ritonavir.  The clinical significance of these elevations is unclear.  Severe hyperlipidemia is known to sometimes cause pancreatitis.  In addition, some patients have reportedly developed symptomatic atherosclerosis and coronary artery disease after initiating PI treatment.  Patients with preexisting hyperlipidemia may require closer monitoring during PI therapy, and adjustments made accordingly in their lipid-lowering regimen.  PI therapy should be administered cautiously in patients with coronary artery disease or a history of ischemic heart disease.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6955, 0, 'Fosfomycin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6956, 0, 'Fosfomycin', 'Diseases requiring hemodialysis', 'Fosfomycin is removed by hemodialysis and should be administered after dialysis sessions.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6957, 0, 'Fosfomycin', 'Kidney Diseases', 'Fosfomycin is eliminated unchanged by the kidney (38%) and in the feces (18%).  The excretion of fosfomycin is significantly decreased and the half-life prolonged in patients with compromised renal function.  Side effects (e.g., diarrhea, headache, nausea, vaginitis) may be prolonged in patients with renal impairment.', '1', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6958, 0, 'Amitriptyline', 'Anticholinergic Syndrome', 'Tricyclic and tetracyclic antidepressants (TCAs) have anticholinergic activity, to which elderly patients are particularly sensitive.  Tertiary amines such as amitriptyline and trimipramine tend to exhibit greater anticholinergic effects than other agents in the class.  Therapy with TCAs should be administered cautiously in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders.  In patients with angle-closure glaucoma, even average doses can precipitate an attack.  Glaucoma should be treated and under control prior to initiation of therapy with TCAs, and intraocular pressure monitored during therapy.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6959, 0, 'Amitriptyline', 'Cardiovascular Diseases', 'Tricyclic and tetracyclic antidepressants (TCAs) may cause orthostatic hypotension, reflex tachycardia, syncope, and dizziness, particularly during initiation of therapy or rapid escalation of dosage.  Imipramine appears to have the greatest propensity to induce these effects, while secondary amines such as nortriptyline may do so less frequently.  Tolerance to the hypotensive effects often develops after a few doses to a few weeks.  Rarely, collapse and sudden death have occurred secondary to severe hypotension.  Other reported adverse cardiovascular effects include tachycardia, arrhythmias, heart block, hypertension, thrombosis, thrombophlebitis, myocardial infarction, strokes, congestive heart failure, and ECG abnormalities such as PR and QT interval prolongation.  Therapy with TCAs should be avoided during the acute recovery phase following myocardial infarction, and should be administered only with extreme caution in patients with hyperthyroidism, a history of cardiovascular or cerebrovascular disease, or a predisposition to hypotension.  Close monitoring of cardiovascular status, including ECG changes, is recommended at all dosages.  Many of the newer antidepressants, including bupropion and the selective serotonin reuptake inhibitors (SSRIs), are considerably less or minimally cardiotoxic and may be appropriate alternatives.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6960, 0, 'Amitriptyline', 'Pheochromocytoma', 'Tricyclic and tetracyclic antidepressants (TCAs) may potentiate the effects of circulating catecholamines.  Enhanced sympathetic activity can provoke hypertensive crises in patients with pheochromocytoma or other tumors of the adrenal medulla, such as some neuroblastomas.  Therapy with TCAs should be administered cautiously in patients with these tumors.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6961, 0, 'Amitriptyline', 'Acute Myocardial Infarction Recovery', 'The use of most tricyclic antidepressants is contraindicated in patients that are going through the acute recovery period after a myocardial infarction.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6962, 0, 'Amitriptyline', 'Depressive Disorder', 'Adult and pediatric patients with depression may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Families and caregivers should be advised of the need for close observation and communication with the treating physician.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6963, 0, 'Amitriptyline', 'Epilepsy', 'Tricyclic antidepressants (TCAs), can lower the seizure threshold and trigger seizures.  These drugs should be used with extreme caution in patients with a history of seizures, or other predisposing factors, such as head trauma, CNS abnormalities, and alcoholism.  Daily dose restrictions might apply for specific antidepressants.  Physicians are encouraged to get additional dosing recommendations on the manufacturer''s prescribing information.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6964, 0, 'Amitriptyline', 'Bone Marrow Failure Disorders', 'The use of tricyclic and tetracyclic antidepressants (TCAs) has rarely been associated with bone marrow suppression.  Leukopenia, agranulocytosis, thrombocytopenia, anemia, eosinophilia, purpura, and pancytopenia have been reported with some TCAs.  Patients with preexisting bone marrow suppression or blood dyscrasias receiving TCAs should be monitored closely during therapy for further decreases in blood counts.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6965, 0, 'Amitriptyline', 'Diabetes Mellitus', 'Both elevation and lowering of blood sugar levels have been reported with the use of some tricyclic antidepressants (TCAs).  Rarely, these effects have also occurred with maprotiline, a tetracyclic antidepressant.  Patients with diabetes should be monitored for worsening control of blood glucose when treated with these agents, particularly during dosage escalation or whenever dosage has been altered.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6966, 0, 'Amitriptyline', 'Liver Diseases', 'Tricyclic and tetracyclic antidepressants (TCAs) are known to undergo metabolism in the liver.  Some of the metabolites, such as those of imipramine, clomipramine and desipramine, may be pharmacologically active.  Many of the metabolites are also excreted by the kidney.  There are very limited data concerning the use of TCAs in patients with renal and/or liver disease.  Therapy with TCAs should be administered cautiously in patients with significantly impaired renal or hepatic function.  Dosage adjustments may be necessary.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6967, 0, 'Amitriptyline', 'Schizophrenia', 'Tricyclic antidepressants (TCAs) may aggravate symptoms of psychosis in schizophrenic patients, particularly those with paranoid symptomatology.  Depressed patients, usually those with bipolar disorder, may experience a switch from depression to mania or hypomania.  These occurrences have also been reported rarely with the tetracyclic antidepressant, maprotiline.  Therapy with these agents should be administered cautiously in patients with schizophrenia, bipolar disorder, or a history of mania.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6968, 0, 'Amitriptyline', 'Tardive Dyskinesia', 'Tricyclic and tetracyclic antidepressants (TCAs) have anticholinergic activity, to which elderly patients are particularly sensitive.  Tertiary amines such as amitriptyline and trimipramine tend to exhibit greater anticholinergic effects than other agents in the class.  As with other drugs that possess anticholinergic activity, TCAs may aggravate tardive dyskinesia or induce previously suppressed symptoms.  Patients with tardive dyskinesia requiring therapy with TCAs should be monitored for exacerbation of the condition.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6969, 0, 'Amitriptyline', 'Alcoholic Intoxication', 'Tricyclic antidepressants can enhance the response to alcohol.  In patients who may use alcohol excessively, it should be borne in mind that the potentiation may increase the danger inherent in any suicide attempt or overdosage.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6970, 0, 'Amitriptyline', 'Bipolar Disorder', 'A major depressive episode can be the initial presentation of bipolar disorder.  Patients with depressive symptoms should be adequately screened to determine if they are at risk for bipolar disorder prior to initiating treatment with a tricyclic antidepressant.  This screening should include a detailed psychiatric history, including a family history of suicide, bipolar disorder, and depression.  It should be noted that tricyclic antidepressants are not approved for use in treating bipolar depression.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6971, 0, 'Amitriptyline', 'Glaucoma', 'Tricyclic antidepressants as other type of antidepressants have an effect on pupil size causing dilation.  This effect can potentially narrow the eye angle resulting in increased intraocular pressure and angle closure glaucoma, especially in predisposed patients.  These drugs should be used with caution in patients with anatomically narrow angle or history of glaucoma.  Doxepin hydrochloride capsules are contraindicated in patients with glaucoma.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6972, 0, 'Amitriptyline', 'Neutropenia', 'The use of some tricyclic antidepressants has been associated with neutropenia (ANC < 500/mm3) and agranulocytosis (ANC < 500/mm3).  Leukocyte and differential blood counts should be performed in patients that develop fever and sore throat during treatment.  Therapy should be discontinued if there is evidence of pathologic neutrophil depression.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6973, 0, 'Amitriptyline', 'Thyroid Diseases', 'Most tricyclic antidepressants should be administered with caution in hyperthyroid patients or those receiving thyroid medication as they may develop arrhythmias when these drugs are given.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6974, 0, 'Amitriptyline', 'Urinary Retention', 'Due to their anticholinergic properties, tricyclic antidepressants should be administered with caution in patients with history of urinary retention.  Particularly doxepin hydrochloride capsules are contraindicated in patients with tendency to urinary retention.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6975, 0, 'Fosinopril', 'Angioedema', 'The use of these agents is contraindicated in patients with hereditary angioedema or a history of idiopathic angioedema.  Patients with a history of angioedema unrelated to ACE inhibitors may be at increased risk of angioedema while receiving an ACE inhibitor.  Patients should be advised to immediately report any signs or symptoms suggestive of angioedema (swelling of face, extremities, eyes, lips, or tongue, or difficulty swallowing or breathing) and to stop taking the medication until otherwise directed by their physician.  Emergency therapy and/or measures to prevent airway obstruction are required for angioedema involving the tongue, glottis, or larynx.  Treatment with ACE inhibitors should be discontinued permanently if angioedema develops in association with therapy.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6976, 0, 'Fosinopril', 'Bone Marrow Failure Disorders', 'ACE inhibitors may cause bone marrow suppression, rarely in uncomplicated individuals but more frequently in patients with renal impairment, especially if they also have a collagen-vascular disease such as systemic lupus erythematosus or scleroderma.  Neutropenia, agranulocytosis, aplastic anemia, hemolytic anemia, eosinophilia and thrombocytopenia have been reported, mostly with captopril.  Therapy with ACE inhibitors should be administered cautiously in patients with preexisting blood dyscrasias or complications that may increase the risk of bone marrow depression during ACE inhibitor therapy.  Monitoring of blood counts, particularly white blood cells, should be considered.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6977, 0, 'Fosinopril', 'Heart Failure', 'ACE inhibitors can cause marked renal impairment in patients whose renal function depends on the activity of the renin-angiotensin-aldosterone system.  In addition, symptomatic and sometimes excessive hypotension can occur in susceptible individuals, particularly during the initiation of treatment, which may compromise renal and myocardial perfusion.  In patients with severe congestive heart failure (CHF), treatment with ACE inhibitors may be associated with oliguria and/or progressive azotemia and, rarely, renal failure, myocardial ischemia and death.  Therapy with ACE inhibitors should be initiated under very close medical supervision in patients with severe CHF, especially when accompanied by volume and/or sodium depletion.  Patients should be monitored closely for several hours after an initial dose until blood pressure has stabilized, and followed closely for the first 2 weeks of treatment and whenever the dosage of ACE inhibitor or diuretic is increased.  If feasible, the risk of severe hypotension may be minimized by reducing or temporarily withholding the dosing of diuretics and/or liberalizing dietary sodium intake for 2 to 3 days prior to starting ACE inhibitor therapy.  In patients who experience a worsening of renal function, discontinuation of ACE inhibitor therapy is usually not required provided there is symptomatic improvement of the heart failure and renal deterioration is well-tolerated.  Transient hypotension is also not a contraindication to further treatment with ACE inhibitors.  After blood pressure stabilizes, therapy can usually be reinstated with caution, although a lower dosage of the ACE inhibitor and/or dosage reduction or discontinuation of concomitantly administered diuretics may be necessary.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6978, 0, 'Fosinopril', 'Diseases requiring hemodialysis', 'Anaphylactoid reactions have been reported in patients undergoing hemodialysis with high-flux polyacrylonitrile membranes and treated concomitantly with an ACE inhibitor.  The frequency and mechanism of this interaction have not been established, and it is not known whether the interaction occurs with other membrane types.  Therapy with ACE inhibitors should be administered cautiously in patients requiring hemodialysis.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6979, 0, 'Fosinopril', 'Hyperkalemia', 'In patients with hyperkalemia, especially those associated with impaired renal function or congestive heart failure, ACE inhibitors may further raise serum potassium levels.  Therapy with ACE inhibitors should be administered cautiously in patients with or predisposed to hyperkalemia, and serum potassium levels should be carefully monitored.  Risk factors for the development of hyperkalemia during ACE inhibitor therapy include renal insufficiency, diabetes mellitus, and the concomitant use of potassium-sparing diuretics, potassium supplements, and/or potassium-containing salt substitutes.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6980, 0, 'Fosinopril', 'Hypotension', 'ACE inhibitors can cause symptomatic hypotension, most often during the initiation of therapy and in patients who are volume- and/or sodium-depleted or treated for congestive heart failure (CHF).  Therapy with ACE inhibitors should be administered cautiously in such patients and in those predisposed to hypovolemic or hyponatremic states (e.g., patients on diuretic therapy, especially if it was recently instituted; those on dietary salt restriction; those with severe or prolonged diarrhea or vomiting; and renal dialysis patients).  Volume and/or sodium depletion should be corrected prior to initiating therapy with ACE inhibitors, and the patient should be hemodynamically stable.  If concomitant diuretics and/or dietary sodium restriction are employed, reducing or temporarily withholding the dosing of diuretics and/or liberalizing dietary sodium intake for 2 to 3 days in advance can help minimize the risk of severe hypotension in patients who are able to tolerate such adjustments.  ACE inhibitors should also be used cautiously in patients in whom excessive hypotension may have serious consequences, such as patients with coronary or cerebrovascular insufficiency.  Patients at risk for excessive hypotension should initiate ACE inhibitor therapy under very close medical supervision, and followed closely for the first 2 weeks of treatment and whenever the dosage of ACE inhibitor or diuretic is increased.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6981, 0, 'Fosinopril', 'Liver Diseases', 'Rarely, elevations of liver enzymes and/or serum bilirubin have occurred with the use of ACE inhibitors.  Patients receiving ACE inhibitors who develop jaundice or marked elevations of hepatic enzymes should discontinue the ACE inhibitor and receive appropriate medical follow-up.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6982, 0, 'Fosinopril', 'Kidney Diseases', 'With the exception of fosinopril, ACE inhibitors (and/or their active metabolites in some cases) are primarily eliminated by the kidney and may accumulate in patients with renal impairment.  ACE inhibitors can also worsen renal function in some patients by blocking the effect of angiotensin II-mediated efferent arteriolar vasoconstriction, thereby decreasing glomerular filtration.  Therapy with ACE inhibitors should be administered cautiously in patients with preexisting renal dysfunction, particularly those with renovascular disease.  Patients with moderate to severe renal impairment usually require lower or less frequent doses and smaller increments in dose.  In addition, a dosage reduction or discontinuation of any concomitantly administered diuretics may be helpful.  Fosinopril probably does not require dosage adjustments unless hepatic function is also significantly impaired.  
In patients with bilateral renal artery stenosis or renal artery stenosis in a solitary kidney, ACE inhibitors may reduce renal perfusion to a critically low level.  Renal function should be monitored closely for the first few weeks of therapy.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6983, 0, 'Fosinopril', 'Liver Failure', 'Fosinopril is primarily metabolized by hepatic and gut wall esterases to its active moiety, fosinoprilat, patients with impaired liver function could develop elevated plasma levels of unchanged fosinopril.  In a study in patients with alcoholic or biliary cirrhosis, the extent of hydrolysis was unaffected, although the rate was slowed.  In these patients, the apparent total body clearance of fosinoprilat was decreased and the plasma AUC approximately doubled.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6984, 0, 'Fostemsavir', 'Hepatitis B', 'Fostemsavir may cause elevations in hepatic transaminases in patients co-infected with hepatitis B or C.  It is recommended to monitor liver function in patients with hepatitis B or C co-infection.  Particular attention should be practiced in initiating or maintaining effective hepatitis B therapy when starting fostemsavir treatment in patients co-infected with hepatitis B.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6985, 0, 'Fostemsavir', 'Long QT Syndrome', 'Fostemsavir has been shown to significantly prolong the QTc interval of the electrocardiogram with higher than recommended dosages.  Fostemsavir should be used with caution in patients with a history of QTc interval prolongation, when co-administered with a drug with a known risk of Torsade de Pointes, or in patients with relevant preexisting cardiac disease.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6986, 0, 'Fostamatinib', 'Diarrhea', 'The use of fostamatinib may cause diarrhea.  Monitor patients for the development of diarrhea during treatment with fostamatinib.  It is recommended to manage diarrhea using supportive care measures, including dietary changes, hydration and/or antidiarrheal medication, early after the onset of symptoms.  Interrupt, dose reduce, or discontinue treatment if diarrhea becomes severe (Grade 3 or above).  Care should be exercised when using this agent in patients with diarrhea.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6987, 0, 'Fostamatinib', 'Liver Diseases', 'The use of fostamatinib may result in elevated liver function tests, mainly ALT and AST.  It is recommended to monitor liver function tests monthly during treatment.  Treatment with fostamatinib should be interrupted, reduced, or discontinued if ALT or AST increase more than 3  ULN.  Use care using this agent in patients with liver problems.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6988, 0, 'Fostamatinib', 'Hypertension', 'The use of fostamatinib may cause hypertension.  It is recommended to monitor blood pressure every 2 weeks until stable, then monthly and to adjust or initiate antihypertensive therapy to ensure maintenance of blood pressure control during treatment.  If increased blood pressure persists despite appropriate therapy, therapy interruption, reduction or discontinuation may be necessary.  Caution should be exercised when using this agent in patients with pre-existing hypertension as they may be more susceptible to the hypertensive effects of fostamatinib.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6989, 0, 'Fostamatinib', 'Neutropenia', 'Neutropenia has been reported in patients treated with fostamatinib.  It is recommended to monitor the ANC monthly, and for infection during treatment and manage toxicity with treatment interruption, reduction or discontinuation.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6990, 0, 'Frovatriptan', 'Coronary Artery Disease', 'The group of drugs known as 5-hydroxytryptamine1 receptor (5-HT1) agonists can cause vasospastic reactions, including coronary vasospasm, peripheral vascular ischemia, and colonic ischemia.  Rarely, serious adverse cardiac events including acute myocardial infarction, arrhythmia, cardiac arrest, and death have been reported within a few hours following the administration of 5-HT1 agonists, in some cases even in patients with no prior history or findings of coronary artery disease (CAD).  Significant elevation in blood pressure, including hypertensive crisis, has also been reported on rare occasions in patients with and without a history of hypertension, as have transient increases in blood pressure and peripheral vascular resistance.  In general, patients with potentially unrecognized CAD as predicted by the presence of risk factors (e.g., hypertension, hypercholesterolemia, tobacco use, obesity, diabetes, strong family history of CAD, female with surgical or physiological menopause, or male over 40 years of age) should not be administered 5-HT1 agonists unless a cardiovascular evaluation provides satisfactory clinical evidence indicating the lack of CAD, ischemic heart disease, or other significant underlying cardiovascular disease.  As a precaution, the manufacturers recommend that the first dose be administered under medical surveillance in such patients, and that electrocardiographic monitoring be considered during the interval immediately following administration to help detect any asymptomatic cardiac ischemia that may occur.  Periodic cardiovascular evaluations should be performed during intermittent, long-term use.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6991, 0, 'Frovatriptan', 'Cardiovascular Diseases', 'The use of 5-hydroxytryptamine receptor (5-HT1) agonists is contraindicated in patients with a history or current symptoms or signs of ischemic cardiac, cerebrovascular, and/or peripheral vascular diseases.  In addition, these agents should not be used in patients with any other significant underlying cardiovascular disease or uncontrolled hypertension.  5-HT1 agonists can cause vasospastic reactions, including coronary vasospasm, peripheral vascular ischemia, and colonic ischemia.  Some serious adverse cardiac events including acute myocardial infarction, arrhythmia, cardiac arrest, and death have been reported within a few hours following the administration of 5-HT1 agonists, in some cases even in patients with no prior history or findings of coronary artery disease (CAD).  Significant elevation in blood pressure, including hypertensive crisis, has also been reported on rare occasions in patients with and without a history of hypertension, as have transient increases in blood pressure and peripheral vascular resistance.  Cerebrovascular events have included cerebral hemorrhage, subarachnoid hemorrhage, and stroke, some resulting in fatalities.  However, the relationship to 5-HT1 agonists is uncertain and, in a number of cases, the cerebrovascular events may have been primary where symptoms were mistaken to be migraine.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6992, 0, 'Frovatriptan', 'Liver Diseases', 'Frovatriptan is primarily metabolized by the liver.  Following oral administration in patients with mild (Child-Pugh 5-6) to moderate (Child-Pugh 7-9) hepatic impairment, the systemic exposure of frovatriptan was approximately twice that observed in young, healthy subjects but still considerably lower than the values attained with higher dosages of frovatriptan (up to 40 mg), which were not associated with any serious adverse effects.  Dosage adjustments are not necessary in patients with mild to moderate hepatic impairment.  Caution is advised in patients with severe hepatic impairment, as there are no clinical or pharmacokinetic data on the use of frovatriptan in this population.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6993, 0, 'Fulvestrant', 'Liver Diseases', 'Fulvestrant is metabolized primarily in the liver.  A dose of fulvestrant 250 mg is recommended in patients with moderate hepatic impairment (Child-Pugh class B).  Care is recommended when using fulvestrant in patients with severe hepatic impairment (Child-Pugh class C) as the agent has not been studied in these patients.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6994, 0, 'Fulvestrant', 'Hemorrhage', 'Fulvestrant injection is administered intramuscularly and site related events have been reported.  It is recommended to use caution in patients with bleeding diatheses, thrombocytopenia, or anticoagulant use.  In addition, caution should be taken while administering fulvestrant injection at the dorsogluteal injection site due to the proximity of the underlying sciatic nerve.', '2', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6995, 0, 'Frangula purshiana bark', 'Inflammatory Bowel Diseases', 'The use of laxatives is contraindicated in patients with inflammatory bowel disease.  Patients with inflammatory bowel disease may experience colonic perforation with use of stimulant laxatives.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6996, 0, 'Frangula purshiana bark', 'Intestinal Obstruction', 'The use of laxatives is contraindicated in patients with intestinal obstruction disorders.  Patients with intestinal obstruction disorders may need their underlying condition treated to correct the constipation.  Some laxatives require reduction in the colon to their active form to be effective which may be a problem in patients with intestinal obstruction.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6997, 0, 'Frangula purshiana bark', 'Appendicitis', 'The use of stimulant laxatives is contraindicated in patients with or who may have acute surgical abdomen or appendicitis.  These patients may be candidates for emergency surgery.  Stimulant laxatives should also not be administered to patients with abdominal pain, particularly if the cause has not been determined.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6998, 0, 'Frangula purshiana bark', 'Rectal Diseases', 'The use of stimulant laxatives is contraindicated in patients with anal or rectal fissures.  These preparations may cause irritation, burning sensation, and proctitis.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (6999, 0, 'Gadobutrol', 'Nephrogenic Fibrosing Dermopathy', 'Gadolinium based contrast agents (GBCAs) increase the risk for nephrogenic systemic fibrosis (NSF) among patients with impaired elimination of the drugs.  Use of these agents should be avoided in these patients unless the diagnostic information is essential and unavailable with non- contrasted MRI or other diagnostic modalities.  NSF may result in fatal or debilitating fibrosis affecting the skin, muscle and internal organs.  The risk of NSF appears to be higher in patients with chronic severe renal disease and patients with acute kidney injury.  Patients should be screened for acute renal injury and other conditions that might affect renal function such as age >60 years old, hypertension, and diabetes.', '3', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source, created_at) VALUES (7000, 0, 'Gadobutrol', 'Kidney Diseases', 'Gadolinium-based contrast agents (GBCAs) increase the risk for nephrogenic systemic fibrosis (NSF) among patients with impaired elimination of the drugs.  Gadobenate ion is eliminated predominately via the kidneys.  The risk for NSF appears highest among patients with chronic, severe kidney disease (GFR <30 mL/min/1.73m2), or acute kidney injury.  It is recommended to avoid the use of GBCAs in these patients unless the diagnostic information is essential and not available with non-contrasted MRI or other processes.  NSF may result in fatal or debilitating systemic fibrosis affecting the skin, muscle and internal organs.  Consider screening patients for acute kidney injury and other conditions that may reduce renal function and for patients at risk for chronically reduced renal function (e.g., age > 60 years, hypertension or diabetes), estimate the glomerular filtration rate (GFR) through laboratory testing.  For patients receiving hemodialysis, physicians may consider the prompt initiation of hemodialysis following the administration of a GBCA to enhance the contrast agent''s elimination.  The usefulness of hemodialysis in the prevention of NSF is unknown.', '3', 'DDInter', 0);
